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ABSTRACT 
Pregnancy represents a unique immunological arrangement where the maternal immune system 
must tolerate and support the genetically foreign fetus.  The mechanisms by which maternal 
tolerance to the fetus is achieved and the consequences if this balance is disrupted are not 
completely understood.  In this work, we have shown for the first time that the placenta 
expresses at least six known human minor histocompatibility antigens (mHAgs), including three 
autosomal antigens, HA-1, BCL2A1 and KIAA0020, and three Y-chromosome-encoded 
antigens, DDX3Y, RPS4Y1 and KDM5D.  In addition, we have shown that expression of at least 
one of these antigens, HA-1, is decreased in term as compared to first trimester placentas 
(P<0.01), is regulated by oxygen and is significantly higher in pre-eclamptic placentas as 
compared to controls (P=0.015).  We also examined the protein content of exosomes released 
from the outermost layer of the placenta (trophoblast-derived exosomes) using mass 
spectrometry and found that, in addition to several exosome markers, trophoblast-derived 
exosomes contain the immune molecule HLA-DR, which is not expressed on the surface of the 
trophoblast.  We then treated dendritic cells with trophoblast-derived exosomes either in the 
presence or absence of the immunostimulatory molecule, LPS.  Dendritic cells treated with 
exosomes alone showed significant increases in IL-8 (P=0.05), VCAM-1 (P=0.01) and CD80 
(P=0.05) mRNAs whereas dendritic cells treated with LPS + exosomes showed a significant 
decrease in CCL7 (P=0.03) and CD40LG (P=0.002) when compared to controls.  In conclusion, 
we have found that the placenta expresses at least six mHAgs, that expression of at least one of 
these mHAgs, HA-1, is regulated by oxygen and is increased in placentas from women with pre-
eclampsia, and that that exosomes released from placental trophoblast cells contain at least one 
known fetal antigen, HLA-DR, and can alter dendritic cell phenotype.  Taken together, these 
findings indicate that the placenta expresses and releases antigenic materials into the maternal 
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blood stream and may affect maternal immune responses to the fetus during pregnancy.  These 
findings may have important implications for the maintenance of a healthy pregnancy, numerous 
pregnancy complications and many other diseases involving immune responses to foreign and 
self-antigens. 
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CHAPTER 1: 
 
REVIEW OF THE LITERATURE 
 
Portions of this chapter have been published in: 
Linscheid, C and Petroff MG (2013). “Minor histocompatibility antigens and the maternal 
response to the fetus during pregnancy.” Am J Reprod Immunol 64(4):304-14. (Linscheid and 
Petroff 2013)  
	   2	  
INTRODUCTION 
The placenta plays a critical role in the success of pregnancy both by facilitating the ever-
evolving physiological demands of the developing fetus and by mediating immune interactions 
between the genetically distinct mother and fetus.  Rather than being a passive barrier, the 
placenta is a dynamic organ with a critical role in maintaining maternal immune tolerance to the 
fetus and, therefore, a successful pregnancy. In human pregnancy, this tolerance is achieved both 
actively, via the expression of immuno-modulatory molecules on the surface of the placenta, and 
passively, through the restricted expression of classical MHC molecules on trophoblast cells 
(Petroff 2005).  Despite these adaptations, the maternal immune system is not naïve to the fetus.  
Rather, there is a robust and growing body of evidence indicating that, in both mice and humans, 
the maternal immune system actively responds to fetal antigens (Tarfuri, Alferink et al. 1995, 
Zhou and Mellor 1998, Aluvihare, Kallikourdis et al. 2004, Piper, McLarnon et al. 2007, 
Lissauer, Piper et al. 2012).   
OVERVIEW OF REPRODUCTIVE IMMUNOLOGY 
An Historical Perspective on Placenta Structure and Function 
 The first scientific description of the placenta occurred c480 BC and has been attributed 
to the ancient Greek physician, Diogenes of Appolonia (De Witt 1959).  Diogenes postulated that 
the placenta served as a source of nutrition for the developing fetus.  This theory was later 
expanded upon by Aritstotle (384-322 BC) and Galen (130-c200 AD), who correctly deduced 
that because the fetus is surrounded by amniotic membranes during development, fetal nutrition 
must be derived from the placenta via the umbilical cord, rather than via uterine paps, as was the 
competing theory of the time (De Witt 1959).  More work in this area was conducted by 
Renaldus Columbus and published in his extensive description of human anatomy, De re 
anatomica (1559), where he correctly stated that, rather than being a source of nourishment, the 
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amniotic fluid served to cushion and protect the fetus as it grew and developed within the uterus 
(Power and Schulkin 2012). 
 The question of the interrelationship between the maternal and fetal circulatory systems 
was the source of much investigation and speculation for many years.  The first proposal that the 
mother and fetus had separate circulatory systems was by Giulio Cesare Aranzi in his 1564 
treatise De humano foetu (Longo 2013).  This hypothesis was expanded upon in the 18th century 
by William and John Hunter who, along with Erasmus Darwin, definitively established that the 
maternal and fetal circulatory systems were separate and that oxygen is one of the major 
substances transferred from mother to fetus via the placenta (Dunn 2003, Pijnenborg and 
Vercruysse 2007, Longo and Reynolds 2010, Pijnenborg, Brosens et al. 2010).  Modern 
understanding of the placenta as an organ was greatly enhanced by the development of light 
microscopy, which precipitated the cellular categorization of placentas of various species by 
Grosser in the early 20th century (Grosser 1909, Grosser 1927, Enders 1965).  Grosser proposed 
six different placental arrangements based on the number of cell layers separating mother and 
fetus and the degree of placental invasion into the maternal uterus; epithelia-chorial, syndesmo-
chorial, endothelio-chorial, hemo-trichorial, hemo-dichorial and hemo-monochorial, with 
epithelial-chorial being the least invasive and hemo-monochorial being the most invasive 
(Grosser 1909, Grosser 1927, Benirschke and Kaufmann 1995). In addition, the 20th century also 
brought about the extensive description of placental pathologies by Benirschke and Kaufmann 
(Benirschke and Kaufmann 1995), which has had important implications for numerous 
pregnancy complications arising from placental dysfunctions.  Despite all of these historical 
advancements, there are still numerous questions surrounding the role of the placenta in maternal 
and fetal physiology, including the maintenance of fetal tolerance without the threat of 
overwhelming maternal and fetal infection.   
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Current Understanding of Placental Structure and Function 
 The placenta forms the physical interface between the mother and fetus during pregnancy 
and in addition to its’ role as an immune organ, performs many critical biological tasks, 
including gas and nutrient exchange and numerous endocrine functions, which are central to fetal 
survival.  The placenta originates from the outer cell mass/trophectoderm and differentiates into 
several distinct trophoblast lineages shortly after implantation, including the invasive 
extravillous trophoblast and the structural villous trophoblast.  The villous trophoblast comprises 
two cell layers, the cytotrophoblast and the syncytiotrophoblast.  The cytotrophoblast is the inner 
villous trophoblast cell layer that fuses to form the outer, multinucleated syncytiotrophoblast.  
The syncytiotrophoblast forms the surface of the placenta and is in direct contact with the 
maternal blood supply (Benirschke, Kaufmann et al. 2006). 
 There are several different extravillous trophoblast cell (EVT) populations. Some EVTs 
anchor the placental villi to the uterine wall during pregnancy, whereas others invade into the 
maternal spiral arteries forming an endovascular trophoblast layer that replaces the maternal 
endothelium that typically lines the maternal vessels (Tarrade, Lai Kuen et al. 2001).  This 
invasion ensures that the endothelium of the spiral arteries are replaced with the invasive 
trophoblast cells and that the contractile smooth muscle cells lining the non-pregnant vessels are 
lost, resulting in a low-pressure, high volume blood delivery system that provides a steady 
supply of oxygenated blood to the developing fetus with very little vascular reactivity (Burton, 
Jauniaux et al. 1999, Jauniaux, Watson et al. 2000).   Defects in trophoblast spiral artery 
remodeling and the resulting alterations in placental blood flow have been implicated in several 
pregnancy complications, including preeclampsia and intrauterine growth restriction.  This 
disruption of placental blood flow ultimately leads to maternal vascular disease, which can result 
in kidney dysfunction, multi-system organ failure, seizures and ultimately death of both mother 
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and infant (Stillman and Karumanchi 2007, Gilbert, Nijland et al. 2008, Gilbert, Ryan et al. 
2008).  Interestingly, preeclampsia also involves increased maternal immune system activation 
and heightened production of pro-inflammatory cytokines, suggesting a link between placental 
dysfunction, maternal vascular disease and maternal immune system activation (Redman and 
Sargent 2003, Redman and Sargent 2004). 
Maternal Immune Cells 
 In addition to the fetally-derived trophoblast, numerous maternal immune cells are 
involved in maintaining immune tolerance during pregnancy.  These cells include uterine NK 
cells, regulatory CD4+ T-cells, maternal antigen presenting cells (macrophages and dendritic 
cells), and cytotoxic CD8+ T-cells.  A balance of tolerogenic and cytotoxic maternal immune 
responses is critical for allowing fetal development while preventing serious infection of both 
mother and fetus. 
 Uterine NK cells (uNK) are a unique type of NK cell found in the decidua.  Originally 
defined as a subset of large, granular lymphocytes, NK cells recognize and kill cells that lack the 
molecules necessary for self-vs.-non-self determination.  These molecules are known as Major 
Histocompatibility Complexes (MHCs) or, in humans, the Human Lymphocyte Antigens (HLAs) 
(Herberman, Nunn et al. 1975, Kiessling, Klein et al. 1975, Timonen, Ortaldo et al. 1981, 
Caligiuri 2008).  There are several types of human NK cells, and their functions are primarily to 
lyse target cells and/or to secrete cytokines and chemokines.  Uterine NK cells, in contrast to the 
predominant population of peripheral blood NK cells, are only weakly cytotoxic and do not kill 
trophoblast cells, despite the fact that trophoblast cells do not express most of the classical (class 
Ia) HLA molecules (King, Birkby et al. 1989).  Instead, extravillous trophoblast cells express 
HLA-C and the non-classical (class Ib) molecules HLA-E, -F and –G (Yelavarthi, Fishback et al. 
1991, King, Burrows et al. 2000, Hunt, Petroff et al. 2005). Interactions between these molecules 
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and inhibitory NK receptors appear to both limit NK cytotoxicity and promote decidual changes 
necessary for successful pregnancy (Ponte, Cantoni et al. 1999, Rajagopalan, Fu et al. 2001). 
 In addition to their lack of cytotoxicity towards trophoblast cells, uterine NK cells are 
critically important in directing trophoblast invasion and remodeling of the maternal spiral 
arteries.   Research in both mice and humans has provided evidence that uterine NK cells 
produce chemokines and angiogenic factors, including IL-8 and IP-10, that promote trophoblast 
invasion and spiral artery remodeling (Hanna, Goldman-Wohl et al. 2006, Zhang, Chen et al. 
2011).  However, it is important to note that the process of spiral artery remodeling is 
significantly different in the mouse as compared to the human; for example, the discovery of 
certain critical factors in the mouse (notably IFN-ϒ) are of unclear relevance to human biology 
(Apps, Sharkey et al. 2011).  
 In addition to uNK cells, one of the most critical immune cell types for a successful 
pregnancy is a class of T-cells, known as regulatory T-cells (T-regs), which function to promote 
tolerance of the fetus during pregnancy, and are critical for preventing autoimmune disease 
(Sakaguchi, Fukuma et al. 1985, Aluvihare, Kallikourdis et al. 2004, Sakaguchi, Sakaguchi et al. 
2011).  Early studies indicating the possible existence of a feto-tolerant class of T-cells showed 
that in female mice, multiparity imparts tolerance to male skin grafts.  This tolerance  could be 
transfered to virgin females by thymocytes and splenocytes, but not by bone marrow cells or 
sera, indicating that there was a group of T-cells responsible for maintaining tolerance (Smith 
and Powell 1977, Ruocco, Chaouat et al. 2014).  The eventual classification of “regulatory T-
cells,” which are phenotypically marked as CD4+CD25+Foxp3+, came with the discovery that 
their elimination leads to early-onset fulminant systemic autoimmune disease, which 
subsequently led to insights regarding the role of T-regs in maintaining maternal tolerance to the 
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fetus (Sakaguchi, Fukuma et al. 1985, Fontenot, Gavin et al. 2003, Hori, Nomura et al. 2003, 
Sakaguchi, Sakaguchi et al. 2011).   
 The role of regulatory T-cells in maintaining fetal tolerance was first demonstrated by 
experiments in mice showing that depletion of CD25+ T-cells resulted in allogeneic, but not 
syngeneic, pregnancy loss, in which fetuses differ genetically from the mother (Aluvihare, 
Kallikourdis et al. 2004, Darrasse-Jeze, Klatzmann et al. 2006).  Further studies revealed that 
induction of pregnancy-specific regulatory T-cell function may occur as early as copulation 
(Guerin, Moldenhauer et al. 2011) and studies in humans have shown a correlation between low 
numbers of uterine regulatory T-cells and unexplained infertility and recurrent pregnancy loss 
(Jasper, Tremellen et al. 2006, Arruvito, Sanz et al. 2007).  Studies in mice have indicated that 
the expansion of regulatory T-cells is not global, but rather that there is enhanced accumulation 
of regulatory T-cells with fetal specificity (Rowe, Ertelt et al. 2012).   
Recognition of fetal antigens by maternal T-cells has been shown to occur via the indirect 
antigen presentation pathway, whereby maternal antigen presenting cells process and present 
fetal antigens to maternal T-cells in the context of MHC molecules (Erlebacher, Vencato et al. 
2007, Guerin, Moldenhauer et al. 2011).  This is in contrast to the direct recognition pathway, 
whereby T-cells recognize a foreign MHC/peptide complex directly.  The two most widely 
studied types of maternal antigen presenting cells are macrophages and dendritic cells.  Both 
dendritic cells and macrophages are derived from circulating monocytes (Randolph, Beaulieu et 
al. 1998) and play important roles in the phagocytosis of foreign and cellular debris and cross-
presentation of antigens to immune cells.  Macrophages are markedly heterogeneous and may be 
classified as displaying either an M1 or M2 phenotype depending on the signals received from 
the surrounding immune environment (Stein, Keshav et al. 1992, Porcheray, Viaud et al. 2005).  
M1 macrophages are potent pro-inflammatory effector cells, whereas M2 macrophages are 
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immunomodulatory and are important for preventing excessive inflammation and contributing to 
homeostatic functions, including angiogenensis (Verreck, de Boer et al. 2004).  Decidual 
macrophages are predominantly M2 and express a high percentage of genes related to immune 
modulation and tissue remodeling, as compared to macrophages in the periphery (Gustafsson, 
Mjosberg et al. 2008).  Functionally, decidual macrophages have been shown to suppress T-cell 
activation as compared to peripheral macrophages, likely via production of Prostaglandin E2, IL-
10 and indoleamine deoxygenase (IDO) (Parhar, Yagel et al. 1989, Ishihara, Sullivan et al. 1991, 
Mizuno, Aoki et al. 1994, Munn, Shafizadeh et al. 1999, Heikkinen, Mottonen et al. 2003, 
McIntire, Ganacias et al. 2008).  Decidual macrophages have also been shown to be intimately 
involved with extravillous trophoblast remodeling of maternal spiral arteries, a process that is 
essential for successful human pregnancy (Smith, Dunk et al. 2009). 
 In comparison to decidual macrophages, which comprise approximately 20-25% of 
decidual leukocytes (which make up approximately 40% of all decidual cells), dendritic cells are 
much less abundant in the decidua, amounting to approximately 2% of all decidual leukocytes 
(Bulmer and Johnson 1984, Lessin, Hunt et al. 1988, Gardner and Moffett 2003).  Nonetheless, 
dendritic cells (DCs) are much more potent stimulators of T-cell responses than macrophages, 
and, similarly to macrophages, alterations in dendritic cell numbers and phenotype have been 
implicated in pre-eclampsia (Hart 1997, Banchereau and Steinman 1998, Steinman and 
Nussenzweig 2002, Darmochwal-Kolarz, Rolinski et al. 2003).  Numerous signals in the 
pregnant decidua, including cytokines produced by uterine NK cells and non-classical MHCs 
expressed by trophoblast cells, are thought to contribute to the development of a more 
tolerogenic decidual DC phenotype (Steck, Rieger et al. 2002, Ristich, Liang et al. 2005).  In 
mouse models, defects in DC function and reduced numbers of DCs in the decidua have been 
implicated in decreased pregnancy success, and the production of IL-10 by DCs has been 
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hypothesized to be critical for maintaining tolerance, both by promoting T-cell tolerance and by 
preventing terminal differentiation of decidual DCs (Fiorentino, Zlotnik et al. 1991, Groux, 
Bigler et al. 1996, Groux, Bigler et al. 1998, Levings, Sangregorio et al. 2001, Piccirillo and 
Shevach 2001, Gorczynski, Hadidi et al. 2002, Blois, Alba Soto et al. 2004, Blois, Alba Soto et 
al. 2004, Miranda, Litwin et al. 2006). 
 In addition to their direct involvement in pregnancy, DCs have been shown to be vitally 
important in regulating tolerance and rejection of transplanted tissues.  Studies in mice have 
shown that administration of immature dendritic cells prior to allograft transplantation is 
associated with decreased rejection and improved graft survival (Lu, Li et al. 1997, Lutz, Suri et 
al. 2000, Roelen, Schuurhuis et al. 2003, Sato, Yamashita et al. 2003, Peche, Trinite et al. 2005, 
Lan, Wang et al. 2006).  Given the historical view of the fetus as the “perfect allograft,” 
(Medawar 1954) strong evidence of the importance of DCs in transplantation success makes 
investigation of their role in pregnancy especially interesting and compelling.  In transplantation, 
DCs are involved with both direct (donor-derived DCs) and indirect (recipient-derived DCs) 
antigen presentation (Larsen, Morris et al. 1990, Auchincloss, Lee et al. 1993, Benichou, 
Valujskikh et al. 1999).  In pregnancy, indirect antigen presentation of fetal antigens has been 
proposed as the primary mechanism by which the maternal immune system is exposed to fetal 
antigens, most notably fetal minor histocompatibility antigens (Erlebacher, Vencato et al. 2007). 
MINOR HISTOCOMPATIBILITY ANTIGENS 
Definition of Minor Histocompatibility Antigens 
 Fetal antigens include both the major histocompatibility complex (MHC) and minor 
histocompatibility antigens (mHAgs) (Tarfuri, Alferink et al. 1995, Goulmy 2006).  MHC 
molecules are responsible for the presentation of foreign peptides to T-cells, which cannot 
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recognize the peptides directly, and also are mediators of transplant rejection via T-cell 
recognition of the foreign MHC. Minor histocompatibility antigens are derived from many 
different types of proteins and can elicit an immune response due to allelic differences between 
individuals (Goulmy 2006), typically single nucleotide polymorphisms (SNPs), insertions, 
deletions or presence of the antigen on the Y-chromosome (Tables 1.1&1.2).  
In order for mHAgs to be recognized by T-cells, the antigens must be presented to T-cells 
in the context of specific class I and/or class II MHC molecules (Tables 1.1&1.2).  MHC Class II 
molecules bind to the T cell receptor of CD4+ T-cells and are primarily expressed on the surface 
of antigen presenting cells, most notably dendritic cells, macrophages and B cells. MHC Class I 
molecules bind to the T-cell receptor of CD8+ T-cells and are present on the surface of most 
nucleated cells where they can present endogenous antigens and facilitate self vs. non-self 
discrimination by the immune system.  In addition, MHC Class I is critical for the indirect 
antigen presentation pathway, in which antigen presenting cells, typically dendritic cells, 
phagocytose exogenous material and process it for cross-presentation via the MHC Class I 
molecule on their cell surface (Bevan 1976, Bevan 1976, Rodriguez, Regnault et al. 1999).  This 
allows recognition of antigens coming from tissues lacking class I MHC molecules, including 
placental trophoblast cells, by CD8+ T-cells, (Petroff 2005). 
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Table 1.1: Y-Chromosome Encoded Minor Histocompatibility Antigens 
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Minor Antigen Gene HLA Peptide Expression (mRNA)2 Ref. 
A1/HY DFFRY A*0101 IVDCLTEMY Ubiquitous (Pierce, Field et 
al. 1999) 
A2/HY KDM5D A*0201 FIDSYICQV Ubiquitous (Ofran, Kim et al. 2010) 
B52/HY RPS4Y1 B*5201 TIRYPDPVI Ubiquitous (Ivanov, Aarts et al. 2005) 
B60/HY UTY B*60 RESEEESVSL Ubiquitous (Vogt, Goulmy 
et al. 2000) 
B7/HY KDM5D B*0702 SPSVDKARAEL Ubiquitous 
(Wang, 
Meadows et al. 
1995) 
B8/HY UTY B*8 LPHNHTDL Ubiquitous (Warren, Gavin 
et al. 2000) 
TMSB4Y/A33 TMSB4Y A*3303 EVLLRPGLHFR Ubiquitous (Torikai, 
Akatsuka et al. 
2004) 
UTY139-147 UTY A*2402 YYNAFHWAI Ubiquitous (Mortensen, 
Rasmussen et al. 
2012) 
DQ5/HY DDX3Y DQB1*05 HIENFSDIDMGE Ubiquitous 
(Vogt, van den 
Muijsenberg et 
al. 2002) 
DRB1/HY DDX3Y DRB1*1501 SKGRYIPPHLR Ubiquitous (Zorn, Miklos et al. 2004) 
DRB3/HY RPS4Y1 DRB3*0301 VIKVNDTVQI Ubiquitous 
(Spierings, 
Vermeulen et al. 
2003) 
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Table 1.2: Autosomally Encoded Minor Histocompatibility Antigens 
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1 Immunogenic amino acid differences are shown in bold and underlined. Peptides generated by alternative splicing 
are shown in bold. Peptides generated by a frameshift mutation are shown in italics. Peptides generated a 
translational termination codon are shown in italics and underlined. Peptides generated by a deletion are underlined. 
2 Tissue expression information was obtained from biogps.org as well as the listed references.  	  
Minor 
Antigen Gene HLA Peptide
1 Expression (mRNA)2 Ref. 
ACC-1 BCL2A1 A*2402 DYLQYVLQI, DYLQCVLQI Restricted 
(Bleakley and Riddell 2011), 
(Kawase, Nannya et al. 
2008), (Akatsuka, Nishida et 
al. 2003) 
ACC-2 BCL2A1 B*4403 KEFEDDIINW Restricted 
(Bleakley and Riddell 2011), 
(Kawase, Nannya et al. 
2008), (Akatsuka, Nishida et 
al. 2003) 
ACC-4 Cathepsin H A*3101 ATLPLLCAR Restricted (Torikai, Akatsuka et al. 2006) 
ACC-5 Cathepsin H A*3303 WATLPLLCAR Restricted (Torikai, Akatsuka et al. 2006) 
ACC-6 HMSD B*4402, B*4403 MEIFIEVFSHF  Restricted 
(Kawase, Akatsuka et al. 
2007) 
CD19 CD19 A1*05, B1*02, DQ WEGEPPCLP Restricted 
(Spaapen, Lokhorst et al. 
2008) 
HA3 Lbc/AKAP13 A*0101 VTEPGTAQY Ubiquitous (Spierings, Brickner et al. 2003) 
HA1 HMHA1 
A*0201, 
A*0206, 
B*60, 
B*40012 
VLHDDLLEA, 
KECVLHDDL Restricted 
(den Haan, Meadows et al. 
1998), (Mommaas, Kamp et 
al. 2002, Torikai, Akatsuka et 
al. 2007, Bleakley and 
Riddell 2011) 
HA2 MYO1G A*0201 YIGEVLVSV Restricted 
(de Bueger, Bakker et al. 
1992, den Haan, Sherman et 
al. 1995, Pierce, Field et al. 
2001) 
HA8 KIAA0020 A*0201 RTLDKVLEV Ubiquitous 
(Brickner, Warren et al. 
2001, Bleakley and Riddell 
2011) 
HB-1 HMHB1 B*4402, B*4403 
EEKRGSLHVW, 
EEKRGSLYVW Restricted 
(Dolstra, Fredrix et al. 1997, 
Dolstra, Fredrix et al. 1999, 
Dolstra, de Rijke et al. 2002) 
HEATR1 HEATR1 B*0801 ISKERAEAL Ubiquitous (Bleakley, Otterud et al. 2010) 
HER2_1170 HER2 A*0201 GCC Restricted (Wenandy, Kollgaard et al. 2009) 
LB-ADIR-1F ADIR/TOR3A A*0201 SVAPALALFPA Restricted (van Bergen, Kester et al. 2007) 
      
LB-
APOBEC3B-
1K 
APOBEC3B B*0702 
KPQYHAEMCFL, 
KPQYHAEMCF, 
KPQYHAEMC 
Restricted (Van Bergen, Rutten et al. 2010) 
LB-
ARHGDIB-
1R 
ARHGDIB B*0702 
LPRACWREA, 
LPRACWREAR, 
LPRACWREART 
Restricted (Van Bergen, Rutten et al. 2010) 
LB-BCAT2- BCAT2 B*0702 QPRRALLFVIL, Ubiquitous (Van Bergen, Rutten et al. 
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1R QPRRALLFVI 2010) 
LB-EBI3-1I EBI3 B*0702 
RPRARYYIQVA, 
RPRARYYIQV, 
RPRARYYIQ, 
AVRPRARYYI 
Restricted (Van Bergen, Rutten et al. 2010) 
LB-ECGF1-1 ECGF1 B*0702 RPHAIRRPLAL Restricted (Slager, Honders et al. 2006) 
LB-ERAP1-
1R ERAP1 B*0702 HPRQEQIALLA Ubiquitous 
(Van Bergen, Rutten et al. 
2010) 
LB-GEMIN4-
1V GEMIN4 B*0702 FPALRFVEV Restricted 
(Van Bergen, Rutten et al. 
2010) 
LB-NUP133-
1R NUP133 B*4001 SEDLILCRL Restricted 
(Griffioen, Honders et al. 
2012) 
LB-PDCD11-
1F PDCD11 B*0702 
GPDSSKTFLCL, 
GPDSSKTFL Ubiquitous 
(Van Bergen, Rutten et al. 
2010) 
LB-PRCP-1D PRCP A*0201 FMWDVAEDLKA, FMWDVAEDL Ubiquitous 
(Van Bergen, Rutten et al. 
2010) 
LB-SON-1R SON B*4001 SETKQRTVL Restricted (Griffioen, Honders et al. 2012) 
LB-SSR1-1S SSR1 A*0201 SLAVAQDLT Restricted (Van Bergen, Rutten et al. 2010) 
LB-SWAP70-
1Q SWAP70 B*4001 MEQLEQLEL Restricted 
(Griffioen, Honders et al. 
2012) 
LB-TRIP10-
1EPC TRIP10 B*4001 GEPQDLCTL Ubiquitous 
(Griffioen, Honders et al. 
2012) 
LB-WNK1-1I WNK1 A*0201 TLSPEIITV Ubiquitous (Van Bergen, Rutten et al. 2010) 
LRH-1 P2RX5 B*0702 TPNQRQNVC  Restricted 
(de Rijke, van Horssen-
Zoetbrood et al. 2005, 
Overes, de Rijke et al. 2008, 
Norde, Overes et al. 2009) 
PANE1 
(CTL-7A7) CENPM A*0301 RVWDLPGVLK  Restricted (Brickner, Evans et al. 2006) 
SLC1A5 SLC1A5 B*4002 AEATANGGLAL Restricted (Bleakley and Riddell 2011), (Kamei, Nannya et al. 2009) 
SP110 SP110 A*0301 SLPRGTSTPK Restricted (Warren, Vigneron et al. 2006) 
UGT2B17 UGT2B17 A*2902, B*4403 AELLNIPFLY  Ubiquitous 
(Murata, Warren et al. 2003, 
Terakura, Murata et al. 2007) 
UGTB17  A*0206 CVATMIFMI  Ubiquitous (Kamei, Nannya et al. 2009) 
UTA2-1 C12orf35 A*0201 QLLNSVLTL Restricted (Oostvogels, Minnema et al. 2012) 
LAMA1 LAMA1 DRB1*0301 LLILRAIPKGIRDKGAK Ubiquitous 
(Stumpf, van der Meijden et 
al. 2009, Stone, Rieck et al. 
2012) 
LB-LY75-1K LY75 DRB1*1301 GITYRNKSLM Restricted (Stumpf, van der Meijden et al. 2009) 
ZNF544 ZNF544 DRB1*0301 KQNSAFINDEKNGADGK Ubiquitous 
(Stumpf, van der Meijden et 
al. 2009, Stone, Rieck et al. 
2012) 
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The Discovery of Minor Histocompatibility Antigens 
The role of mHAgs in eliciting an immune response has been demonstrated using 
transplantation studies.  mHAgs were first discovered due to their role in modulating graft 
rejection and graft-versus-host disease in HLA-matched transplant recipients (Goulmy, 
Termijtelen et al. 1976, Goulmy, Gratama et al. 1983, Goulmy, Schipper et al. 1996).  The first 
mHAg, a member of the HY family of mHAgs, was discovered following the rejection of 
transplanted HLA-matched bone marrow cells from a male donor by a female recipient (Goulmy, 
Termijtelen et al. 1976).  It was shown that cytotoxic T-lymphocytes (CTLs) isolated from the 
recipient’s blood had the capacity to lyse HLA-matched male cells, suggesting that the immune 
target was encoded by the Y-chromosome (Goulmy, Termijtelen et al. 1977).  Shortly after this 
discovery, the same group of investigators found that mHAgs could contribute to graft-versus-
host disease, as donor CTLs can target and lyse recipient cells expressing a Y-chromosome-
encoded antigen (Goulmy, Gratama et al. 1983). 
Since these original discoveries, fifty unique mHAgs derived from forty-three genes have 
been found (Tables 1.1&1.2). These mHAgs arise from SNPs, presence on the Y-chromosome, 
deletions, insertions, frameshift mutations, nonsense mutations and splice variants.  mHAgs are 
encoded on the Y-chromosome (Table 1.1) and on many autosomes (Table 1.2).  Expression of 
some mHAgs is restricted to hematopoietic cells or a select group of tissues, whereas other 
mHAgs are expressed ubiquitously.  Given the numerous potential HLA combinations as well as 
the vast number of SNPs present in the population, it is likely that many more mHAgs exist that 
have not yet been identified. 
One of the major constraints on research involving mHAg-specific CD8+ T-cells is their 
relative rarity in both peripheral blood and at their target sites.  Research using multimeric MHC 
reagents (MHC multimers) has estimated the prevalence of HY-specific T-cells in peripheral 
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blood following multiple pregnancies with male babies at 0.0001% to 0.03% of the total CD8+ 
T-cell population (Piper, McLarnon et al. 2007).  MHC multimers are complexes comprised of 
2-10 or more linked peptide-MHC ligands that can bind T-cells through the T cell receptor in an 
antigen-specific manner (Altman, Moss et al. 1996, Batard, Peterson et al. 2006).  This allows 
for identification and quantification of T-cells specific for a particular antigen.  However, in 
order to identify and characterize mHAg-specific T-cells, it is often necessary to expand the ex 
vivo population using cytokines and antigen, thus potentially altering the functionality of these 
cells both as a consequence of antigen/cytokine exposure and as a result of multimer-binding 
itself (Lyons, Roszkowski et al. 2006, Laugel, van den Berg et al. 2007, Chattopadhyay, 
Melenhorst et al. 2008).   Therefore, caution should be used when assessing the in vivo 
functional significance of these cells ex vivo. 
Minor Histocompatibility Antigens and Transplantation Outcomes 
 Immune responses to mHAgs in the context of transplantation can have both beneficial 
and detrimental consequences for the patient.  mHAgs appear to be the primary mediator of 
graft-versus-host disease in HLA-matched transplantations (Goulmy, Termijtelen et al. 1976, 
Goulmy, Termijtelen et al. 1977, Goulmy, Gratama et al. 1983, Goulmy, Schipper et al. 1996), 
leading to the need for increased immunosuppression as well as other negative health outcomes 
including dermatitis, kidney failure and even death.  However, mHAg specific donor T-cells can 
also play an important role in mediating graft-versus-leukemia effects or graft-versus-tumor 
effects (Marijt, Heemskerk et al. 2003, Goulmy 2004), which can significantly prolong the lives 
of patients who receive transplantations to treat various types of cancers and can help ensure 
longer periods of disease-free survival.   
 Recently researchers have proposed that modulation of T-cells specific for mHAgs may 
provide a unique opportunity for augmenting graft-versus-leukemia and graft-versus-tumor 
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effects (Kircher, Stevanovic et al. 2002, Warren, Fujii et al. 2010), thus providing a potential 
avenue for increasing disease-free survival while subsequently reducing the need for 
immunosuppressive drugs.  In this paradigm, donor T-cells specific for a particular mHAg whose 
expression is restricted to leukemic/tumor cells are isolated from the recipient’s blood following 
the initial transplant and expanded ex vivo (Kircher, Stevanovic et al. 2002, Warren, Fujii et al. 
2010).  These T-cells are then re-infused into the recipient following a disease relapse.  A 
preliminary clinical trial targeting the mHAg HA-1 showed some success in treating disease 
relapse, although a high percentage of the participants experienced serious side effects (Warren, 
Fujii et al. 2010).  
MINOR ANTIGENS IN PREGNANCY 
One important feature of the placenta is the release of large amounts of trophoblast debris 
into the maternal blood supply during pregnancy.  This release has been postulated to result from 
biological functions of the trophoblast, particularly the continual renewal of the 
syncytiotrophoblast layer, which occurs via fusion of the underlying cytotrophoblast and release 
of apoptotic or necrotic syncytiotrophoblast into the periphery (Huppertz, Frank et al. 1998, 
Huppertz, Kaufmann et al. 2002, Huppertz, Kingdom et al. 2003).  As a consequence of this 
continual syncytiotrophoblast renewal, placental debris containing fetal mHAgs could be 
released into the maternal blood stream, phagocytosed and processed by maternal dendritic cells 
and presented to maternal CD8+ T-cells, thus eliciting a maternal immune response to the fetus 
(Erlebacher, Vencato et al. 2007).  
Histocompatibility Antigen 1 (HA-1) is a widely studied mHAg that has been found on 
Hofbauer and trophoblast cells in the human placenta as outlined in Chapter 2 (Holland, 
Linscheid et al. 2012), and immune recognition of HA-1 has been shown to be important for 
bone marrow transplantation outcomes (Goulmy, Schipper et al. 1996).  The antigenic peptide 
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that arises from HA-1 is the result of a single nucleotide polymorphism (SNP) between the non-
immunogenic peptide (KECVLRDDLLEA) and the immunogenic peptide 
(KECVLHDDLLEA)(den Haan, Meadows et al. 1998).  The immunogenic peptide can be 
presented in the context of at least four different Class I MHCs, including HLA-A*0201 (Table 
1.2). As a result of the immunogenic SNP, the binding affinity of the HA-1H peptide to the HLA-
A*0201 peptide binding groove on antigen presenting cells (APCs) is increased (Nicholls, Piper 
et al. 2009), thus leading to an immunogenic peptide that can be recognized by HLA-A*0201 
restricted T-cells.  
Recognition of the HA-1 antigen can occur in the pathological situations of graft-versus-
host disease and graft rejection, as well as in the physiological situation of pregnancy.  In graft-
versus-host disease, donor HLA-A*0201-restircted T-cells can recognize the immunogenic 
peptide in the antigen binding groove, thus eliciting an immune response targeting the recipients’ 
tissues (Goulmy, Schipper et al. 1996, Mutis, Gillespie et al. 1999).  Graft rejection occurs when 
recipient HLA-A*0201-restricted T-cells respond to and target the immunogenic peptide on the 
graft itself (Krishnan, Higgins et al. 2007).  In the case of pregnancy, maternal HLA-A*0201 
restricted T-cells can recognize fetal immunogenic HA-1, as evidenced by the presence of HA-1-
specific T-cells in maternal blood following pregnancy (Verdijk, Kloosterman et al. 2004).  The 
source of fetal HA-1 could be fetal cells that cross the placenta and enter the maternal blood 
stream and organs (microchimerism), cells and vesicles released from the placenta, or both.  In 
each of the above situations, the T cells responding to the antigen are both restricted by HLA-
A*0201 and are derived from an individual lacking the immunogenic HA-1H allele.  
The probability of this interaction varies depending on the population frequency of both 
mHAg alleles and the MHC(s) restricting the immunogenic peptide.  In the case of HA-1, the 
population frequency of HA-1H in a North American Caucasian population is approximately 
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44% (Tseng, Lin et al. 1998) and the likelihood that an individual will possess one of the four 
MHCs capable of presenting HA-1H (A*0201, A*0206, B*60 or B*40012) (den Haan, Meadows 
et al. 1998, Mommaas, Kamp et al. 2002, Torikai, Akatsuka et al. 2007, Bleakley and Riddell 
2011) is at least 48.1% (Gonzalez-Galarza, Christmas et al. 2011).  Consequently, the possibility 
that two individuals will be discordant for HA-1 and that the individual with the non-
immunogenic form of HA-1 will have the correct MHC to present the immunogenic peptide is 
approximately 11.9%: 
P(HA1H) X P(HA1R) X P(MHC) = 44% X 56% X 48.1% = 11.9% 
Thus, histoincompatibility between individuals is far from a rare event: given the large number 
of mHAgs discovered so far, it is very likely that for a given pregnancy, there will be at least one 
if not many fetal mHAgs that could be recognized by the mother’s immune system.  
The role of mHAgs in pregnancy was first considered due to a finding by a number of 
researchers that parous female donors are more likely to elicit graft-versus-host disease in 
transplant recipients than non-parous or male donors (Flowers, Pepe et al. 1990, Gratwohl, 
Hermans et al. 2001, Kollman, Howe et al. 2001, Randolph, Gooley et al. 2004, Takami, 
Sugimori et al. 2004, Loren, Bunin et al. 2006). These researchers hypothesized that this was due 
to the formation of mHAg-specific T-cells in the mother during or immediately following 
pregnancy.  This postulate has been confirmed in mice, where researchers have found that CD4+ 
and CD8+ T-cells can develop in response to the endogenous fetal antigen, HY (James, Chai et 
al. 2003).  Other mouse studies have demonstrated that the presentation of fetal antigens to 
maternal T-cells can begin as early as copulation and that paternal antigens can be found in the 
seminal fluid (Robertson 2005, Moldenhauer, Diener et al. 2009, Robertson, Guerin et al. 2009).  
In women, a number of studies have found T-cells specific for at least three mHAgs, HA-1, HA-
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2 and HY, following pregnancy (Verdijk, Kloosterman et al. 2004, Piper, McLarnon et al. 2007, 
van Halteren, Jankowska-Gan et al. 2009).  These T-cells have been found up to twenty-two 
years following delivery of the baby, suggesting that at least a small cohort of these cells can 
persist for long periods of time (Verdijk, Kloosterman et al. 2004).  It is thought that during 
normal pregnancy these cells are prevented from attacking the placenta and fetus via numerous 
tolerogenic mechanisms, thus allowing for a successful pregnancy.  A disruption of this tolerance 
could have significant effects on clinical outcome, as is evidenced by the links between mHAg 
expression, recognition by the maternal immune system and secondary recurrent miscarriage 
(Nielsen, Steffensen et al. 2009, Christiansen, Steffensen et al. 2010, Ooi, Russell et al. 2011). 
A recent study has confirmed that HY-specific CD8+ T-cells are elicited in maternal 
blood during human pregnancy with a male fetus, and not necessarily as a result of parturition 
(Lissauer, Piper et al. 2012).  These cells retained their proliferative capacity as well as their 
ability to lyse target cells and produce IFN-γ in vitro.  The authors proposed that this indicates 
that fetus-specific T-cells are not completely deleted during pregnancy, as previously suggested 
(Tafuri, Alferink et al. 1995, Jiang and Vacchio 1998, Vacchio and Hodes 2003).   
As to why fetal antigen-specific T-cells elicited during pregnancy do not normally cause 
rejection of the fetus, there are at least three non-mutually exclusive possibilities.  The first is 
that the T-cells are incompletely activated during pregnancy, and thus lack effector function in 
vivo. The second hypothesis is that other cell types, most notably regulatory CD4+ T-cells, 
prevent rejection of the fetus by promoting local and systemic tolerance, as indicated by the fact 
that regulatory T-cells are required for the success of allogeneic pregnancies in mice (Aluvihare, 
Kallikourdis et al. 2004, Kahn and Baltimore 2010, Shima, Sasaki et al. 2010).  The third 
hypothesis is that the fetal antigen-specific T-cells are unable to traffic to the maternal-fetal 
interface, and thus cannot mediate direct rejection of the fetus.  This hypothesis is supported by 
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recent work that showed an inability of maternal T-cells to traffic into the decidua during 
pregnancy as a result of epigenetic modifications leading to the loss of expression of specific 
chemokine genes by the decidual stromal cells (Nancy, Tagliani et al. 2012).  In addition, the 
highly restricted expression of class I MHC molecules by placental trophoblast (Petroff 2005) 
most likely renders antigen-specific T-cells wholly or largely unable to target the placenta 
directly. 
Minor Histocompatibility Antigens are Expressed in the Placenta  
There are at least two likely sources of fetal mHAgs during pregnancy: the placenta and 
fetal cells trafficking from the fetus into the maternal blood supply (microchimerism) (Evans, 
Lambert et al. 1999, Adams, Lambert et al. 2003, Khostrotehrani and Bianchi 2005, Nelson 
2008).  In Chapter 2, we show that at least six fetal mHAgs are expressed in human placental 
lysate, fetal cord blood and, most significantly, purified trophoblast cells.  These findings 
provide strong evidence that the human placenta is one likely source of maternal immune 
exposure to fetal antigens during pregnancy (Holland, Linscheid et al. 2012).  The close physical 
relationship between the syncytiotrophoblast, which covers the outer surface of the placenta, and 
the maternal blood supply, which surrounds the placenta, provides a likely avenue for maternal 
immune exposure to fetally-derived mHAgs (Chamley, Chen et al. 2011, Petroff 2011).  In 
addition to this close physical proximity, the syncytiotrophoblast undergoes a continual renewal 
process wherein the underlying cytotrophoblast fuses to give rise to the multinucleated 
syncytiotrophoblast and the excess, dead or damaged syncytiotrophoblast debris is released into 
the maternal blood space.  This results in a large volume of fetally-derived placental debris being 
released into the maternal blood supply during pregnancy.  
In addition to the larger, shed debris, there is growing evidence that 
microvesicles/nanoparticles and exosomes are actively secreted from the surface of the placenta 
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into the maternal blood space during pregnancy (Taylor, Akyol et al. 2006, Redman and Sargent 
2007, Burton and Jones 2009). The total volume of this deported material has been estimated at 
1g/day for the term placenta.  Most of this placental material is easily cleared by the maternal 
system during normal pregnancy, but large, multinucleated syncytiotrophoblast debris has been 
found in the lungs of women who died of eclampsia (Attwood and Park 1961, Ilke 1964, 
Huppertz, Frank et al. 1998, Huppertz, Kaufmann et al. 2002). Given the robust expression of 
fetal mHAgs in the syncytiotrophoblast and the large amount of syncytiotrophoblast debris that 
is released into the maternal system, it seems highly likely that the placenta serves as a source of 
fetal antigens during pregnancy. 
Clinical implications of Fetal Antigens 
 Of particular interest is the role that the mHAgs expressed in syncytiotrophoblast debris 
may play in the development or manifestation of numerous pregnancy complications. In Chapter 
3, we show that expression of at least one mHAg, HA-1, is upregulated in preeclamptic placentas 
as compared to normotensive control placentas (Linscheid C and Petroff MG, in revision).  We 
hypothesize that this increase in HA-1 expression may contribute to disruption of the overall 
immunologic balance by increasing the antigenic load encountered by the maternal immune 
system in the context of increased proinflammatory cytokine release, a feature of preeclampsia 
and other pregnancy complications (Kronborg, Gjedsted et al. 2011).  Specifically, the increased 
release of placental debris that is characteristic of preeclampsia (Attwood and Park 1961, Ilke 
1964, Huppertz, Frank et al. 1998, Knight, Redman et al. 1998, Huppertz, Kaufmann et al. 2002, 
Goswami, Tannetta et al. 2006, Chen, Huang et al. 2012), compounded by the upregulation of 
HA-1 expression in the deported syncytiotrophoblast, combined with an increase in 
inflammatory cytokines, most notably TNF-α and IL-6 (Kronborg, Gjedsted et al. 2011, Lee, 
Romero et al. 2012), could alter the phenotype of both the dendritic cells that are presenting 
	   24	  
antigen to maternal T-cells as well as the T-cells themselves to promote anti-fetal immune 
responses, either during the current pregnancy or during subsequent pregnancies. 
 Dysfunction of the maternal immune system has been implicated in a number of other 
pregnancy complications, including secondary recurrent miscarriage.  Epidemiologic evidence 
suggests that the recognition of fetal mHAgs may play an important role in secondary recurrent 
miscarriage, particularly if the preceding live birth was a male baby (Nielsen, Steffensen et al. 
2009, Christiansen, Steffensen et al. 2010, Ooi, Russell et al. 2011).  Specifically, Christiansen 
et. al. have found that women who experience secondary recurrent miscarriage are more likely 
than the general population to possess the specific Class II MHC allele that  presents Y-
chromosome-encoded mHAgs and that secondary recurrent miscarriage is more likely to occur in 
women who have previously given birth to a male baby (Nielsen, Steffensen et al. 2009, 
Christiansen, Steffensen et al. 2010). This presents the possibility that the development of 
secondary recurrent miscarriage is related to the generation of a maternal immune response 
specific for Y-chromosome-encoded antigens during the preceding, successful pregnancy.  One 
theory regarding this phenomenon is that pregnancy complications late in the first pregnancy 
may disrupt the tolerogenic environment required for maintaining maternal immune tolerance 
towards the fetus and that this disruption contributes to the failure of subsequent pregnancies, 
especially those with a male fetus (Christiansen, Steffensen et al. 2011).  It is important to note 
that disruption of the tolerogenic environment and maternal T-cell recognition of both autosomal 
and Y-chromosome encoded fetal mHAgs may contribute to many cases of idiopathic infertility 
as well as numerous pregnancy complications.  
 A recent paper by Rowe et. al. (2012) found that in mice there is a substantial expansion 
of fetal-specific regulatory T-cells (T-regs) during primary and subsequent pregnancies (Rowe, 
Ertelt et al. 2012).  The authors also found that resorption rates were significantly decreased in 
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second pregnancies, due to a rapid expansion of a memory population of fetal-antigen specific T-
regs that were formed during the first pregnancy.  The authors propose that this mechanism may 
help explain why preeclampsia is more common in primiparous women as well as providing 
some insights as to why preeclampsia risk increases with interpregnancy interval.  The role of 
these fetus-specific T-regs in secondary recurrent miscarriage is unclear, but it seems possible 
that a failed expansion of fetal-specific T-regs during the first pregnancy or a loss of fetal-
specific T-regs between the first and second pregnancies could contribute to the manifestation of 
secondary recurrent miscarriage. 
MICROPARTICLES RELEASED FROM THE PLACENTA MAY INFLUENCE 
MATERNAL IMMUNE CELLS 
Description of Microparticles 
 A wide variety of vesicles/particles are released from cells, including cellular debris, 
microvesicles and exosomes.  Cellular debris are much larger than microvesicles or exosomes 
and are generally the result of surface epithelial shedding or cell death (Thery, Boussac et al. 
2001).  Microvesicles are generally derived from the surface membrane of the cell of origin, 
whereas exosomes are smaller (50-150nm) and are derived from the late multivesicular 
endosome. 
Discovery and Classification of Exosomes 
 Exosomes were first discovered independently by two research groups studying 
reticulocytes using electron microscopy and pulse-chase experiments (Harding, Heuser et al. 
1983, Pan, Teng et al. 1985).  Exosomes remained minimally studied until researchers found that 
exosomes secreted from B cells and dendritic cells could have potent immunomodulatory effects 
(Raposo, Nijman et al. 1996, Zitvogel, Regnault et al. 1998).  In addition to reticulocytes, 
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dendritic cells and B cells, exosomes have been isolated from numerous cell lines, cancer tissues, 
cultured primary cells and bodily fluids, including T-cells, NK cells, macrophages, cultured 
trophoblast cells and maternal blood during pregnancy (Chaput, Flament et al. 2006, Iero, 
Valenti et al. 2008, Cocucci, Racchetti et al. 2009, Hedlund, Stenqvist et al. 2009, Chen, Liu et 
al. 2010, Atay, Gercel-Taylor et al. 2011, Chaput and Thery 2011, Dragovic, Gardiner et al. 
2011, Huotari and Helenius 2011, Clifton, Stark et al. 2012, Filipazzi, Burdek et al. 2012).  
Currently, exosomes are defined as cup-shaped vesicles (visualized using electron microscopy) 
that measure 50-150nm in diameter with a density between 1.13-1.19 g/ml.  Several different 
surface markers are currently used to identify exosomes, including various Annexins, Alix, CD9, 
CD63 and CD81.  Given the relatively short period of time that exosomes have been extensively 
studied, there is still some debate about what parameters qualify a vesicle as an exosome and the 
methods by which exosomes should be ideally obtained (Chaput and Thery 2011).   
 Exosomes originate from multivesicular bodies/late endosomes (subsequently referred to 
as MVBs) and involve the packaging of exosomes for secretion rather than for degradation by 
the lysosome.  Several components of cellular machinery have been identified as important for 
this process, most notably the ESCRT (endosomal sorting complex required for transport) 
proteins Alix and Tsg101 and the RAB family of small GTPases (Thery, Boussac et al. 2001, 
Savina, Fader et al. 2005, Hsu, Morohashi et al. 2010, Ostrowski, Carmo et al. 2010).  The 
ESCRT complex is involved with targeting mono-ubiquitinated proteins to MVBs, where they 
can either be packaged into exosomes or undergo degradation in the lysosome.  However, it is 
important to note that not all proteins found in exosomes are ubiquitinated, suggesting alternate 
mechanisms for the inclusion of different cellular materials in exosomes (Katzmann, Stefan et al. 
2003, Skinner, O'Neill et al. 2009, Wollert and Hurley 2010).  The RAB GTPases are important 
for trafficking of exosomes to the cell surface, fusion of the multivesicular body with the plasma 
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membrane and secretion of exosomes into the extracellular environment.  Several different RAB 
proteins have been identified as important for the biogenesis of exosomes, including Rab11, 
Rab27 and Rab35, but no single protein has been found to be critical for exosome production and 
secretion (Savina, Fader et al. 2005, Hsu, Morohashi et al. 2010, Ostrowski, Carmo et al. 2010).  
This provides unique challenges for the study of the functions of exosomes, given that complete 
elimination of exosomes from a particular biological system – and the possible consequences of 
such elimination - have not yet been demonstrated.  However, numerous studies, primarily in 
cancer biology, have found potent immune effects for exosomes derived from a variety of 
sources (Bobrie, Colombo et al. 2011). 
Functions of Exosomes 
 In addition to proteins involved in their formation, exosomes contain a wide variety of 
proteins, mRNAs and miRNAs, some of which are found in most exosomes studied from a wide 
variety of biological sources, and others that appear to be more closely related to the cell of 
origin.  For example, syncytiotrophoblast-derived exosomes express a number of highly-
conserved exosome markers, including CD9, CD63, CD81 and LAMP-1 as well as a variety of 
proteins closely associated with the placenta, including B7-H1, B7-H3 and placental alkaline 
phosphatase (Mincheva-Nilsson and Baranov 2010, Kshirsagar, Alam et al. 2012, Mincheva-
Nilsson and Baranov 2014).  Notably, expression of HLA-G was only seen in exosomes from 
placental explants and cytotrophoblast cells and this expression was lost when the exosomes 
were derived from syncytialized trophoblast cells (Kshirsagar, Alam et al. 2012).  This loss of 
expression is consistent with earlier research indicating the expression of membrane-bound 
HLA-G on extravillous trophoblast cells, but not the syncytiotrophoblast (Yelavarthi, Fishback et 
al. 1991, Ishitani, Sageshima et al. 2003, Morales, Pace et al. 2003). 
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 Research regarding the role of exosomes in pregnancy is relatively new, but a number of 
studies focusing on the immune effects of cancer-derived exosomes provide compelling evidence 
the exosomes can have potent immunomodulatory effects.  Numerous tumor-derived exosomes 
have been shown to express the pro-apoptotic molecules FasL and TRAIL, contributing to 
apoptosis of tumor-specific T-cells and tumor evasion of the adaptive immune response 
(Andreola, Rivoltini et al. 2002, Martinez-Lorenzo, Anel et al. 2004, Abusamra, Zhong et al. 
2005, Huber, Fais et al. 2005, Bergmann, Strauss et al. 2009).  In addition to promoting 
apoptosis of cytotoxic CD8+ T-cells, cancer-derived exosomes appear to increase the number of 
regulatory CD4+CD25+Foxp3+ T-cells, potentially contributing to increased tolerance of tumor 
cells (Szajnik, Czystowska et al. 2010, Wada, Onishi et al. 2010).  This increase in regulatory T-
cells is mediated, in large part, by TGF-β, which is also vitally important for establishing 
pregnancy, suggesting potentially overlapping roles for exosomal proteins in both tumor biology 
and pregnancy (Robertson, Ingman et al. 2002). 
 Recent studies on pregnancy-associated exosomes have indicated that some pregnancy 
complications, including pre-term birth and preeclampsia, are associated with alterations in 
exosome number and function.  Specifically, the concentration of exosomes in the plasma of 
women who delivered prematurely was lower than in women who delivered at term and 
exosomes from premature delivers were less effective at promoting a tolerogenic T-cell 
phenotype as compared to those isolated from women who delivered at term, as defined by 
inhibition of IL-2 production by activated T-cells (Sabapatha, Gercel-Taylor et al. 2006, Taylor, 
Akyol et al. 2006).  In addition, placental exosomes isolated from maternal blood decreased 
expression of NKG2D receptors on CD8+ T-cells, leading to impaired receptor-mediated 
cytotoxicity (Mincheva-Nilsson, Nagaeva et al. 2006). 
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 The role of placental exosomes in pre-eclampsia is less clear, with some groups reporting 
increased and other groups reporting decreased exosome/microparticle production in pre-
eclamptic pregnancies as compared to controls.  These differences are likely related to 
differences in how exosomes/microparticles were isolated and defined and the markers used to 
identify the exosomes in maternal plasma (Harlow, Brown et al. 2002, VanWijk, Nieuwland et 
al. 2002, Bretelle, Sabatier et al. 2003, Gonzalez-Quintero, Jimenez et al. 2003, Holthe, Lyberg 
et al. 2005, Meziani, Tesse et al. 2006, Lok, Nieuwland et al. 2007).  Some researchers have 
proposed opposite effects for microparticles and exosomes in pre-eclamptic pregnancies, with 
microparticles associated with increased endothelial dysfunction, hypercoagulability and 
increased maternal inflammation, and exosomes associated with the opposite effects (Toth, Lok 
et al. 2007).  
 However, recent work on the role of exosomes derived from the first trimester 
trophoblast cell line, Swan71, indicates that placental exosome-associated fibronectin may 
increase maternal inflammation by upregulating IL-1β production by macrophages (Atay, 
Gercel-Taylor et al. 2011, Atay, Gercel-Taylor et al. 2011).  There is clearly a lack of research on 
the similarities and differences between placental exosomes and syncytiotrophoblast 
microparticles, both with respect to vesicle content and their effects on maternal immune cells. 
RESEARCH OBJECTIVES 
Pregnancy presents numerous challenges to the maternal immune system, which must 
simultaneously tolerate the semiallogeneic fetus and protect both the mother and fetus from 
potentially life-threatening infections.  The mechanisms by which this is achieved are varied and 
include the recognition of fetal antigens by maternal T-cells.  There are a number of studies to 
suggest that this process has important implications for both maternal and fetal health.  
Developing a better understanding of the cellular interactions that mediate this tolerance may 
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contribute to both the development of more successful transplantation protocols as well as the 
prevention and/or treatment of common pregnancy complications.  
 In this Chapter 2 of this work we investigate the expression of fetal antigens in the human 
placenta and the possibility that the placenta may act as a source of fetal antigens during 
pregnancy.  Chapter 3 focuses on how expression of one of these antigens, HA-1, is regulated in 
the human placenta, both across gestation in normal pregnancy and in pre-eclampsia.  The final 
set of experiments in Chapter 4 examines the proteins associated with trophoblast-derived 
microparticles and exosomes isolated from primary trophoblast cells and the effect of these 
trophoblast-derived exosomes on dendritic cells.  Together, these experiments will provide new 
and important information about the expression of fetal antigens in the human placenta, how 
these antigens are expressed and regulated in normal and pre-eclamptic pregnancies and the role 
of placental exosomes and other shed microparticles in influencing the maternal immune 
response during pregnancy.  As a whole, this work will provide important insights into the role 
of the immune system in normal pregnancy, pregnancy complications and beyond.   
  
  
	   31	  
 
 
 
 
CHAPTER 2: 
	  
EXPRESSION OF FETAL MINOR HISTOCOMPATIBILITY ANTIGENS IN THE 
HUMAN PLACENTA: A POTENTIAL SOURCE OF MATERNAL IMMUNE 
EXPOSURE TO FETAL ANTIGENS DURING PREGNANCY 
 
 
Holland OJ*, Linscheid C*, Hodes HC, Nauser TL, Gilliam M, Stone P, Chamley LW, Petroff 
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ABSTRACT 
The purpose of this study was to determine whether human minor histocompatibility antigens are 
present in the human placenta.  To do this, transcript levels of human minor histocompatibility 
antigens HMHA1, KIAA0020, BCL2A1, KDM5D, DDX3Y and RPS4Y1 in placental lysate, 
purified trophoblast cells and fetal cord blood were determined using PCR.  Protein expression 
patterns for HMHA1, KIAA0020, BCL2A1 and RPS4Y1 were examined in placental and 
extraplacental membrane sections across gestation using immunohistochemistry. The autosomal 
minor histocompatibility antigens, HMHA1, KIAA0020 and BCL2A1 were found in placental 
lysate, purified trophoblast cells and fetal cord blood for all of the samples analyzed using RT-
PCR, whereas the Y-chromosome encoded antigens, KDM5D, DDX3Y and RPS4Y1, were only 
found in tissues from pregnancies with male infants.  Using immunohistochemistry, we 
discovered protein expression of HMHA1, KIAA0020, BCL2A1 and RPS4Y1 in both placental 
tissues and extraplacental membranes, with staining patterns that varied according to antigen and 
gestational age. These results provide new evidence that the placenta can act as a source of fetal 
antigens during pregnancy and may affect the maternal immune response to the fetus during 
pregnancy.  This phenomenon has important implications for our understanding of transplant 
immunology as well as numerous pregnancy complications.  
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INTRODUCTION 
 Pregnancy is not an immunologically benign event.  Rather, it is a series of carefully 
orchestrated interactions involving the maternal, paternal and fetal systems with the ultimate goal 
of fetal tolerance leading to the uncomplicated birth of a healthy infant.  The numerous 
interactions required for a healthy pregnancy have long been of interest to researchers.  In the 
1950s, Medawar proposed the paradox of pregnancy whereby the fetus acts as a semi-allograft, a 
view that is still discussed today (Medawar 1954). We are interested in the mechanisms by which 
the maternal system recognizes and tolerates the fetal allograft and the consequences when these 
mechanisms dysfunction. 
 Placental and fetal growth and development have been postulated to be associated with 
chronic exposure of the maternal immune system to fetal antigens.  Studies in both mice and 
women have provided compelling evidence that paternally-inherited antigens are detected by 
maternal lymphocytes (James, Chai et al. 2003).  In mice, maternal lymphocyte exposure to a 
model paternal antigen can occur as early as insemination.  This exposure appears to wane until 
the placenta matures and the maternal blood supply to the placenta is established, at which point 
the placenta is inundated with maternal blood.  This contact between maternal blood and the 
placental surface accommodates antigen efflux into the maternal circulation in the form of 
trophoblast debris, fetal cells and placental exosomes.  This efflux persists for the last half of 
pregnancy in mice and the last two-thirds of pregnancy in women (Erlebacher, Vencato et al. 
2007, Moldenhauer, Hayball et al. 2010, Taglauer, Adams Waldorf et al. 2010). 
 The interface between the maternal blood supply and the fetus consists of the 
syncytiotrophoblast, which covers the placental villi and is in direct contact with the maternal 
blood supply.  This syncytium is a single, multinucleated cell that is the result of fusion of the 
underlying cytotrophoblast cells and is of fetal origin (Benirschke, Kaufmann et al. 2006).  
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During pregnancy, large amounts of syncytial debris are shed into the maternal blood supply, 
providing a likely avenue for maternal exposure to fetal antigens expressed by the 
syncytiotrophoblast during pregnancy.  This debris may include apoptotic syncytial knots, 
exosomes, syncytiotrophoblast microparticles and other foreign material that may elicit a 
tolerogenic response from the maternal immune system (Schmorl 1893, Huppertz, Kingdom et 
al. 2003, Benirschke, Kaufmann et al. 2006, Lapaire, Holzgreve et al. 2007).   
 Proteins that have the ability to induce immune responses do so as a result of 
polymorphisms between two individuals, and are classified as either major or minor 
histocompatibility antigens (MHC and mHAg, respectively).  Antibodies to paternally-inherited 
MHC are common in multiparous women (Bouma, van Caubergh et al. 1996), and can be 
detected in mice as well (Tarfuri, Alferink et al. 1995).  Experimental systems using mice have 
shown that T and B cells vigorously respond to naturally inherited MHC and mHAg with 
evidence that fetal MHC-specific CD8+ T cells undergo proliferation, deletion and tolerance 
during pregnancy (Tarfuri, Alferink et al. 1995).  Furthermore, maternal anti-fetal CD4+ and 
CD8+ T cells express an array of modulating receptors that may function to ensure safe passage 
of pregnancy (Taglauer, Yankee et al. 2009, Taglauer, Adams Waldorf et al. 2010).  In humans, 
cohorts of mHAg-reactive maternal CD8+ T cells are often expanded as a result of pregnancy, 
and are reported to possess a “memory” phenotype.  These include the Y-chromosome-encoded 
antigens A2/HY and B7/HY, as well as the autosomally encoded polymorphic antigen HMHA1 
(Verdijk, Kloosterman et al. 2004) (James, Chai et al. 2003, Piper, McLarnon et al. 2007).  
Despite this increasingly well-documented interaction between fetal alloantigens and the 
maternal immune system, maternal anti-fetal T cells and antibodies are normally harmless, and 
robust maternal tolerance of these fetal antigens is the norm rather than the exception.   
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  Despite the presumed relationship between maternal immune reactivity to fetal minor 
histocompatibility antigens, trophoblast shedding, and fetal microchimerism (Gratwohl, Hermans 
et al. 2001, Christiansen, Steffensen et al. 2010), the identity and sources of fetal antigens have 
not been systematically investigated.  The placenta is a likely source of fetal antigen since 
murine studies suggest that a model mHAg from trophoblast cells can stimulate maternal 
lymphocytes (James, Chai et al. 2003) and studies in the human placenta indicate that where the 
placenta interfaces with maternal blood, there is shedding of large amounts of apoptotic cells and 
placental debris, both of which could be phagocytosed by maternal antigen presenting cells and 
presented to maternal T-cells, thus eliciting a maternal immune response (Huppertz, Frank et al. 
1998, Adams, Yan et al. 2007, Germain, Sacks et al. 2007).  
 In this chapter we chose to analyze the expression of six well-characterized minor 
histocompatibility antigens shown in Table 2.1: HMHA1, KIAA0020 and BCL2A1 (autosomal 
antigens) and KDM5D, RPS4Y1 and DDX3Y (Y-chromosome-encoded antigens).  Of these six 
antigens, three (HMHA1, KIAA0020 and KDM5D) are known to elicit maternal immune 
responses during pregnancy (James, Chai et al. 2003, Piper, McLarnon et al. 2007, van Halteren, 
Jankowska-Gan et al. 2009).  Here we show for the first time that minor histocompatibility 
antigens are expressed in the human placenta during pregnancy and may be shed into the 
maternal circulation where they could potentially interact with the maternal immune system and 
contribute to maternal recognition of the fetus.  
 
  
	   36	  
 
 
 
 
 
 
 
Table 2.1: Human Minor Histocompatibility Antigens Expressed in the Placenta 
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Minor 
Antigen 
Gene Chromosome HLA-
Restriction 
Function Tissue 
Expression 
(mRNA) 
References 
HA-11 HMHA1 19p13.3 HLA-A*0201, 
HLA-A*0206, 
HLA-B*60, 
HLA-B*40012 
Rho GTPase 
activating 
protein 
Hematopoietic 
cells 
(den Haan, 
Meadows et al. 
1998, Wilke, Pool 
et al. 1998, 
Mommaas, Kamp 
et al. 2002, de 
Kreuk, Schaefer et 
al. 2013) 
HA-8 KIAA0020 9p24.2 HLA-A*0201 RNA binding 
protein 
(putative) 
Broad (Brickner, Warren 
et al. 2001) 
ACC-1, 
ACC-2 
BCL2A1 15q24.3 HLA-A*2402; 
HLA-B*4403 
Negative 
regulator of 
apoptosis 
Hematopoietic 
cells 
(Akatsuka, Nishida 
et al. 2003) 
A2/HY; 
B7/HY 
KDM5D Yq11 HLA-A*0201; 
HLA-B*2705 
Protein 
containing zinc 
finger domains 
Broad; high in 
hematopoietic 
cells 
(Wang, Meadows 
et al. 1995) 
B52/HY; 
DRB3/HY 
RPS4Y1 Yp11.3 HLA-B*5201; 
DRB3*0301 
RNA binding 
protein  
Broad (Spierings, 
Vermeulen et al. 
2003, Ivanov, 
Aarts et al. 2005)  
DQ5/HY; 
DRB1/HY 
DDX3Y Yq11a DQB1*05; 
DRB1*1501 
RNA helicase, 
involved in 
spermatogenesis 
Broad; high in 
testis 
(Rosinski, Fujii et 
al. 2008) 
1Abbreviations: HA, histocompatibility antigen; HMHA1, human minor histocompatibility antigen 1; HLA, human 
leukocyte antigen; GTP, guanosine triphosphate; BCL2A1, B cell lymphoma 2 related protein A1; KDM5D, lysine 
demethylase 5D; RPS4Y1, ribosomal protein S4, Y-linked; DDX3Y, DEAD box polypeptide 3, Y-linked. 
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The role of these antigens is not confined to pregnancy.  Recent work in transplant 
immunology has indicated that male recipients of parous female hematopoietic stem cell 
transplantations have both higher rates of graft-versus-host disease and graft-versus-leukemia 
effects, likely as a result of male minor antigen-specific T-cells provided by the female graft 
(Randolph, Gooley et al. 2004, Takami, Sugimori et al. 2004, Loren, Bunin et al. 2006).  A case 
study involving a matched human histocompatibility leukocyte antigen (Hladunewich, Derby et 
al.) transplant from a female to a male sibling has confirmed that male minor antigen-specific T 
cells and antibodies can be generated following male to female transplantation (Zorn, Miklos et 
al. 2004).  Work done by Verdjik et. al. suggests that these minor histocompatibility antigen-
specific T cells are not a temporary finding, but may persist up to twenty-two years following 
pregnancy (Verdijk, Kloosterman et al. 2004).   The presence of minor antigen-specific T cells 
has also been implicated in the development of graft-versus-leukemia effects following cord 
blood transplantation, which contains a significant number of minor antigen-specific T-cells 
(Goulmy 2006).  These findings suggest that understanding the source of these minor antigens 
during pregnancy and the mechanism by which they traffic into maternal circulation is of critical 
importance not only to reproductive immunologists, but to the broader world of transplant 
biology as well. 
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MATERIALS AND METHODS 
Tissue procurement 
This research was conducted in accordance with the Helsinki Declaration and was 
approved by the University of Kansas Medical Center Institutional Review Board.  Term 
placentas with no associated pathologies of pregnancy were collected following elective 
Caesarian sections with no associated labor.  First and second trimester placentas were collected 
following elective pregnancy termination in association with the University of Chicago Tissue 
Collection Core (HD049480) and the Center for Women’s Health in Overland Park, KS.  For 
extraction of RNA and protein, villous placenta was frozen in liquid nitrogen and stored at -80° 
C.  For immunohistochemistry, samples of villous plaenta with attached basal plate, as well as 
extraplaental membranes, were obtained and prepared by fixation in 4% paraformaldehyde 
(Sigma-Aldrich, St. Louis, MO) overnight.  Samples were then dehydrated and embedded in 
paraffin.  
Cytotrophoblast isolation   
Cytotrophoblast cells were isolated as previously described (Petroff, Chen et al. 2003).  
Briefly, term placentas were collected following normal, Caesarian deliveries and approximately 
40g of villous material was dissected.  The tissue was rinsed with 0.9% NaCl saline and 
subjected to enzymatic digestion using Trypsin and DNase.  After washing, the pellet was 
resuspended in HBSS and layered over a Percoll gradient (Sigma-Aldrich, St. Louis, MO).  Cells 
were further washed and subjected to immuno-magnetic purification, using anti-class I MHC-
coated magnetic beads.  Cell purity was assessed using anti-cytokeratin 7 by 
immunohistochemistry or flow, resulting in greater than 90% purity.  Cells were then stored at -
80°C for RNA isolation. 
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Isolation and reverse transcription of RNA and PCR  
 RNA was extracted from whole placenta, purified cytotrophoblast cells and fetal cord 
blood using TRI Reagent (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
directions.  The RNA concentration was quantified using spectrophotometry and 1ug of RNA 
was reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) 
and random primers (Invitrogen, Carlsbad, CA) in a reaction volume of 20ul.  A parallel reaction 
that included RNA but no Superscript III Reverse Trascriptase was also included as a control to 
ensure the absence of genomic DNA in samples.  Two microliters of the reverse transcription 
(RT) reaction were subjected to polymerase chain reaction (PCR) using Taq DNA polymerase 
(Fermentas, Glen Burnie, MD).  Primers for DDX3Y and RPS4Y1 were designed using 
PrimerBLAST (NCBI).  Primers were produced by Integrated DNA Technologies (Coralville, 
Iowa).  Primer sequences were as follows: DDX3Y forward, 5’ TGC TGT CGT ATA GCT GTG 
GG 3’; DDX3Y reverse, 5’ TCT CGA GAC CCA AAA CTG CT 3’; RPS4Y1 forward, 5’ AGA 
TTC TCT TCC GTC GCA GA 3’; RPS4Y1 reverse, 5’ CAT AGA CCA GGC GGA AAT GT 
3’.  PCR was carried out for 35 cycles at 63°C.  RT-PCR for HMHA1, KIAA0020, BCL2A1 and 
KDM5D was carried out using TaqMan Gene Expression Assays (Applied Biosystems, Foster 
City, CA).  The assay numbers used were as follows: Hs00299628_m1 for HMHA1, 
Hs00972109_m1 for KIAA0020, Hs00187845_m1 for BCL2A1 and Hs01104415_m1 for 
KDM5D.  Hs99999903 for beta-actin was used as a control. 
Immunohistochemistry   
Histological preparations of tissues were cut into 10-µm sections and were stained as 
previously described (Holets, Hunt et al. 2006).  Antibodies specific for HMHA1, KIAA0020 
and RPS4Y1 were purchased from Sigma-Aldrich (St. Louis, MO); BCL2A1 was purchased 
from Epitomics (Burlingame, CA).  
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RESULTS 
RNA for mHAg in the placenta and cord blood 
To determine whether the placenta or fetal blood cells could serve as sources of mHAg, 
whole placental lysates, purified cytotrophoblast cells and fetal cord blood mRNAs were 
examined by real time RT-PCR for the presence of four genes known to encode mHAg proteins.  
Expression of mRNA for HMHA1, KIAA0020, BCL2A1, and KDM5D was found in placental 
lysates, purified cytotrophoblast cells and fetal cord blood (Figure 2.1A).  No expression of the 
Y-chromosome encoded mHAg KDM5D was found in samples from pregnancies with a female 
fetus.  Because of lack of availability of TaqMan real-time PCR gene expression assay kits that 
distinguish between the male and female isoforms of the DDX3Y (DDX3X) and RPS4Y1 
(RPS4X) genes, we designed primers for conventional RT-PCR that would distinguish these 
transcripts.  Like KDM5D, DDX3Y and RPS4Y1 were identified in whole placenta, 
cytotrophoblast cells and cord blood from male, but not female, fetuses (Figures 2.1B&C). 
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Figure 2.1: Minor antigen mRNA expression in placenta, cytotrophoblast cells and fetal 
cord blood.   
Real-time RT-PCR for autosomally-encoded mHAg HMHA1, KIAA0020 and BCL2A1, and the 
Y chromosome encoded mHAg KDM5D, for placental lysate and purified cell populations.  Data 
are expressed as the mean difference in Ct values between the gene of interest and β-actin for the 
same samples ± SEM, calculated as described in the Materials and Methods.  Average β-actin 
values ± SEM in each sample were: 24.9 ± 0.59 (placenta); 21.4 ± 0.24 (cytotrophoblast); 26.53 
± 1.56 (cord blood mononuclear cells).  (B) and (C) Conventional RT-PCR data for placental 
lysate and purified cells, respectively.  G3PDH was used as a control; sex of the infant is 
indicated by symbols above each lane. Ct, threshold cycle number; CT, cytotrophoblast cells; 
CB, cord blood mononuclear cells; M, Molecular weight marker. 
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Analysis of mHAg Proteins in the Placenta  
General properties of mHAg immunoreactivities in the placenta 
After determining that mRNA for all six minor histocompatibility antigens could be 
found in the placenta, purified cytotrophoblasts and fetal cord blood, we examined placental 
tissue sections for minor antigen protein expression using immunohistochemistry.  10 µm 
sections from first trimester, second trimester and term placental villi and placental membranes 
were stained for HMHA1, KIAA0020, BCL2A1 and RPS4Y1.  All four minor antigens were 
found in both villous and extravillous trophoblast cells, with substantial variation occurring 
between samples and across gestation (Figures 2.2 & 2.3).  Expression of HMHA1 and RPS4Y1 
was exclusively cytoplasmic (Figures 2.2A, B, G, H and 2.3A, B, G, H) whereas both 
cytoplasmic and nuclear staining was seen for KIAA0020 and BCL2A1 (Figures 2.2 C-F and 2.3 
C-F).  It is also important to note here that the RPS4Y1 antibody recognized both the male and 
female versions of the protein, so both male and female placentas stained with the same patterns.  
We attempted to examine expression of both DDX3Y and KDM5D, but were unable to do so 
using the currently available antibodies. 
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Figure 2.2: Minor histocompatibility antigen expression in first and second trimester 
placentas.  
 A, C, E, G, I: first trimester placenta (gestational age 8-12 weeks); B, D, F, H, J: second 
trimester placenta (gestational age 13-21 weeks).  Reddish-brown staining represents specific 
immunoreactivity of mHAg-specific antibodies with cells; bluish-purple staining represents the 
hematoxylin counterstain.  Arrows indicate syncytiotrophoblast; arrowheads indicate Hofbauer 
cells.  EVT, extravillous trophoblasts; IVS, intervillous space. 
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Figure 2.3: Minor histocompatibility antigen expression in term placentas and 
extraplacental membranes.   
A, C, E, G, I: term placenta; B, D, F, H, J: extraplacental membranes.  Arrows indicate 
syncytiotrophoblast; arrowheads indicate Hofbauer cells.  Amn, amnion membrane; BP, basal 
plate; Ch, chorion membrane; IVS, intervillous space; Decid., decidua. 
  
	   48	  
 
	   49	  
Villous Trophoblast Cells   
The staining of the syncytiotrophoblast was highly variable for all four antigens, with 
some areas of robust protein expression and other regions with little or no protein expression.    
Expression of BCL2A1 was generally stronger in the first and second trimester 
syncytiotrophoblast, as compared to term placentas, and several of the term placentas examined 
(3/8) had strong BCL2A1 only in areas resembling syncytial knots/aggregates (Figures 2.2E, F 
and 2.3E). 
KIAA0020 and RPS4Y1 were found in the villous trophoblast of all of the samples 
examined across gestation (Figures 2.2C, D, G, H and 2.3C, G).  KIAA0020 was found in the 
cell cytoplasm throughout gestation and some first trimester sections had nuclear staining as 
well.  Expression of KIAA0020 was often stronger in the syncytiotrophoblast as compared to the 
cytotrophoblast. 
HMHA1 expression was strongest in the first trimester syncytiotrophoblast, with many of 
the second trimester and all of the term placental sections lacking trophoblast expression of 
HMHA1 (Figures 2.2A, B and 2.3A). 
Extravillous Trophoblast Cells 
 All four antigens were expressed in extravillous trophoblast cells (EVTs).  KIAA0020, 
HMHA1 and RPS4Y1 were all found in extravillous trophoblast cells throughout gestation 
(Figures 2.2A, C, G and 2.3B, D, G, H).  Expression of BCL2A1 was weaker in the term EVTs 
when compared to EVTs from first trimester placentas (Figures 2.2E and 2.3F).  
Fetal Leukocytes 
Fetal leukocytes were generally negative for KIAA0020, BCL2A1 and RPS4Y1 with a 
few weakly positive cells scattered throughout the samples.  HMHA1 stained moderately in term 
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fetal leukocytes, but was either weak or negative in the fetal leukocytes present in first and 
second trimester samples. 
Hofbauer Cells 
Hofbauer cells, also known as placental macrophages, stained strongly for HMHA1 
across gestation (Figures 2.2A, B and Figure 2.3A) and were weakly positive for KIAA0020, 
BCL2A1 and RPS4Y1 in second trimester, but not first or term placentas (Figures 2.2C-H and 
2.3C, E, G). 
Endothelial Cells 
 Endothelial cells were positive for KIAA0020, but lacked expression of the other 
antigens throughout gestation, with the occasional exception of RPS4Y1 (Figures 2.2C,D and 
Figure 2.3C). 
Maternal Leukocytes 
  KIAA0020, BCL2A1 and RPS4Y1 were generally negative in maternal leukocytes with 
an occasional weakly positive cell.  Maternal leukocytes located both within the peripheral blood 
and decidual tissues stained moderately for HMHA1 in both first and third trimester tissues 
(Figures 2.2A, B and 2.3A). 
Decidua 
BCL2A1 was not expressed in either the basal plate or in decidual tissues associated with 
extraplacental membranes (Figure 2.3F) whereas the three other minor antigens, HMHA1, 
RPS4Y1 and KIAA0020, were expressed in decidual tissues (Figure 2.3B, D, H).  
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DISCUSSION 
 In this chapter we have shown, for the first time, the expression of minor 
histocompatibility antigens in the placenta.  Using PCR, we demonstrated that mRNA for the 
autosomal mHAgs HMHA1, KIAA0020 and BCL2A1 and the Y-chromosome encoded mHAgs 
KDM5D, DDX3Y and RPS4Y1 is found in placental tissues and fetal cord blood.  Using 
immunohistochemistry, we were able to show that four of the six minor histocompatibility 
antigens studied were expressed by a number of different cell types found in the placenta 
including syncytiotrophoblast, cytotrophoblast, extravillous trophoblast, leukocytes and 
macrophages.  This study provides support for earlier work indicating that pregnancy can lead to 
the expansion of minor-antigen specific T-cells (James, Chai et al. 2003, Verdijk, Kloosterman et 
al. 2004, Mommaas, Stegehuis-Kamp et al. 2005, Piper, McLarnon et al. 2007, Burlingham and 
Goulmy 2008). 
 This process has important implications for HLA-identical hematopoietic stem cell 
transplantation (HSCT).  Recent research has shown that multiparous donors are associated with 
increased rates of graft-versus host disease in both male and female recipients, possibly due to 
mHAg immunization during pregnancy (Loren, Bunin et al. 2006).   Pregnancy-induced mHAg 
immunization can also be beneficial to HSCT recipients in cases where minor antigen mismatch 
leads to an enhanced graft-versus-leukemia effect (Randolph, Gooley et al. 2004, Takami, 
Sugimori et al. 2004).   
 In addition to the importance of minor histocompatibility antigens in transplant biology, 
recent research has indicated a potential role for Y-chromosome encoded minor 
histocompatibility antigens in the occurrence of several pregnancy-associated complications 
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including secondary recurrent miscarriage and villitis of unknown etiology.  Secondary recurrent 
miscarriage (SRM) is defined as three or more consecutive miscarriages following a birth at 
twenty-four weeks gestation or later.  At least two independent studies have found a significant 
association between the development of SRM and prior birth of a male infant and it has been 
suggested that this may be due, at least in part, to an aberrant maternal immune response to Y-
chromosome encoded antigens (Christiansen, Steffensen et al. 2010, Ooi, Russell et al. 2011).  
Researchers have also found that maternal carriage of HY-restricting class II alleles is associated 
with poor pregnancy outcomes in women with a prior live birth of a male infant and a diagnosis 
of SRM (Nielsen, Steffensen et al. 2009).  Our data indicates that maternal exposure to Y-
chromosome encoded fetal antigens is likely to occur during pregnancy as a result of both 
syncytiotrophoblast shedding and fetal microchimerism.   
 Villitis of unknown etiology (VUE) is a relatively common placental pathology in which 
maternal immune cells infiltrate placental villi.   The etiology and importance of this lesion has 
been widely debated, with some pathologists proposing a fetal transplant rejection mechanism 
and others advocating for an as yet unidentified infectious agent (Redline 2007).  Two recent 
studies have shown an increase in the prevalence of VUE in pregnancies resulting from egg 
donation as compared with other pregnancies conceived using IVF, although it is important to 
note that in only one of these studies was this finding significant (Styer, Parker et al. 2003, Perni, 
Predanic et al. 2005).  The association of VUE with ovum donation provides support for the 
theory that VUE represents a maternal immune response to the fetus given that in ovum donation 
pregnancies the fetus is completely genetically foreign to the mother.  Our work in this paper 
showing that the placenta expresses mHAgs provides a potential mechanism by which the 
maternal immune system is exposed to fetal antigens.  This is of particular importance given the 
association between VUE and small for gestational age infants (Becroft, Thompson et al. 2005).  
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More work is needed to elucidate the molecular relationships between fetal mHAg expression, 
VUE and pregnancy outcomes. 
 In conclusion, we have demonstrated that fetal mHAgs are expressed in the placenta and 
fetal cord blood.  This finding provides support for the hypothesis that mHAg-specific T-cells 
are generated during pregnancy as the result of both syncytiotrophoblast shedding from the 
placenta into the maternal blood supply and fetal microchimerism.  This research provides 
important insight into the mechanisms by which the maternal immune system is induced to 
tolerate the fetal allograft during pregnancy.  Further work is needed to elucidate the interactions 
between fetal mHAgs and maternal immune cells leading to both tolerance and aberrant maternal 
immune activation. 
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ABSTRACT 
Maternal T-cells reactive towards paternally inherited fetal minor histocompatibility antigens are 
expanded during pregnancy, and can persist for many years following pregnancy.  Placental 
trophoblast cells express at least four of these antigens, including human minor 
histocompatibility antigen 1 (HMHA1 or HA-1).  In this study, we investigated oxygen as a 
potential regulator of HA-1 expression, and further, whether HA-1 expression is altered in 
placentas from preeclamptic patients.  Expression and regulation of HA-1 mRNA and protein 
were examined by qRT-PCR and immunohistochemistry, respectively, using first, second, and 
third trimester placentas, first trimester placental explant cultures, and purified cytotrophoblast 
cells.  Low oxygen conditions were achieved by varying ambient oxygen, and were mimicked 
using cobalt chloride.  Lastly, HA-1 mRNA and protein expression levels were evaluated in 
preeclamptic and matched control placentas.  HA-1 protein expression was significantly higher 
in the syncytiotrophoblast of first trimester as compared to second and third trimester placentas 
(P<0.01).  HA-1 mRNA was increased in cobalt chloride-treated first trimester placental 
explants and purified term cytotrophoblast cells (P=0.04 and P<0.01, respectively) and in 
purified term cytotrophoblast cells cultured under 2% as compared to 8% and 21% oxygen 
(P<0.01).  HA-1 mRNA expression in preeclamptic vs. control placentas was increased 3.3-fold 
(P=0.015).   HA-1 protein expression was increased in syncytial aggregates and in the 
syncytiotrophoblast of preeclamptic vs. control placentas (P=0.03).  Placenta HA-1 expression is 
regulated by oxygen and is increased in the syncytiotrophoblast of preeclamptic as compared to 
control placentas.  Increased HA-1 expression, combined with increased preeclamptic 
syncytiotrophoblast deportation, provides a novel potential mechanism for exposure of the 
maternal immune system to increased fetal antigenic load during preeclampsia.   
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INTRODUCTION 
Pregnancy is a unique biological process wherein the female is confronted with an 
antigenically foreign fetus that is permitted and encouraged to flourish, despite a surrounding 
immunological environment that can recognize it as foreign.  Thus, the success of pregnancy 
depends on maternal immunological acceptance of the fetus.  An understanding of the biological 
mechanisms responsible for this immunological tolerance is of significant interest: not only is the 
health of both mother and baby of paramount importance, also, the success of the immunological 
relationship between the two may inform medical success with transplantation, immune-
mediated rejection of tumors and avoidance of autoimmune disease. 
Preeclampsia is a common and dangerous complication that is specific to pregnancy and 
affects 5-8% of pregnancies worldwide (Duley 2009).  It is a syndrome characterized by new 
onset maternal hypertension after 20 weeks gestation and proteinuria.  If untreated, preeclampsia 
can lead to maternal seizures, multi-system organ failure and even death of both mother and 
baby.  The only successful treatment of preeclampsia is delivery of the baby and the placenta; 
making preeclampsia one of the leading causes of iatrogenic prematurity (Pennington, Schlitt et 
al. 2012).  Numerous studies have indicated a central, causative role for the placenta in the 
manifestation of preeclampsia; for example, preeclampsia can develop in molar pregnancies, in 
which no fetus is present (Soper, Mutch et al. 2004), and further, delivery of the placenta, not the 
baby, relieves the maternal symptoms (Redman and Sargent 2003).  Although the 
pathophysiology of preeclampsia is not well understood, alterations in vascular reactivity leading 
to both increased placental oxidative stress and enhanced maternal immune activation are key 
components of this syndrome (Tannetta and Sargent 2013). 
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The placenta plays an important role in modulating the response of the maternal immune 
system to the baby during pregnancy.  While the placenta tightly restricts its expression of the 
highly polymorphic Human Leukocyte Antigens (Hunt, Andrews et al. 1987), which govern 
adaptive immune recognition, it does express polymorphic fetal proteins encoded outside the 
HLA complex, known as minor histocompatibility antigens (Holland, Linscheid et al. 2012) , 
that can be recognized by maternal immune cells.  The immunogenic peptides derived from 
minor histocompatibility antigens (mHAg) arise due to allelic polymorphisms, presence on the 
Y-chromosome, or common allelic deletions.  Minor antigens are important in the success or 
failure of hematopoietic stem cell and solid organ transplants (Goulmy, Schipper et al. 1996, 
Goulmy 2006, Dierselhuis and Goulmy 2009).  Exposure of an untolerized individual to these 
antigens, either as the result of pregnancy or allogeneic transplantation, can lead to the expansion 
of minor antigen-specific T cells (Verdijk, Kloosterman et al. 2004, Krishnan, Higgins et al. 
2007).  Further, the presence of minor antigen-specific T cells in allogeneic transplants has been 
linked to increased rates of graft rejection, graft-versus-host disease, and graft-versus-leukemia 
effects, indicating that, at least in the context of transplantation, these T cells are functional and 
pathophysiologically relevant (Goulmy, Termijtelen et al. 1976, Goulmy, Gratama et al. 1983, 
Goulmy, Schipper et al. 1996, Dierselhuis and Goulmy 2009).    
Our work outlined in Chapter 2 has demonstrated that the placenta is a source of fetal 
antigens during pregnancy, and thus contributes to maternal immunological recognition of the 
fetus (Holland, Linscheid et al. 2012).  T cells with specificity for paternally-inherited fetal 
antigens expand during pregnancy and can persist for up to 22 years following delivery of the 
baby (Verdijk, Kloosterman et al. 2004, Piper, McLarnon et al. 2007, Lissauer, Piper et al. 2012).  
In mice, MHC class I and class II-restricted presentation of paternally inherited fetal minor 
antigens occurs through the action of maternal antigen presenting cells, and results in expansion 
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of CD4+ and CD8+ T cells specific for both natural and model fetal antigens (James, Chai et al. 
2003, Darrasse-Jeze, Klatzmann et al. 2006, Moldenhauer, Diener et al. 2009, Robertson, Guerin 
et al. 2009, Perchellet, Jasti et al. 2013).  
HA-1 (also called HMHA1 for human minor histocompatibility antigen 1) functions as a 
Rho GTPase activating protein (de Kreuk, Schaefer et al. 2013), is expressed in the human 
placenta (Holland, Linscheid et al. 2012) and is important for graft outcomes in HLA-matched 
hematopoietic stem cell transplantations.  A study of 148 HLA-matched bone marrow transplant 
pairs noted that a mismatch of HA-1 alone was significantly correlated with increased graft-
versus-host disease (Goulmy, Schipper et al. 1996).   HA-1 is antigenic due to a single nucleotide 
polymorphism in which the arginine in the peptide sequence KECVLRDDLLEA is changed to a 
histidine, giving rise to the immunogenic peptide KECVLHDDLLEA.  This single nucleotide 
polymorphism results in increased binding affinity of the peptide to the appropriate major 
histocompatibility complex (MHC) for immune recognition, in this case HLA-A*0201, A*0206, 
B*60 or B*40012 (den Haan, Meadows et al. 1998, Mommaas, Kamp et al. 2002, Torikai, 
Akatsuka et al. 2007, Nicholls, Piper et al. 2009, Bleakley and Riddell 2011).  HA-1-specific 
CD8+ T cells have been identified in human pregnancies where the mother expresses the non-
immunogenic form of the peptide and the fetus expresses the immunogenic form (Verdijk, 
Kloosterman et al. 2004).  Given the expansion of specific T cells during pregnancy and the 
importance of HA-1 in transplantation immunology, we investigated the expression and 
regulation of HA-1 in the human placenta during pregnancy, when the placenta and fetus 
together act as an allograft that can be recognized by the maternal immune system. 
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MATERIALS AND METHODS 
Sample Collection 
 Samples were collected in accordance with the Helsinki Declaration using protocols 
approved by the Institutional Review Boards of the University of Kansas Medical Center and 
Saint Luke’s Hospital.  First trimester placentas were obtained from women undergoing elective 
pregnancy terminations at the Center for Women’s Health in Overland Park, Kansas.  Normal 
term placentas, defined as placentas from pregnancies with no noted complications other than 
fetal malpresentation (including intrauterine growth restriction and diabetes), were obtained 
following non-laboring Caesarian deliveries at the University of Kansas Medical Center and 
Saint Luke’s Hospital.  Fixed and frozen tissues from preeclamptic placentas, together with 
gestational age- and mode of delivery-matched control placentas were obtained from the 
Research Centre for Women’s and Infants’ Health Biobank at Mount Sinai Hospital, Toronto, 
Canada.  Control placentas were selected primarily based on the mode of delivery and 
gestational age and could not be from pregnancies complicated by pre-eclampsia, gestational 
hypertension or intrauterine growth restriction. Clinical data for these samples are provided in 
Table 3.1.  The only significant difference between the control and preeclampsia groups was that 
infants in the preeclampsia group weight significantly less than those in the control group 
(p<0.01).  This is not unexpected given the high concordance of preeclampsia and intrauterine 
growth restriction. 
Placental Explant Preparation 
First trimester (n=6) villi were dissected and explants of approximately 500mg were 
cultured in 12-well plates fitted with Netwell inserts (Corning, Tewksbury, MA).  Explants were 
cultured in DMEM-F12 media (Corning Cellgro, Herndon, VA) containing 10% fetal bovine 
serum (Atlanta Biologicals, Lawrenceville, GA), 5ng/ml epidermal growth factor (PeproTech, 
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Rocky Hill, NJ), 5µg/ml insulin (Sigma-Aldrich, St. Louis, MO), 10µg/ml transferrin (Sigma-
Aldrich), 100µg/ml L-glutamine (Corning Cellgro), 20nM sodium selenite (Sigma-Aldrich), 400 
IU hCG (Sigma-Aldrich), 100µg/ml streptomycin (Corning Cellgro) and 100 IU penicillin 
(Corning Cellgro).  
Cytotrophoblast Isolation 
 Cytotrophoblast cells were isolated as previously described (Petroff, Chen et al. 2003, 
Petroff, Phillips et al. 2006).  Briefly, term placentas were collected following normal, non-
laboring, Caesarian deliveries and approximately 40g of villous material was dissected.  The 
tissue was rinsed with 0.9% NaCl and subjected to enzymatic digestion using Trypsin (Gibco, 
Grand Island, NY) and DNase (Sigma-Aldrich).  After washing, the cell pellet was resuspended 
in Hank’s balanced salt solution (HBSS) with 25mM HEPES buffer (Cellgro, Manassas, VA) 
and layered over a Percoll gradient (Sigma-Aldrich).  Cells were further washed and subjected to 
negative immuno-magnetic selection, using an anti-class I (W6/32) MHC antibody and magnetic 
beads.  Cell purity was assessed by flow cytometry using an anti-cytokeratin 7 antibody 
(Millipore, Billerica, MA).  Only cell preparations resulting in greater than 90% purity were 
used.  
Cobalt Chloride Treatment 
First trimester placental explants (n=6) and purified term cytotrophoblast cells (n=5) were 
plated and cultured overnight at 37oC with 5% carbon dioxide, 95% normal air.  Following 
overnight culture, the media was removed and replaced with control media (no cobalt chloride) 
or media containing 100µM cobalt chloride.  Samples were cultured for 24 hours and then 
collected.  Purified cytotrophoblast cells were lysed in TRI Reagent (Sigma-Aldrich) and 
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processed for RNA isolation as described below; placental explants were frozen in liquid 
nitrogen prior to mRNA analysis. 
Oxygen Cultures 
Purified cytotrophoblast cells (n=6) were plated and cultured overnight at 37oC with 5% 
carbon dioxide, 95% normal air.  Culture media were pre-equilibrated for at least twelve hours in 
the oxygen chambers.  After overnight plating, cytotrophoblast cells were washed with pre-
equilibrated medium to remove any cellular debris.  Cells were then cultured under 2% or 8% 
oxygen or ambient air (21% oxygen) for 24 hours using an InVivo 300 (Ruskinn/Baker, Sanford, 
ME) or an H35 (Hypoxygen, Frederick, MD) hypoxia chamber or in a standard incubator for the 
ambient air condition.  After 24 hours, cells were collected in TRI Reagent and processed as 
described below.  
RNA Isolation and RT-PCR 
RNA was extracted from purified cytotrophoblast cells, first trimester placental explants 
and frozen placental tissues using TRI Reagent according to the manufacturer’s directions.  The 
RNA concentration was quantified using spectrophotometry and 0.5µg of RNA was reverse 
transcribed using Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) and random 
primers (Invitrogen, Carlsbad, CA) in a reaction volume of 20 µl.  A parallel reaction that 
included RNA but no reverse transcriptase was included as a control to ensure the absence of 
genomic DNA in the samples.  2 µl of the reverse transcription (RT) reaction was subjected to 
polymerase chain reaction (PCR) using Taq DNA polymerase (Fermentas, Glen Burnie, MD).  
RT-PCR for HA-1 was carried out using a TaqMan Gene Expression Assay (HA-1 assay number 
Hs00299628_m1, Applied Biosystems, Foster City, CA).  Assay number Hs99999903 for beta-
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actin was used as a control.  Average fold change for each sample was calculated using ddCt 
values and normalized to the beta-actin control. 
Immunohistochemistry  
Paraformaldehyde-fixed (4%), paraffin embedded placentas cut to a thickness of 5µm 
were collected from preeclamptic (n=8) and gestational age- and mode of delivery-matched 
control women (n=8) at the Research Center for Women’s and Infants’ Health Biobank at Mount 
Sinai Hospital, Toronto, Canada.  Slides were deparaffinized in Histo-clear (Fisher Scientific, 
Pittsburgh, PA), rehydrated and stained as previously described (Holets 2006).  Briefly, tissues 
were subjected to heat antigen retrieval using Reveal buffer (BioCare Medical, Walnut Creek, 
CA).  Nonspecific antibody binding was blocked in 10% goat serum (Sigma-Aldrich).  A rabbit 
polyclonal primary antibody targeting human HA-1 (Sigma-Aldrich, 12 µg/ml) or a rabbit IgG 
control antibody (Vector Labs, Burlingame, CA, 12ug/ml) was added to tissue sections, which 
were then incubated overnight at 4°C.  Following addition of biotinylated goat anti-rabbit 
secondary antibodies (Vector Labs, 10 µg/ml) and depletion of endogenous peroxidases, binding 
of primary antibody was detected using streptavidin-peroxidase and aminoethyl carbazole 
(Invitrogen, Carlsbad, CA).   
H-score Quantification of HA-1 Expression 
Expression of HA-1 in first trimester, second trimester, term uncomplicated and 
preeclamptic placental tissues was calculated using the H-score method (Goulding, Pinder et al. 
1995).  Briefly, 10-20 400X images were taken of each placenta using a Nikon 80i microscope.  
The expression of HA-1 in each placental villus was scored by a blinded reviewer as 3 (strong 
immunoreactivity), 2 (moderate), 1 (weak), or 0 (no immunoreactivity).  At least 20 villi were 
quantified for each placenta.  The H-score was quantified using the following formula: H-score = 
3*(%strong) + 2*(%moderate) + 1*(%weak). 
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Statistical Analyses 
All statistical analyses were conducted using the SigmaStat software (Systat, Chicago, 
IL). The differences between HA-1 mRNA expression in cobalt chloride-treated and untreated 
first trimester placental explants and purified term cytotrophoblast cells were calculated using 
two-tailed, paired T-tests.  The differences in HA-1 mRNA expression across gestation and in 
purified term cytotrophoblast cells cultured at 2%, 8% and 21% oxygen were calculated using 
one-way ANOVAs on Ranks with Student-Newman-Keuls post-tests.  The differences between 
HA-1 mRNA expression and H-scores in preeclamptic and normal placental tissues were 
calculated using a two-tailed, paired T-test.  All results with a P-value of ≤ 0.05 were considered 
significant different. 
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RESULTS 
HA-1 is Expressed in Placental Tissues Across Gestation 
As illustrated in Chapter 2, HA-1 and other mHAgs are expressed in placental lysate, 
purified cytotrophoblast cells and fetal cord blood (Holland, Linscheid et al. 2012).  
Nonquantitative analysis suggested that HA-1 is strongly expressed in the syncytiotrophoblast of 
first trimester, but is reduced in second and third trimester placentas.  To further explore the 
possibility of differential regulation of HA-1 in the placenta across gestation, we used 
semiquantitative analysis to examine expression of HA-1 protein in the syncytiotrophoblast of 
first (n=5), second (n=4) and third (n=5) trimester placentas (Figure 3.1).  The overall cellular 
distribution of HA-1 agreed with our previous findings:  Hofbauer cells from all stages of 
gestation exhibited strong staining for HA-1, while immunoreactivity in trophoblast populations 
was most evident in the first trimester.  Furthermore, H-score analysis revealed that HA-1 protein 
was more than 4- and nearly 40-fold higher in the syncytiotrophoblast of the first trimester 
placentas as compared to the second (P=0.001) and third (P<0.001) trimester placentas, 
respectively.  In contrast, second trimester syncytiotrophoblast HA-1 expression did not differ 
from that observed at term (P>0.05).  Although there was a small subset of second trimester and 
term placentas with clear expression of HA-1 in the syncytiotrophoblast, most second trimester 
and term placentas showed little or no HA-1 expression in the syncytiotrophoblast, suggesting 
that in many cases HA-1 expression in the syncytiotrophoblast may be confined to the first 
trimester. 
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Figure 3.1: Expression of HA-1 in the human placenta across gestation.   
HA-1 expression in the syncytiotrophoblast (small arrows) and Hoffbauer cells (large arrows) of 
first trimester (n=5), second trimester (n=4) and term placental sections (n=5) was examined.  
Expression of HA-1 protein in the syncytiotrophoblast was quantified by a blinded reviewer 
using the H-score method. Expression of HA-1 in the syncytiotrophoblast was significantly 
higher in first trimester placentas as compared to second trimester (P<0.01) and third trimester 
placentas (P<0.01).  There was no significant difference in HA-1 protein expression between the 
second and third trimester placentas (P=0.277). * = P<0.01, ns=no significance 
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Cobalt Chloride Treatment Increases the Expression of HA-1 mRNA in First Trimester 
Placental Explants and Purified Term Cytotrophoblast Cells 
 Oxygen tension in the placenta increases dramatically from the first to the second 
trimester of pregnancy as a result of trophoblast remodeling of the maternal spiral arteries, 
suggesting that oxygen could be, at least in part, responsible for the observed alterations in HA-1 
expression across gestation (Jauniaux, Watson et al. 2000).  Therefore, to examine potential 
regulation of HA-1 expression by oxygen, we treated first trimester placental explants and 
purified term cytotrophoblast cells with 100µM of the hypoxia mimetic, cobalt chloride (CoCl2).  
Cells or explants were treated in the presence or absence of 100µM CoCl2 for twenty-four hours, 
and HA-1 mRNA was quantified by real time RT-PCR (Figure 3.2).  There was a significant 
increase in HA-1 mRNA expression in the first trimester placental explants (n=6, p=0.04) and in 
the purified term cytotrophoblast cells (n=5, p<0.01) treated with cobalt chloride as compared to 
the untreated controls.   
  
	   68	  
Figure 3.2: Cobalt chloride increases HA-1 mRNA expression in culture.   
First trimester explants (n=6) and purified term trophoblast cells (n=5) were cultured in the 
presence of cobalt chloride, a hypoxia mimetic.  HA-1 mRNA expression, determined using 
qRT-PCR, was normalized to beta-actin and fold change relative to the untreated controls was 
calculated using the ddCt method.  HA-1 mRNA expression was significantly elevated in the 
first trimester placental explants and purified term cytotrophoblast cells treated with 100µM 
cobalt chloride as compared to the untreated controls (P=0.04 and P<0.01, respectively).   
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Low Oxygen Increases the Expression of HA-1 mRNA in Purified Term Cytotrophoblast 
Cells 
To directly examine a potential role of oxygen in regulating HA-1 mRNA expression, 
purified term cytotrophoblast cells (n=6) were cultured at 2% (hypoxia for the term placenta), 
8% (normoxia for the term placenta) and 21% (ambient) oxygen for twenty-four hours. The 
expression of HA-1 mRNA was then determined using qRT-PCR.  HA-1 mRNA expression was 
significantly different between all three groups (p<0.01), with the highest expression seen in the 
cells cultured at 2% oxygen (Figure 3.3).  
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Figure 3.3: HA-1 mRNA expression in purified term trophoblasts cultured under low 
oxygen.   
Purified term trophoblast cells from normal, C-section deliveries (n=6) were cultured in 2%, 8% 
or 21% oxygen for twenty-four hours.  HA-1 mRNA expression, determined using qRT-PCR, 
was normalized to beta-actin and fold change relative to the 21% oxygen condition was 
calculated using the ddCt method.  HA-1 mRNA expression was significantly higher in the 8% 
and 2% oxygen conditions as compared to 21% oxygen (P<0.01).  HA-1 mRNA expression was 
also significantly higher in the 2% oxygen condition as compared to the 8% oxygen condition 
(P<0.01). *=P<0.01 
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HA-1 is Increased in the Syncytiotrophoblast of Preeclamptic Placentas 
Previously published observations of increased expression of HIF-1α in preeclamptic 
placentas (Caniggia and Winter 2002), the disrupted placental blood flow characteristic of this 
disease (Steel, Pearce et al. 1990, North, Ferrier et al. 1994), and the observed upregulation of 
HA-1 mRNA by low oxygen, led us to postulate that HA-1 expression may be dysregulated in 
placentas from preeclamptic patients.  Preeclamptic and control placentas were matched for 
gestational age and mode of delivery (Table 3.1).  Using qRT-PCR, we found that HA-1 mRNA 
expression (n=9 matched pairs) was significantly increased in placentas from preeclamptic 
pregnancies as compared to control placentas (Figure 3.4, p=0.015).  We also used 
immunohistochemistry to determine the expression of HA-1 protein in the syncytiotrophoblast of 
preeclamptic and control placentas (n=8 matched pairs; pair 4 was excluded due to poor tissue 
fixation).  HA-1 protein expression, as scored by a blinded reviewer using the H-score method, 
was significantly higher in the syncytiotrophoblast of preeclamptic placentas when compared to 
the matched control placentas (Figure 3.4, p=0.03).  Interestingly, although the expression of 
HA-1 in the syncytiotrophoblast of the control placentas was significantly decreased as 
compared to the preeclamptic placentas, there was still a high level of HA-1 expression in the 
Hofbauer cells (placental macrophages) of both the preeclamptic and control placentas.   
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Table 3.1: Clinical Characteristics of Preeclamptic and Matched Control Placentas 
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Sample Clinical 
Diagnosis 
GA 
(weeks/ 
days) 
Ethnicity Age Parity 
(G/P) 
Antenatal 
glucocorti
coids? 
(Y/N) 
Maternal 
cigarette 
use? 
(Y/N) 
BMI Mode of 
Delivery 
Fetal 
Birth 
Weight 
Fetal 
Sex 
(M/F) 
1 - PE PE 34/6 East Indian 37 3/1 N N 19.8 Vaginal 2140g F 
1 - C PTL 34/5 Caucasian 31 1/0 N N 25.9 Vaginal 2710g M 
2 - PE PE 37/2 Caucasian 37 3/0 N N 19.4 Vaginal 2710g M 
2 - C Labor 37/0 Asian 30 1/0 N N 21.5 Vaginal 2870g M 
3 - PE PE/HELLP 36/5 Caucasian 31 1/0 N/A N 24.3 C-
section 
2640g M 
3 - C Placenta 
praevia 
36/3 Black 35 2/1 N N 26.7 C-
section 
2665g M 
4 - PE PE/HELLP/ 
IUGR 
32/4 Caucasian 39 2/0 Y N 33.9 C-
section 
1220g F 
4 - C PTL 32/4 Caucasian 33 1/0 Y N 21.1 C-
section 
2080g M 
5 - PE PE 36/2 Asian 38 1/0 N N 21.6 Vaginal 2265g M 
5 - C PTL 35/6 Asian 32 1/0 Y N 19.8 Vaginal 2920g F 
6 - PE PE/IUGR 34/1 Black 24 1/0 N N 23.6 C-
section + 
labor 
1550g F 
6 - C PTL 34/1 Caucasian 27 4/1 Y N 26.1 C-
section + 
labor 
2360g M 
7 - PE PE 36/0 Caucasian 37 1/0 N N 26.4 C-
section + 
labor 
2280g M 
7 - C PTL 35/4 Other 36 1/0 N N 21.1 C-
section + 
labor 
3030g F 
8 - PE PE/IUGR 31/5 Black 38 4/1 Y N 26.2 Vaginal 890g F 
8 - C PTL 32/1 Caucasian 29 2/1 Y N 17.9 Vaginal 1810g M 
9 - PE PE/IUGR 34/4 Native 
Canadian 
37 4/0 Y N 25.1 C-
section + 
labor 
1673g F 
9 - C PTL 34/6 Caucasian 36 2/1 N N 35.1 C-
section + 
labor 
2180g M 
 
Table 3.1: GA = Gestational Age, G/P = Gravidity/Parity, PE = Preeclampsia, C = Control, PTL 
= Pre-term Labor, HELLP = Hemolysis, Elevated Liver enzymes, Low Platelets, IUGR = 
Intrauterine Growth Restriction, N/A = Not Available, BMI = Body Mas Index, M = Male, F = 
Female 
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Figure 3.4: HA-1 expression is increased in preeclamptic placentas as compared to 
controls.   
Whole placental lysate and placental sections were obtained from preeclamptic and gestational-
age and mode of delivery matched controls.  HA-1 mRNA expression was determined using 
qRT-PCR normalized to beta-actin.  HA-1 mRNA expression (fold change) was significantly 
higher in the preeclamptic placentas as compared to the control placentas (n=9, P=0.015). HA-1 
protein expression the syncytiotrophoblast layer (arrows) of preeclamptic and control placentas 
was determined by a blinded reviewer using the H-score method.  HA-1 protein expression in the 
syncytiotrophoblast was significantly elevated in the preeclamptic placentas as compared to the 
controls (n=8, P=0.03). PE = Preeclampsia. 
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DISCUSSION 
This chapter is the first work to investigate the mechanisms that regulate the expression 
of the minor histocompatibility antigen HA-1.  We found that expression of HA-1 is significantly 
higher in the syncytiotrophoblast of first as compared to second and third trimester placentas.  
We also found that treatment with cobalt chloride, culture in hypoxic conditions, and 
preeclampsia all increase trophoblast expression of HA-1.  One of the major changes that occurs 
during the transition from the first to the second trimester of pregnancy is a dramatic increase in 
placental oxygen delivery as a result of maternal spiral artery remodeling by invasive trophoblast 
cells and the loss of cytotrophoblast cell aggregates which block arterial blood flow to the 
placenta during early pregnancy (Burton, Jauniaux et al. 1999, Jauniaux, Watson et al. 2000).  
This process may help explain why HA-1 expression in the syncytiotrophoblast decreases as 
normal gestation progresses but appears to be maintained in preeclampsia, where the remodeling 
of the spiral arteries is defective. 
The increased expression of HA-1 in purified cytotrophoblast cells following treatment 
with CoCl2 and culture in a low oxygen environment suggests that HA-1 expression may be 
regulated, at least in part, by oxygen in vivo.  This regulation likely occurs via the oxygen-
sensitive transcription factor, hypoxia inducible factor (HIF) 1α.  Under normoxic conditions, 
HIF-1α is hydroxylated by prolyl hydroxylase, which directs its ubiquitination and degradation, 
thus preventing its action, while under hypoxic or stress conditions, or in vitro in the presence of 
cobalt ions, the prolyl hydroxylase is impaired and HIF-1α function is maintained (Maxwell, 
Wiesener et al. 1999, Lee, Keith et al. 2001, Semenza 2004).  In support of the idea that HIF-1α 
regulates HA-1 expression in trophoblast cells, there are at least 3 sequences (5’-GCGTG-3’) in 
the upstream promoter region of the HA-1 gene that could serve as HIF-1α binding sites (800, 
219 and 100 base pairs upstream of the HA-1 transcription start site).  HIF-1α expression is also 
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increased in preeclamptic as compared to normal placentas (Caniggia and Winter 2002).  HIF-1α 
expression in the preeclamptic placenta may be due to changes in oxygen tension, but HIF-1α 
can also be upregulated by other processes that occur in preeclampsia, including oxidative stress 
(Wang, Leng et al. 2011) and heightened proinflammatory cytokines (Thornton, Lane et al. 
2000).  One notable limitation of this study as a model of pre-eclampsia is the culture of purified 
cytotrophoblast cells at static oxygen conditions, rather than cycling conditions of hypoxia and 
normoxia, which would more closely mimic pre-eclampsia in vitro (Burton 2009).  We chose to 
examine HA-1 expression at static oxygen conditions in order to better clarify the precise role of 
oxygen in directly regulating HA-1 expression and remain interested in future studies examining 
the role of varying oxygen conditions in regulating HA-1 expression. 
HA-1-specific CD8+ T cells have been found in the peripheral blood following human 
pregnancy (Verdijk, Kloosterman et al. 2004), indicating that exposure of the maternal immune 
system to fetal HA-1 occurs during normal pregnancies.  Several factors may alter maternal 
exposure to HA-1, and possibly other minor histocompatibility antigens, in preeclampsia.  
Initially, the alteration in placental blood flow at the maternal-fetal interface in preeclamptic 
women leads to areas of ischemia/reperfusion (Hung, Skepper et al. 2001), which results in the 
production of reactive oxygen species (ROS) (Hung, Skepper et al. 2002, Jauniaux, Poston et al. 
2006, Burton 2009, Burton, Woods et al. 2009) and an increased deportation of 
syncytiotrophoblast fragments (Knight, Redman et al. 1998, Huppertz, Kaufmann et al. 2002, 
Huppertz, Kingdom et al. 2003, Goswami, Tannetta et al. 2006, Reddy, Zhong et al. 2008).  The 
increased release of syncytiotrophoblast microparticles into the peripheral blood, together with 
increased HA-1 expression could mean that the maternal immune system is exposed to higher 
concentrations of HA-1 in preeclampsia than in normal pregnancies.   
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Second, the production of acute phase reactants and pro-inflammatory cytokines, 
specifically TNF-α and IL-6 (Kronborg, Gjedsted et al. 2011), is characteristic of preeclampsia.  
This increase in pro-inflammatory cytokines together with increased expression of fetal antigen 
could combine to elicit a heightened antigen-specific maternal immune response in pregnancies 
complicated by preeclampsia.  Although heightened fetal antigen-specific immune responses in 
preeclampsia have not been definitively shown to date, some authors have suggested the 
possibility that disruptions in maternal-fetal tolerance (Redman and Sargent 2003, Redman and 
Sargent 2004, Martinez-Varea, Pellicer et al. 2014), a shift from Th2-mediated immunity to Th1-
mediated immunity (Sakai, Tsuda et al. 2002, Szarka, Rigo et al. 2010), and a reduction in 
quantity or function or regulatory T cells (Hsu, Santner-Nanan et al. 2012) may play important 
roles in the pathophysiology of preeclampsia. 
 In conclusion, we have shown that low oxygen levels as well as preeclampsia increase 
HA-1 expression by trophoblast cells of the human placenta.  The increased expression of HA-1 
in the syncytiotrophoblast of preeclamptic placentas combined with increased 
syncytiotrophoblast deportation and elevated levels of proinflammatory cytokines may have 
significant effects on maternal immune activation during preeclamptic as compared to normal 
pregnancies.  The effects of this enhanced immune activation on current and subsequent 
pregnancies is unknown and may provide important insights into the manifestation of 
preeclampsia, other pregnancy complications and the success or failure of HA-1-mismatched 
transplantations.   Further, given the function HA-1 as a Rho GTPase activating protein, and the 
potential for HA-1 expression to influence actin cytoskeletal remodeling (de Kreuk, Schaefer et 
al. 2013), the regulation of HA-1 expression is likely to be important for understanding not only 
the maternal immune response to the fetus during uncomplicated and preeclamptic pregnancies, 
but other biological processes as well. 
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CHAPTER 4: 
CHARACTERIZATION OF TROPHOBLAST-DERIVED MICROPARTICLES AND 
THEIR EFFECTS ON THE MATERNAL IMMUNE SYSTEM 
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ABSTRACT 
Pregnancy is a unique, naturally-occurring immunological event wherein two genetically distinct 
individuals co-exist in one body.  The placenta forms the interface between these two individuals 
and is an important mediator of maternal-fetal immune interactions.  It has long been known that 
the placenta releases large amounts of syncytiotrophoblast-derived material into the maternal 
circulation.  Recently, it has been discovered that this material includes actively secreted 
exosomes, which have been implicated in a number of disease states, most notably cancer.  In 
this chapter, we analyzed the protein content of primary human trophoblast-derived exosomes 
and microparticles and examined the effects of trophoblast-derived exosomes on human 
dendritic cells, both in the presence and absence of lipopolysaccharide (LPS).  Using mass 
spectrometry, we found that trophoblast-derived exosomes contain numerous exosome markers, 
including Alix and Syntenin, as well as proteins related to intracellular transport and localization, 
cellular stress responses, coagulation and hemostasis, and inflammatory responses.  Surprisingly, 
trophoblast exosomes expressed HLA-DR, which is not expressed on the surface of trophoblast 
cells.  In addition, we found that primary trophoblast-derived exosomes and microparticles can 
be taken up by human dendritic cells and that treatment of dendritic cells with trophoblast-
derived exosomes resulted in increased mRNA levels of CD80 (P=0.05), an activation marker, 
as well as IL-8 (P=0.05) and VCAM-1 (P=0.01), both of which are involved in angiogenesis, 
when compared to vehicle-treated controls.  In addition, dendritic cells that were treated with 
LPS + exosomes showed significantly decreased mRNA expression of CD40LG (P=0.002) and 
CCL7 (P=0.03), which are important for dendritic cell activation and migration, when compared 
to dendritic cells treated with LPS alone.  These findings provide important insights into the 
mechanisms by which trophoblast exosomes may alter maternal immune function during 
pregnancy. 
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INTRODUCTION 
Pregnancy provides a unique opportunity to study how two genetically distinct 
individuals can co-exist without either immune system mounting a severe and detrimental 
immune response to the other.  The mechanisms by which the maternal immune system 
recognizes but does not reject the developing fetus are not yet completely understood.  Further 
investigation of how rejection and tolerance are mediated in this naturally occurring system will 
help us better understand how successful pregnancies are maintained and the role of the immune 
system in many biological processes, including solid organ and hematopoietic transplantations.  
In this chapter we will examine how cellular materials released from the placenta during 
pregnancy can influence the maternal immune response to the fetus. 
The placenta is a highly proliferative organ and large amounts of cellular materials are 
released from the surface of the placenta into the maternal blood supply during pregnancy. These 
materials include large, multinucleated syncytial knots, apoptotic debris and cell fragments, 
microvesicles and exosomes (Jones and Fox 1980, Huppertz, Frank et al. 1998, Huppertz, 
Kaufmann et al. 2002, Sargent, Germain et al. 2003). This release of placental materials into the 
maternal bloodstream is one route by which the maternal immune system may be exposed to 
fetal antigens during pregnancy (Chamley, Chen et al. 2011, Holland, Linscheid et al. 2012).  In 
this chapter we will use mass spectrometry to examine the contents of shed exosomes and larger 
microparticles as well as investigate the effects of trophoblast-derived exosomes on dendritic 
cells (DCs), a subset of immune cells responsible for the presentation of both foreign and innate 
antigens to CD8+ T-cells.   
Dendritic cells comprise 2-8% of the maternal immune cells in the decidua during 
pregnancy (Bartmann, Segerer et al. 2014) and play an important role in mediating the 
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relationship between the innate and adaptive immune systems.  In part, dendritic cells are 
responsible for the phagocytosis, processing and presentation of antigens to T-cells.  This is 
important for immune recognition and response to foreign antigens (including fetal antigens), as 
well as self antigens. Despite their relatively low proportions in the decidua, dendritic cells are 
one of the primary cell types involved in indirect antigen presentation to T-cells, a process that is 
critical for maternal immune recognition of fetal antigens (Erlebacher, Vencato et al. 2007), 
making it highly likely that they are involved in maternal immune responses during pregnancy.  
Resting dendritic cells that lack the co-stimulatory molecules necessary for CD8+ T-cell 
activation can lead to tolerance rather than CD8+ T-cell-mediated cytotoxicity (Probst, McCoy et 
al. 2005).  Despite a well-established role in CD8+ T-cell activation, relatively little is known 
about peripheral dendritic cells during pregnancy.  Recent work in mice suggests that the 
decidual environment may block dendritic cell migration, even in the presence of a strong 
immuno-stimulatory molecule such as LPS, suggesting that intrinsic characteristics of the 
pregnant uterus may prevent migration of decidual dendritic cells to peripheral lymph nodes 
where antigen cross-presentation to maternal T-cells could occur (Collins, Tay et al. 2009).  
However, this does not address the possibility that fetal antigens released into the peripheral 
blood may encounter maternal dendritic cells, leading to cross-presentation of fetal antigens to 
maternal CD8+ T-cells.  In addition, myeloid dendritic cells isolated from pregnant women prior 
to 37-weeks gestational age showed lower levels of the activation markers, CD80, CD86 and 
HLA-DR, suggesting that basal activation of myeloid dendritic cells is decreased during 
pregnancy (Bachy, Williams et al. 2008).  Dendritic cells from the blood of pregnant women also 
demonstrated increased production of the anti-inflammatory cytokine, IL-10, when stimulated 
with either TNF-α or IL-1β, as compared to non-pregnant dendritic cells (Bachy, Williams et al. 
2008).  The phenotype of dendritic cells during pregnancy is particularly important given their 
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role in cross-presenting antigens to T-cells.  We are interested in how materials from the placenta 
may affect dendritic cell phenotype and function during human pregnancy. 
 Exosomes and larger microparticles provide one potential source for maternal immune 
exposure to fetal antigens.  Exosomes are small, cup-shaped nanoparticles (50-150nm) derived 
from late multi-vesicular endosomes that were first discovered in the context of their release 
from tumor cells and are actively secreted rather than passively shed (Taylor and Doellgast 1979, 
Trams, Lauter et al. 1981, Chaput and Thery 2011).  In addition to tumor cells, exosomes are 
released by many different cell types including reticulocytes, dendritic cells and placental 
trophoblasts (Pan, Teng et al. 1985, Knight, Redman et al. 1998, Zitvogel, Regnault et al. 1998, 
Mincheva-Nilsson and Baranov 2010).  Increased release of microparticles from the placenta has 
been implicated in preeclampsia, a common pregnancy complication characterized by elevated 
blood pressure and proteinuria and a leading cause of premature delivery (Knight, Redman et al. 
1998, Goswami, Tannetta et al. 2006, Reddy, Zhong et al. 2008, Burton and Jones 2009).  Recent 
work suggests that placental exosomes may play a role in maternal immune modulation (Taylor, 
Akyol et al. 2006, Hedlund, Stenqvist et al. 2009).  Specifically, circulating exosomes from 
women who delivered prematurely expressed significantly lower levels of the Class II MHC, 
HLA-DR, and were less effective at preventing activation of T-cells when compared to 
exosomes from women who delivered at term, suggesting that during normal pregnancy, 
exosomes may play an important role in modulating maternal immune responses (Taylor, Akyol 
et al. 2006).  Expression of NKG2D ligands on exosomes from first-trimester placental explants 
has also been shown to decrease activation of CD8+ T-cells, providing further evidence for an 
immunosuppressive role of placental exosomes (Hedlund, Stenqvist et al. 2009).  Interestingly, 
recent work using a trophoblast cell line, Swan71, has indicated that trophoblast-derived 
exosomes are capable of recruiting monocytes and stimulating the production of the pro-
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inflammatory cytokine, IL-1β, via exosome-associated fibronectin (Atay, Gercel-Taylor et al. 
2011, Atay, Gercel-Taylor et al. 2011).  This work suggests that placental exosomes may have 
both tolerogenic and pro-inflammatory effects on maternal immune cells.  It is not clear if these 
differences are primarily related to the source of the exosomes (peripheral blood vs. placental 
explant vs. cell line) or the target cell type (T-cells vs. monocytes).   
 In order to address some of these questions, we will examine the effects of primary 
trophoblasts on dendritic cells directly, in an attempt to create in vitro model for the role of 
trophoblast-derived exosomes in modulating maternal immune responses to fetal antigens.  
Notably, our lab has found that the cancer antigen, 5T4 (also known as trophoblast glycoprotein), 
is expressed at high levels in placental exosomes, suggesting that exosomes may act as a source 
of fetal antigen during pregnancy (M. Petroff, unpublished).  This work is the first investigation 
of the effects of placental exosomes and microparticles on dendritic cell phenotype and will 
provide important information about how antigenic materials released from the placenta can 
modulate the maternal immune response to the fetus during pregnancy. 
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MATERIALS AND METHODS 
Tissue Collection 
All tissues were collected in accordance with protocols approved by the University of 
Kansas Medical Center Institutional Review Board.  Trophoblast cells were isolated from term 
placentas obtained from non-laboring Caesarian sections as previously described (Petroff, Chen 
et al. 2003, Petroff, Phillips et al. 2006). Briefly, approximately 40g of villous tissue was 
dissected and rinsed in sterile saline (0.9% NaCl). The tissue was subjected to enzymatic 
digestion with Trypsin (Gibco, Grand Island, NY) and DNase (Sigma-Aldrich, St. Louis, MO).  
The cell digest was then resuspended in Hank’s balanced salt solution with 25mM HEPES buffer 
(Cellgro, Manassas, VA) and layerd over a Percoll (Sigma-Aldrich) gradient (5%-70% Percoll in 
HBSS + 25mM HEPES).  The cell fraction containing trophoblasts (approximately 40-50% 
Percoll, densities 1.052-1.065 g/ml) was carefully aspirated and washed repeatedly with IMDM 
media (Cellgro) containing 10% FBS (Atlanta Biologicals, Flowery Branch, GA), 1X L-
glutamine (Cellgro) and 1X antibiotic/antimycotic (Cellgro).  Cell purity was assessed by flow 
cytometry using an antibody against cytokeratin 7 (Millipore, Billerica, MA).  Only preparations 
with >90% purity were used in experiments. 
Trophoblast Culture 
Purified cytotrophoblast cells were plated at a density of 20x106 cells per 60mm culture 
dish overnight in exosome-free cytotrophoblast culture media at 37oC with 5% carbon dioxide, 
95% normal air.  Cells were then washed in pre-equilibrated exosome-free media to remove any 
cellular debris and cultured at 8% oxygen in cytotrophoblast culture media containing 5 ng/ml 
human epidermal growth factor (hEGF, Peprotech, Rocky Hill, NJ) for 3 days using an H35 
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hypoxia chamber (Hypoxygen, Frederick, MD).  Following culture, exosomes and larger 
microparticles were collected as described below. 
Exosome and Microparticle Collection 
Following trophoblast culture, exosomes and larger microparticles (referred to as 10K 
microparticles) were isolated and previously described (Kshirsagar, Alam et al. 2012, Cronqvist, 
Salje et al. 2014).  Briefly, cell culture supernatants were subjected to repeated centrifugations at 
300xg, 2000xg and 10,000xg (10, 20 and 30 minutes, respectively) at 4°C.  The supernatant and 
pellet obtained following the 10,000xg centrifugation were separated and the pellet was 
resuspended in 1ml of 1X PBS (Cellgro) and stored at -80°C for analysis as the 10K 
microparticle fraction.  The remaining supernatant was centrifuged at 150,000xg for 70 minutes 
at 4°C to isolated the exosomal fraction.  The exosome pellet was then washed twice in 1X PBS 
(100,000xg for 70 minutes at 4°C) and then resuspended in 50-100µl 1X PBS and stored at -
80°C for exosome experiments.  Exosome protein concentrations were determined with the DC 
Protein Assay (Bio-Rad, Hercules, CA) according to the manufacturer’s directions. 
Nanoparticle Tracking Analysis - NTA 
All exosome and microparticle preparations were analyzed using nanoparticle tracking 
analysis using a NanoSight LM14, software version 2.3 Build 0011 (NanoSight Ltd. Amesbury, 
UK).  Samples were diluted in sterile 1XPBS and the absence of particles in the PBS was 
confirmed prior to each recording.  Samples were vortexed extensively prior to loading and each 
sample was recorded 5 times for 60 seconds using the default recording settings at ambient 
temperature.  
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Electron Microscopy  
Exosomes and 10K microparticles were fixed in 1% gluteraldehyde and embedded on 
formvar-carbon grids.  Exosomes and microparticles were imaged by the University of Kansas 
Electron Microscopy Core using a JEOL JEM-1400 Transmission Electron Microscope. Grid 
squares examined for morphology and purity were chosen at random to avoid selection bias. 
Mass Spectrometry  
Exosome and 10K microparticles were washed in 1ml of 1X PBS and centrifuged at 
100,000xg for 70 minutes at 4°C.  The pellets were resuspended in sample buffer containing 1M 
Tris-HCl (Sigma-Aldrich), 20% SDS (Bio-Rad), 20% glycerol (Acros, Waltham, MA), 5% beta-
mercaptoethanol (Sigma) and 0.48g 8M Urea (Expedeon, San Diego, CA).  Samples were run on 
a 12% SDS-PAGE gel (Bio-Rad) for 1 hour at 120V.  Each lane was cut into 12 equal bands and 
each band was subjected to trypsin digestion using 12.5 µg/mL trypsin in 25mM NH4HCO3.  
Individual peptides were identified using HPLC MS/MS with multidimensional protein 
identification technology (MUD PIT) and only proteins with two more identified peptides were 
included in our analyses.   
Dendritic Cell Culture  
Dendritic cells were derived in vitro from peripheral mononuclear cells (PBMCs) isolated 
from a healthy male donor as previously described (Kanof, Smith et al. 1996).  Approximately 
100ml of peripheral blood was collected in heparinized tubes and diluted in an equal volume of 
1X PBS.  Whole blood was centrifuged for 15 minutes at 200xg.  The pellet was diluted in an 
equal volume of 1X PBS, layered over a cushion of Histopaque 1077 (Sigma-Aldrich) and 
centrifuged for 30 minutes at 900xg (20°C, no brake).  The mononuclear fraction was carefully 
aspirated and washed several times in RPMI-1640 (Cellgro) containing 10% FBS.  The isolated 
PBMCs were differentiated into dendritic cells as previously described(O'Neill and Bhardwaj 
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2005).  Briefly, PBMCs were cultured for 2 hours in RPMI-10 and washed to remove non-
adherent cells.  Adherent monocytes were cultured in RPMI-10 for 5 days with 200 IU/µl 
interleukin-4 (IL-4, R&D Systems, Minneapolis, MN) and 100 IU/µl granulocyte-macrophage 
colony-stimulating factor (GM-CSF, R&D Systems).  Cytokines were added on day 3 and 
immature dendritic cells were harvested on day 5, counted and replated (1.5x106 cells per 
condition) overnight.  The dendritic cells were then treated for 18 hours with vehicle (PBS), LPS 
alone (1 µg/ml, Sigma-Aldrich), LPS (1 µg/ml) + exosomes (20µg) or exosomes (20µg) alone. 
Treated dendritic cells were then collected for analysis of purity by flow cytometry or collected 
in TriReagent (Ambion, Austin, TX) for RT-PCR analysis.  Dendritic cell purity was >80% as 
assessed using an antibody against HLA-DR (Biolegend, San Diego, CA). 
Immunofluorescence  
To determine if human dendritic cells were able to phagocytose placental exosomes and 
10K microparticles, the exosomes and 10K microparticles were centrifuged at 10,000xg for 30 
minutes at 4°C (for the 10K microparticles) or at 150,000xg for 70 minutes at 4°C (for the 
exosomes) and were labeled with the green fluorescent dye PKH67 (Sigma), according to the 
manufacturer’s directions, and co-cultured overnight with PKH26-labeled dendritic cells, such 
that only those dendritic cells able to phagocytose PKH26 would exhibit red fluorescence.  The 
dendritic cells treated or not treated with labeled exosomes were imaged using a Nikon TE-
2000U confocal microscope to determine if the exosomes and 10K microparticles would co-
localize with the phagocytosis dye, PKH26, indicating possible phagocytosis of the exosomes 
and 10K microparticles. 
RT-PCR 
RNA was extracted from treated dendritic cells using an RNeasy Mini Kit (Qiagen, 
Germantown, MD) for PCR Array experiments or TRI Reagent (Sigma) for RT-PCR 
	   91	  
confirmation experiments.  All extractions were carried out according to the manufacturer’s 
directions and RNA concentrations were determined using the NanoChip on a 2100 Agilent 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).  For PCR Array experiments, cDNA was 
synthesized from 100ng total RNA using the RT First Strand Kit (Qiagen) and RT-PCR was 
carried out using the RT Profiler PCR Array for human dendritic and antigen presenting cells 
(Qiagen, cat# 330231 PAHS-406ZA).  All samples were run in triplicate and average fold-
change for each sample was calculated using the ddCt method, using beta-2-microglobulin for 
normalization.  Genomic DNA contamination and reverse transcription controls were used for 
each plate to ensure validity.  Eleven potential mRNA targets were identified from the array and 
selected for RT-PCR confirmation.  For RT-PCR confirmation, we repeated the experiment three 
more times using different exosome preparations and freshly isolated dendritic cells from the 
same male donor.  Dendritic cell RNA was isolated as described above and 0.5µg of RNA was 
reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) and 
random primers (Invitrogen) in a reaction volume of 20 µl.  A parallel reaction that included 
RNA but no reverse transcriptase was included as a control to ensure the absence of genomic 
DNA in the samples.  2 µl of the reverse transcription (RT) reaction was subjected to polymerase 
chain reaction (PCR) using Taq DNA polymerase (Fermentas, Glen Burnie, MD).  RT-PCR for 
eleven target genes and the housekeeping gene, beta-2-microglobulin, was carried out using the 
following TagMan Gene Expression Assays (Applied Biosystems, Foster City, CA).  The 
mRNAs assayed were: CD40 ligand (assay number: Hs00163934_m1), CD40 (assay number: 
Hs01002913_g1), CCL7 (assay number: Hs00171147_m1), CD1B (assay number: 
Hs00957537_m1), CD80 (assay number: Hs00175478_m1), CLEC4C (assay number: 
Hs01092462_m1), FLT3 (assay number: Hs00174690_m1), FLT3 ligand (assay number: 
Hs00957747_m1), IL-8 (Hs00174103_m1), RAC1 (assay number: Hs01902432_s1), and 
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VCAM1 (assay number: Hs01003372_m1). All samples were run in triplicate and average fold 
change for each sample was calculated using ddCt values and normalized to the beta-2-
microglobulin control (assay number: Hs00984230_m1). 
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RESULTS  
Isolation of Trophoblast-Derived Microparticles and Exosomes  
 Exosomes and microparticles were isolated from primary trophoblast cells as described 
above.  We used both electron microscopy and Nanoparticle Tracking Analysis to confirm that 
the isolated fractions contained exosomes and microparticles.  The exosomal fraction was 
relatively homogenous and consisted of rounded and/or cup-shaped structures, consistent with 
previous reports of placental exosomes (Dragovic, Gardiner et al. 2011) (Figures 4.1A&C, 
4.2A).  In addition, NTA analysis of the exosomes indicated that the average size was 131nm 
and that the sample preparations were relatively homogeneous. The microvesicle fraction, in 
contrast, was heterogeneous when viewed by electron microscopy, with particles ranging in size 
from 30nm to 1µm and had an average size of 176nm when analyzed using NTA (Figures 
4.1B&D and 4.2B).  
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Figure 4.1: Comparison of exosomes and 10K microparticles by nanoparticle tracking 
analysis.  
Exosomes and 10K microparticles were isolated for purified term trophoblast cells cultured at 
8% oxygen with 5ng/ml hEGF for 3 days.   A. Representative NTA profile for 5 replicates from 
a single exosome experiment.  Y-axis measures the number of particles (108/ml). B. NTA profile 
for 5 replicates from a single 10K experiment.  C. Representative NTA image for primary 
trophoblast-derived exosomes.  D. Representative NTA image for primary trophoblast-derived 
10K microparticles.  
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Figure 4.2: Electron microscopy of trophoblast-derived exosomes and microparticles.  
Exosomes and 10K microparticles were isolated from purified term trophoblast cells by 
ultracentrifugation.  Exosome and microparticle pellets were fixed in 1% gluteraldehyde and 
imaged using a JEOL JEM-1400 Transmission Electron Microscope. A. Representative electron 
microscopy image of trophoblast-derived exosomes. Exosome sizes range from 49.1nm to 114 
nm. B. Representative electron microscopy image of trophoblast-derived 10K microparticles.  
Microparticle sizes range from 195nm to 304nm. 
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Protein Analysis of Exosomes and Microparticles  
 Exosomes have been shown to have a wide variety of contents, including microRNAs, 
mRNAs and proteins.  To determine the protein content of trophoblast-derived exosomes and 
microparticles, 35 µg of protein from matched exosome and 10K samples was loaded onto a 12% 
SDS PAGE gel and each band was separately excised, subjected to trypsin digestion and 
analyzed using HPLC MS/MS with multidimensional protein identification technology (MUD 
PIT).  Proteins were only considered positive identifications if two or more separate peptides 
were identified using HPLC MS/MS.  8 proteins were identified in both the exosome and 10K 
fractions, including several cytoskeletal proteins.  Interestingly, only 2 of the identified proteins 
were unique to the 10K fraction, whereas there were 32 proteins that were found in the exosome 
fraction but not in the 10K fraction (Table 4.1).  The proteins unique to the exosome fraction 
included several proteins that have been identified as exosome markers, including Hsc70, 
GAPDH, Annexin A2, Alpha-enolase, Syntenin, Annexin A5 and Alix (Mathivanan and 
Simpson 2009, Mathivanan, Fahner et al. 2012, Simpson, Kalra et al. 2012).   
All of the identified proteins were analyzed using the open-source pathway analysis 
program, G-Profiler (Reimand, Arak et al. 2011).  Four primary functional pathways were 
identified using this approach: localization and transport, stress response, coagulation and 
hemostasis and inflammatory response (Table 4.2).  In addition, three cytoskeletal keratins were 
identified in our exosomes (KRTs 1, 2, and 9), all of which had been previously identified in 
exosomes from other cell types (Mathivanan and Simpson 2009, Mathivanan, Fahner et al. 2012, 
Simpson, Kalra et al. 2012).   
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Table 4.1: Proteins from Trophoblast-derived Exosomes and Microparticles 
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Exosomes Only 10K Microparticles Only Both Exosomes and 10K 
Microparticles 
Actin-Fimbrin Complex Keratin 16 Alpha-2 Macroglobulin 
Albumin Keratin 17 Apolipoprotein B 
Alix  Fibronectin 1 
Alpha tubulin  Inter-alpha inhibitor H2 
Alpha-2-HS-glycoprotein  Keratin 1 
Alpha-enolase  Keratin 2 
Alpha-fetoprotein  Keratin 9 
Annexin A1  Vitamin D-binding protein X1 
Annexin A11   
Annexin A2   
Annexin A3   
Annexin A5   
Annexin A6   
Apolipoprotein E   
Complement C3   
DaxxH3.3   
Dipeptidyl-peptidase 4   
Facilitated glucose 
transporter member 1 
  
GAPDH   
Gelsolin   
Hemoglobin   
Hemoglobin Bart’s   
Histone H2A type 2-C   
HLA-DR   
Hsc70   
Inter-alpha inhibitor H3   
Lumican   
Protein 14-3-3   
Serpin peptidase inhibitor, 
clade F 
  
Syndecan binding protein 
(syntenin) 
  
Thrombin   
Thrombospondin-1   
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Table 4.2: G:Profiler Pathway Analysis on Trophoblast-derived Exosomes 
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Exosome	  
Markers	  
Localization	  and	  
Transport	  
Stress	  Response	   Coagulation	  and	  
Hemostasis	  
Inflammatory	  
Response	  
Alix	   Actin-­‐Fimbrin	  
Complex	  
Actin-­‐Fimbrin	  
Complex	  
Actin-­‐Fimbrin	  
Complex	  
Alpha-­‐2-­‐HS-­‐
glycoprotein	  
Alpha-­‐enolase	   Albumin	   Albumin	   Albumin	   Annexin	  A1	  
Annexin	  A2	   Alix	   Alpha-­‐2-­‐HS-­‐
glycoprotein	  
Alpha	  feto-­‐protein	   Complement	  C3	  
Annexin	  A5	   Alpha	  feto-­‐protein	   Annexin	  A1	   Alpha-­‐2-­‐HS-­‐
glycoprotein	  
HLA-­‐DR	  
GAPDH	   Alpha	  tubulin	   Annexin	  A2	   Alpha-­‐enolase	   Serpin	  peptidase	  
inhibitor,	  clade	  F	  
Hsc70	   Alpha-­‐2-­‐HS-­‐
glycoprotein	  
Annexin	  A3	   Annexin	  A1	   Thrombospondin	  
Syndecan	  
binding	  protein	  
(syntenin)	  
Annexin	  A1	   Annexin	  A5	   Annexin	  A2	   	  
	   Annexin	  A2	   Complement	  C3	   Annexin	  A3	   	  
	   Annexin	  A3	   DaxxH3.3	   Annexin	  A5	   	  
	   Annexin	  A6	   Dipeptidyl-­‐peptidase	  
4	  
Annexin	  A6	   	  
	   Annexin	  A11	   Facilitated	  glucose	  
transporter	  1	  
Complement	  C3	   	  
	   Complement	  C3	   GAPDH	   DaxxH3.3	   	  
	   Dipeptidyl-­‐
peptidase	  4	  
Gelsolin	   Dipeptidyl-­‐peptidase	  
4	  
	  
	   Facilitated	  glucose	  
transporter	  1	  
Hemoglobin	   Facilitated	  glucose	  
transporter	  1	  
	  
	   Gelsolin	   Hsc70	   GAPDH	   	  
	   Hemoglobin	   Serpin	  peptidase	  
inhibitor,	  clade	  F	  
Gelsolin	   	  
	   Hsc70	   Syndecan	  binding	  
protein	  (syntenin)	  
Hemoglobin	   	  
	   Protein	  14-­‐3-­‐3	   Thrombin	   Hsc70	   	  
	   Syndecan	  binding	  
protein	  (syntenin)	  
Thrombospondin-­‐1	   Inter-­‐alpha	  inhibitor	  
H3	  
	  
	   Thrombin	   	   Lumican	   	  
	   Thrombospondin-­‐1	   	   Protein	  14-­‐3-­‐3	   	  
	   	   	   Serpin	  peptidase	  
inhibitor,	  clade	  F	  
	  
	   	   	   Syndecan	  binding	  
protein	  (syntenin)	  
	  
	   	   	   Thrombin	   	  
	   	   	   Thrombospondin-­‐1	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Phagocytosis of Trophoblast-Derived Exosomes and 10K Microparticles by Human 
Dendritic Cells  
 To begin determining the potential functional impact of trophoblast-derived exosomes on 
human dendritic cells, we investigated whether monocyte-derived dendritic cells are capable of 
phagocytosing trophoblast-derived exosomes and/or microparticles.  To do this, exosomes and 
microparticles were stained with a green fluorescent dye, PKH67, and co-cultured individually 
with dendritic cells that were labeled with PKH26, a red fluorescent dye that does not bind to the 
cell surface, but rather only remains visible when it is phagocytosed, making it a good marker of 
dendritic cells with phagocytic capabilities (Atay, Gercel-Taylor et al. 2011). 
 Many of the dendritic cells did not show co-localization of the phagocytic dye and the 
exosomes, suggesting that most of the dendritic cells were functional but did not phagocytose the 
exosomes (Figure 4.3).  However, there were a substantial number of dendritic cells that 
displayed co-localization of the phagocytic dye and the exosomes (Figure 4.3E,F).  The patchy 
distribution of the green staining (exosomes) and co-localization with the red phagocytic dye is 
to be expected if the exosomes are enclosed within phagocytic vesicles, rather than being 
adhered to the outside of the cells, and is similar to a previous report in a paper outlining 
phagocytosis of trophoblast-derived exosomes by macrophages (Atay, Gercel-Taylor et al. 
2011).  Co-localization of the green 10K microparticles and the red phagocytic dye was less 
convincing, with most, if not all, of the dendritic cells displaying only red staining (Figure 
4.3B,C).   
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Figure 4.3: Uptake of Trophoblast-derived 10K Microparticles and Exosomes by Human 
Dendritic Cells.   
Human dendritic cells were co-cultured with PKH67-stained, human trophoblast-derived 10K 
microparticles (A-C) and exosomes (D-F).  The dendritic cells were treated with a red dye, 
PKH26, to confirm their ability to phagocytose.  Co-staining of green and red (yellow) indicates 
dendritic cells containing either microparticles or exosomes.  The star indicates a group of 
dendritic cells that are stained only with the red, phagocytic dye, indicating DCs capable of 
phagocytosis that have not phagocytosed labeled exosomes or microparticles.  The small arrow 
shows an area of a dendritic cell containing neither red nor green dye, whereas the large arrow 
shows the patchy distribution of green exosomes co-localized with the red phagocytic dye, 
suggesting that the exosomes are likely contained within phagocytic vesicles.   
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Effects of Trophoblast-Derived Exosomes on Human Dendritic Cells  
 Human dendritic cells were isolated as described above and treated for 18 hours with 
vehicle (PBS), LPS alone (1 µg/ml), LPS (1 µg/ml) + exosomes (20µg) or exosomes (20µg) 
alone.  We used LPS to stimulate the dendritic cells because we wanted to examine the effects of 
trophoblast-derived exosomes in both non-inflammatory and pro-inflammatory conditions.  This 
is particularly important given the possibility that trophoblast-derived exosomes may have 
different effects on dendritic cells depending on whether or not the dendritic cells are being 
activated by another stimulus.  The effects of the four treatment conditions were first examined 
using a commercially-available PCR array for human dendritic and antigen-presenting cells.  
Using the RT2 PCR Data Analysis Software from Qiagen, we identified 11 mRNAs that 
appeared to differ between experimental and control groups (p<0.1) (Table 4.3).   
 In order to confirm these effects, we repeated the experiment 3 more times using 
additional dendritic cells and exosome preparations.  We analyzed the candidate mRNAs 
identified during the first set of experiments using qRT-PCR.  In order to completely account for 
the total biological variability between samples, we combined the data from both experiments, 
and found that treatment of dendritic cells with trophoblast-derived exosomes increased 
expression of CD80, IL-8 and VCMA1 mRNAs when compared to vehicle-treated controls 
(p=0.05, 0.05 and 0.01, respectively, Figure 4.4).  In addition, treatment of dendritic cells with 
LPS + exosomes significantly decreased expression of CD40LG and CCL7 when compared to 
samples treated with LPS alone (p=0.002 and 0.03, respectively, Figure 4.5).  Notably, CD80 
was originally predicted to differ between the LPS and LPS + exosome-treated conditions, but 
was only significantly different between the vehicle and exosome-treated conditions.   
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Table 4.3: Potentially Significant Dendritic Cell mRNAs Identified Using PCR Array 
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Vehicle-Alone vs. Exosomes LPS Alone vs. LPS + Exosomes 
RAC1 CD1B 
IL-8 CD40LG 
VCAM1 CD40 
 CD80 
 CLEC4C 
 FLT3 
 FLT3LG 
 CCL7 
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Figure 4.4: Treatment of Human Dendritic Cells with Trophoblast-Derived Exosomes 
Significantly Increases Expression of CD80, IL-8 and VCAM1.   
Dendritic cells (1.5X106 cells/condition, n=6) were treated with vehicle (PBS) or trophoblast-
derived exosomes suspended in PBS (20µg exosomes) for 18 hours.  Expression of CD80, IL-8 
and VCAM1 mRNAs was significantly increased (p=0.05, 0.05 and 0.01, respectively) in the 
dendritic cells treated with exosomes as compared to vehicle-treated controls. 
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Figure 4.5: Treatment of Human Dendritic Cells with Trophoblast-Derived Exosomes + 
LPS Significantly Decreases Expression of CCL7 and CD40LG When Compared to 
Dendritic Cells Treated with LPS Alone.   
Dendritic cells (1.5X106 cells/condition, n=6) were treated with LPS (1µg/ml) or LPS (1µg/ml) + 
trophoblast-derived exosomes (20µg) for 18 hours.  Expression of CCL7 and CD40LG mRNAs 
was significantly decreased in the dendritic cells treated with LPS + exosomes as compared to 
dendritic cells treated with only LPS (p=0.002 and 0.03, respectively). 
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DISCUSSION 
In this chapter we have shown that human dendritic cells can take up trophoblast-derived 
exosomes and microparticles and that trophoblast-derived exosomes contain a unique set of 
proteins and can affect dendritic cell phenotype.  In order to determine how the protein contents 
of primary trophoblast-derived exosomes compare to other published descriptions of exosome 
contents, we compared the proteins found in our preparations of primary trophoblast-derived 
exosomes to published lists of proteins found in exosomes from Swan71 cells (Atay, Gercel-
Taylor et al. 2011), a commonly used extravillous trophoblast cell line, and human dendritic cells 
(Thery, Boussac et al. 2001) (Fig. 4.6).  In addition to their size and morphology (Figure 4.1 & 
4.2), the trophoblast-derived exosomes contained a number of proteins identified as exosome 
markers, including ALIX, numerous Annexins, Hsc70 and Syntenin.  Interactions between 
Syntenin and ALIX have recently been shown to be important for exosome biogenesis (Baietti, 
Zhang et al. 2012) and various Annexins and Hsc70 have been widely used as exosome markers 
in a variety of cell types and model systems (Hegmans, Bard et al. 2004, Mathivanan and 
Simpson 2009, Mathivanan, Fahner et al. 2012, Simpson, Kalra et al. 2012). 
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Figure 4.6: Comparison of Primary Trophoblast-Derived Exosomes to Swan71 and 
Dendritic Cell-derived Exosomes.   
The protein contents of primary trophoblast-derived exosomes were compared to published lists 
of proteins found in exosomes from a commonly used extravillous trophoblast cell line, Swan-
71, and primary human dendritic cells.  Of the 32 proteins found in primary trophoblast-derived 
exosomes, 13 were found in all three exosome types, 3 were found in both primary trophoblast 
and dendritic cell-derived exosomes, 6 were found in both primary trophoblast and Swan71-
derived exosomes and 9 were unique to the trophoblast-derived exosomes. 
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 One of the most surprising findings was that the primary trophoblast-derived exosomes 
contained the Class II MHC, HLA-DR.  It has long been known that trophoblast cells do not 
express Class II MHCs on the surface, presumably to avoid rejection of the placenta by the 
maternal immune system  (Chatterjee-Hasrouni, Montgomery et al. 1983, Hunt and Hsi 1990, 
Murphy, Choi et al. 2004).  However, there has been at least one report of intracellular, but not 
extracellular, HLA-DR in human trophoblast cells (Ranella, Vassiliadis et al. 2005) and 
researchers studying placental exosomes found in peripheral maternal blood have also reported 
presence of HLA-DR (Taylor, Akyol et al. 2006).  Taken together, these results suggest that 
trophoblast-derived exosomes may contain HLA-DR, which could have important implications 
for maternal immune recognition of the fetus during pregnancy. 
Intriguingly, other researchers have proposed a link between maternal and paternal HLA-
DR and HLA-DQ disparity and a decrease in rheumatoid arthritis symptomology during 
pregnancy.  This suggests a connection between maternal immune recognition of paternally -
inherited fetal MHC Class II molecules and decreased maternal rheumatoid arthritis 
symptomology during pregnancy (Nelson, Hughes et al. 1993).   However, how the maternal 
immune system could be exposed to paternally-inherited antigens during pregnancy has never 
been clearly defined.  Our findings here suggest that trophoblast-derived exosomes could be a 
source of maternal immune exposure to paternal HLA-DR during pregnancy. 
In addition, research by de Luca Brunori et al. has indicated that preeclampsia is 
significantly more common in pregnancies where there is a high level of similarity between 
maternal and paternal HLA-DR molecules (de Luca Brunori, Battini et al. 2000, de Luca 
Brunori, Battini et al. 2003).  In these studies, the authors hypothesized that maternal immune 
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exposure to paternal HLA-DR likely occurred during sexual intercourse (de Luca Brunori, 
Battini et al. 2000, de Luca Brunori, Battini et al. 2003).  Our findings that HLA-DR is expressed 
by purified term trophoblast-derived exosomes provides another possible explanation, that 
exposure to paternal HLA-DR occurs throughout the pregnancy and not just following exposure 
to paternal semen.  
At least two other proteins found in the exosomes have been associated with pre-
eclampsia.  Alterations in expression levels of alpha-2-HS-glycoprotein (also known as Fetuin 
A) in trophoblast cells and in maternal serum have been associated with pre-eclampsia 
(Molvarec, Kalabay et al. 2009, Gomez, Anton et al. 2012).  In addition, decreased levels of the 
anti-angiogenic factor, thrombospondin-1, in maternal circulation has been associated with 
HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, a severe form of pre-
eclampsia (Stenczer, Molvarec et al. 2012).  In both cases, the connections between materials 
contained in exosomes from normal trophoblasts, the altered release of trophoblast debris and 
exosomes from the placenta in pre-eclampsia and the effects of the contents of theses exosomes 
on maternal cells is unclear.  However, we hope that by documenting the inclusion of these 
proteins in trophoblast-derived exosomes, we can come one step closer to understanding the 
intricate balance of released trophoblast-derived microparticles and the maternal immune system 
that is important for successful pregnancy outcomes (Chua, Wilkins et al. 1991, Knight, Redman 
et al. 1998, Goswami, Tannetta et al. 2006, Redman and Sargent 2007, Redman and Sargent 
2008).  
Interestingly, treatment of human dendritic cells with trophoblast exosomes lead to 
increased expression of both IL-8 and VCAM-1, both of which are closely associated with 
angiogenesis (Koch, Polverini et al. 1992, Fukushi, Ono et al. 2000, Simonini, Moscucci et al. 
2000, Hou, Ryu et al. 2014).  Recent work on the effects of exosomes derived from chronic 
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myelogenous leukemia cells on endothelial cells also showed increased expression of IL-8 and 
VCAM-1 (Taverna, Flugy et al. 2012).  Studies in mice have indicated that uterine dendritic cells 
(uDCs) are required for successful pregnancy and that depletion of uDCs leads to embryo 
resorption.  MRI studies in these mice indicated defective decidual vascular expansion, likely as 
a result of decreased release of molecules involved in angiogenesis from the uDCs (Plaks, 
Birnberg et al. 2008).  Together, these data suggest that trophoblast-derived exosomes may be 
interacting with uDCs to increase the release of pro-angiogenic molecules important for a 
successful pregnancy. 
Treatment of dendritic cells with trophoblast-derived exosomes also resulted in increased 
mRNA expression of the dendritic cell activation marker, CD80.  Increased dendritic cell 
activation is associated with increased pro-inflammatory cytokine production, another 
component of pre-eclampsia (Benyo, Smarason et al. 2001, Hung, Charnock-Jones et al. 2004, 
Redman and Sargent 2004, Redman and Sargent 2005, Sharma, Norris et al. 2010, Szarka, Rigo 
et al. 2010).  This may help explain the relationship between the increased release of placental 
microvesicles in pre-eclamptic as compared to control pregnancies and increases in pro-
inflammatory cytokine production (Knight, Redman et al. 1998, Tannetta, Dragovic et al. 2013). 
Taken together, these findings may help elucidate a recently proposed hypothetical link between 
trophoblast-derived exosomes, spiral artery remodeling and preeclampsia pathogenesis 
(Salomon, Yee et al. 2014).    
Interestingly, two of the proteins found in exosomes (Complement C3 and Gelsolin) have 
been implicated in modulating the maternal immune response to foreign pathogens.  Expression 
of Complement C3 by first trimester trophoblast cells occurs in response to high levels of IFN-
gamma, suggesting a potential role in trophoblast response to exogenous pathogens (Bulla, Bossi 
et al. 2009).  Perhaps more intriguing is the possibility that the role of Gelsolin in binding LPS in 
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the amniotic fluid and decreasing LPS-mediated maternal immune system activation (Sezen, 
Bongiovanni et al. 2009), could also occur via exosome-associated Gelsolin, either directly at the 
maternal-fetal interface or in maternal peripheral blood during pregnancy. 
This could explain, at least in part, the decreased dendritic cell mRNA expression of both 
CD40 LG and CCL7 in dendritic cells treated with LPS + trophoblast exosomes as compared to 
dendritic cells + LPS alone.  Both CD40LG and CCL7 are important in dendritic cell activation 
and migration (de la Rosa, Longo et al. 2003, Gunn 2003) and by blocking LPS-induced up 
regulation of CCL7 and CD40LG, trophoblast-derived exosomes may help prevent dendritic cell 
activation and migration to lymph nodes, thus decreasing fetal antigen cross-presentation to 
maternal T-cells in the context of increased inflammation.  
Taken together, these data provide compelling evidence that trophoblast-derived 
exosomes may have multiple effects on the maternal immune system, and may be involved in 
both the maintenance of normal pregnancy and the development of pregnancy complications, 
such as pre-eclampsia.  More work is needed to clarify the causal relationships between 
trophoblast-derived exosomes and maternal immune responses. 
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CHAPTER 5: 
GENERAL DISCUSSION 
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PREGNANCY AS AN IMMUNE PARADOX 
In the early 1950s, Sir Peter Medawar proposed for the first time the idea that pregnancy 
posed a unique “immune paradox,” an idea that has provided the foundation for the field of 
reproductive immunology.  Medawar put forth three potential explanations for why the 
genetically foreign fetus was not rejected by the maternal immune system: the fetus and the 
mother are physically separated; the fetus is does not express the antigens necessary to elicit an 
immune response; and/or that the mother’s immune system does not respond to fetal antigens 
(Medawar 1954, Billington 2003).  We now know that none of these theories completely explain 
the complex immunologic relationships between the mother and fetus during pregnancy.  This 
dissertation seeks to clarify some of the relationships between the maternal and fetal immune 
systems; specifically, how fetal antigens are released into the maternal blood during both normal 
and preeclamptic pregnancies and how the maternal immune system responds to these antigens. 
Numerous pregnancy complications, including preeclampsia, have been linked to 
placental dysfunction and increased activation of the maternal immune system (Benyo, Smarason 
et al. 2001, Goldman-Wohl and Yagel 2002, Redman and Sargent 2004, Germain, Sacks et al. 
2007, Gilbert, Nijland et al. 2008, Gilbert, Ryan et al. 2008, Kronborg, Gjedsted et al. 2011, Lee, 
Romero et al. 2012).  Preeclampsia affects 5-8% of pregnancies worldwide (Duley 2009) and, if 
untreated, can lead to maternal kidney dysfunction, multi-system organ failure, and even death of 
both the mother and infant.  Currently, the only successful treatment for preeclampsia is delivery 
of the placenta, making preeclampsia one of the leading causes of iatrogenic prematurity 
(Pennington, Schlitt et al. 2012).  However, the precise role of the placenta in both the 
manifestation and continued pathogenesis of preeclampsia has yet to be definitively determined. 
	   122	  
EXPRESSION OF MINOR HISTOCOMPATIBILITY ANTIGENS IN THE HUMAN 
PLACENTA 
In this work, we have shown that that the placenta expresses at least six known fetal 
minor histocompatibility antigens (mHAgs) and that both shed trophoblast debris and fetal 
leukocytes may act as sources of fetal antigen exposure for the maternal immune system during 
pregnancy (Holland, Linscheid et al. 2012).  This discovery provides new insights into the 
sources of fetal antigens during pregnancy and is a significant contribution to the increasing body 
of literature showing that maternal T-cells specific for fetal antigens are expanded during 
pregnancy and can persist for many years following parturition (James, Chai et al. 2003, Piper, 
McLarnon et al. 2007, Moldenhauer, Hayball et al. 2010). 
This finding has important implications for both pregnancy and transplantation 
immunology, where mHAgs have been shown to be important for graft-versus-tumor effects as 
well as graft-versus-host disease (Randolph, Gooley et al. 2004, Takami, Sugimori et al. 2004, 
Loren, Bunin et al. 2006).  By better understanding the mechanisms by which mHAgs are 
regulated in both grafted tissues and in the placenta, as well as the different immune molecules 
governing activation vs. tolerance to mHAgs, we can gain important insights into the 
mechanisms by which tumors, transplants and fetuses are either rejected or tolerated by the 
immune system.  Chapter 2 provides important insights into the localization of mHAgs in the 
placenta and the importance of the placenta in modulating maternal immune responses to the 
fetus during pregnancy. 
REGULATION OF FETAL MINOR HISTOCOMPATIBILITY ANTIGEN 
EXPRESSION 
In addition to showing that fetal mHAgs are expressed in the placenta, this work also 
demonstrates that expression of least one mHAg, HA-1, decreases with increasing gestational 
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age (Figure 3.1), is regulated by oxygen (Figures 3.2 and 3.3) and is increased in the placentas of 
women with preeclampsia as compared to control placentas (Figure 3.4).  We have hypothesized 
that increased expression of HA-1, and potentially other mHAgs, in concordance with the 
increased release of syncytiotrophoblast debris and production of proinflammatory cytokines 
(Redman and Sargent 2001, Redman and Sargent 2003, Redman and Sargent 2004, Redman and 
Sargent 2005), both characteristic of preeclampsia, could shift the maternal immune system from 
a more tolerogenic to a more activated phenotype (Figure 5.1). 
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Figure 5.1: A Model of Increased HA-1 Expression and Maternal Immune Activation in 
Normal vs. Preeclamptic Pregnancies.   
Preeclampsia is characterized by impaired remodeling of the maternal spiral arteries, leading to 
altered blood flow to the placenta and areas of ischemia/reperfusion.  This altered oxygen 
delivery leads to increased expression of the minor histocompatibility antigen, HA-1, as well as 
increased release of necrotic trophoblast debris into the maternal blood supply.  Together, these 
factors may contribute to the enhanced maternal immune system activation seen in preeclampsia 
as compared to normal pregnancies. 
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In addition to a potential role in the altered maternal immune responses that are 
characteristic of preeclampsia, the altered expression of HA-1 in hypoxic tissues may provide 
important information for transplant rejection, where the graft may express higher levels of HA-1 
and possibly other antigens as a result of decreased blood flow, which often occurs in grafted 
tissues following transplantation (Rosenberger, Mandriota et al. 2002).  In Chapter 3, we showed 
that increased expression of HA-1 in response to low oxygen is likely mediated by the 
transcription factor, Hypoxia Inducible Factor-1 α (HIF-1α), which is increased in both 
preeclamptic placentas (Caniggia and Winter 2002) and in transplanted tissues, where it is also 
correlated with an increased risk of rejection (Rosenberger, Pratschke et al. 2007).  Taken 
together, these findings suggest a possible role for altered blood flow, increased antigen 
expression and altered immune responses in both preeclamptic pregnancies and in the rejection 
of transplanted tissues. 
TROPHOBLAST-DERIVED EXOSOMES AND THE MATERNAL IMMUNE 
RESPONSE 
In addition to the expression and regulation of fetal mHAgs in the placenta, we also 
found evidence that one of the classical MHC Class II molecules, HLA-DR, that is not expressed 
on the surface of the placenta, presumably to avoid maternal immune detection, may have 
another route of maternal immune exposure via release of exosomes from trophoblast cells 
(Chapter 4).  Major Histocompatibility Complexes (MHC or HLAs, in humans) are the structures 
on the surface of cells that are responsible for self versus non-self discrimination and the 
presentation of antigens, whereas minor histocompatibility antigens (mHAgs) are numerous 
proteins with a variety of different functions that can be presented by specific MHCs and can 
elicit immune responses due to differences between individuals, typically single nucleotide 
polymorphisms (SNPs), allelic insertions or deletions, or presence on the Y-chromosome 
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(Goulmy 2006).  For example, certain mHAgs, including the Y-chromosome encoded antigens 
DDX3Y and RPS4Y1, can be presented by specific HLA-DRs (Spierings, Vermeulen et al. 
2003, Zorn, Miklos et al. 2004). 
Our finding that HLA-DR is expressed in exosomes derived from purified trophoblast 
cells (Table 4.1, Figure 4.6) was surprising, given the historical assertion that the surface of the 
placenta does not express the classical MHC molecules (Chatterjee-Hasrouni, Montgomery et al. 
1983, Hunt and Hsi 1990).  However, this discovery is in agreement with work by other 
researchers indicating that HLA-DR is expressed inside trophoblast cells, but not on the surface, 
and that placental exosomes found in peripheral maternal blood during pregnancies also contain 
HLA-DR (Ranella, Vassiliadis et al. 2005, Taylor, Akyol et al. 2006).  Taken together, our 
findings that mHAgs are expressed in the placenta (Chapter 2), that at least one mHAg, HA-1, is 
regulated by oxygen and is increased in preeclampsia (Chapter 3) and that exosomes from 
trophoblast cells contain HLA-DR (Chapter 4), it is clear that the fetus is neither entirely 
physically separate from the mother, nor is the feto-placental unit entirely lacking in potentially 
antigenic materials, two of the original hypotheses put for by Medawar (Medawar 1954, 
Billington 2003).  This leaves us with examination of Medawar’s third hypothesis; that the 
maternal immune system is unable to respond to fetal/placental antigens. 
Work by other researchers on exosomes, small cup-shaped nanovesicles containing 
microRNAs, mRNAs and proteins, suggests that the can have potent immunomodulatory effects 
(Raposo, Nijman et al. 1996, Bodey, Bodey et al. 1997, Skokos, Le Panse et al. 2001, Clayton, 
Mitchell et al. 2008).  In order to determine the effects of trophoblast-derived exosomes in the 
context of maternal immune recognition of fetal antigens, we decided to investigate the response 
of dendritic cells, which are critically important for cross-presentation of antigens to T-cells, to 
exosomes from cultured primary trophoblast cells.  Using qRT-PCR, we found that treatment of 
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human dendritic cells with trophoblast exosomes lead to upregulation of CD-80, IL-8 and 
VCAM-1 mRNAs (Figure 4.4).  CD-80 is a marker of dendritic cell activation, whereas IL-8 and 
VCAM-1 are both associated with angiogenesis (Koch, Polverini et al. 1992, Fukushi, Ono et al. 
2000, Simonini, Moscucci et al. 2000, Hou, Ryu et al. 2014).  This is particularly interesting 
given work by other researchers indicating that defective spiral artery remodeling, a process that 
is similar to angiogenesis, is implicated in the development of preeclampsia (Lockwood, Huang 
et al. 2011, Plaisier 2011).   
When dendritic cells were treated with trophoblast-derived exosomes in the presence of 
the pro-inflammatory molecule, LPS, exosomes lead to decreased mRNA expression of 
CD40LG and CCL7 (Figure 4.5), both of which are involved in dendritic cell activation and 
migration (de la Rosa, Longo et al. 2003, Gunn 2003).  Notably, the dendritic cell mRNAs that 
were altered by the presence of trophoblast-derived exosomes were different in the untreated 
cells as compared to those treated with LPS, suggesting that there may be multiple factors in the 
exosomes that influence dendritic cell phenotype depending on the surrounding immune 
environment.  
CONCLUSIONS 
These data clearly indicate that trophoblast cells produce exosomes that can influence 
maternal immune cell phenotype, indicating that the maternal immune system does, in fact, 
respond to materials released from the placenta during pregnancy, some of which express fetal 
antigens.  This is a significant contribution to the wider field of placental immunology, where 
many other researchers have previously shown that the maternal immune system responds to the 
fetus and placenta in a variety of different ways (Tafuri, Alferink et al. 1995, Jiang and Vacchio 
1998, Petroff, Chen et al. 2003, Aluvihare, Kallikourdis et al. 2004, Hiby, Walker et al. 2004, 
Erlebacher 2010, Hiby, Apps et al. 2010) and that the immune relationship during pregnancy is a 
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complex and dynamic interplay of both fetal and maternal signals, rather than a lack of 
interaction, as was originally proposed by Medawar in his transformative treatise that gave rise 
to the field of placental immunology (Medawar 1954).  Given the rapid expansion of this field of 
study, our findings that the placenta expresses fetal mHAgs (Chapter 2), that at least one of these 
antigens is regulated by oxygen and upregulated in preeclampsia (Chapter 3), and that 
trophoblast-derived exosomes contain a number of immune molecules, including HLA-DR, and 
can alter maternal dendritic cell phenotype (Chapter 4), are significant immunological advances 
and may provide the foundation for future investigations in the field of placental immunology 
and, potentially, beyond. 
  
	   130	  
 
 
 
 
 
CHAPTER 6: 
REFERENCES 
	   	  
	  
	  
	  
 
 
  
	   131	  
(2004). "ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic 
disease." Obstetrics and gynecology 103(6): 1365-1377. 
Abusamra, A. J., Z. Zhong, X. Zheng, M. Li, T. E. Ichim, J. L. Chin and W. P. Min (2005). 
"Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis." Blood Cells 
Mol Dis 35(2): 169-173. 
Adams, K. M., N. C. Lambert, S. Heimfeld, T. S. Tylee, J. M. Pang, T. D. Erickson and J. L. 
Nelson (2003). "Male DNA in female donor apheresis and CD34-enriched products." 
Blood 102(10): 3845-3847. 
Adams, K. M., Z. Yan, A. M. Stevens and J. L. Nelson (2007). "The changing maternal "self" 
hypothesis: a mechanism for maternal tolerance of the fetus." Placenta 28(5-6): 378-382. 
Akatsuka, Y., T. Nishida, E. Kondo, M. Miyazaki, H. Taji, H. Iida, K. Tsujimura, M. Yazaki, T. 
Naoe, Y. Morishima, Y. Kodera, K. Kuzushima and T. Takahashi (2003). "Identification 
of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific 
minor histocompatibility antigens." J Exp Med 197(11): 1489-1500. 
Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, 
A. J. McMichael and M. M. Davis (1996). "Phenotypic analysis of antigen-specific T 
lymphocytes." Science 274(5284): 94-96. 
Aluvihare, V. R., M. Kallikourdis and A. G. Betz (2004). "Regulatory T cells mediate maternal 
tolerance to the fetus." Nat Immunol 5(3): 266-271. 
Andreola, G., L. Rivoltini, C. Castelli, V. Huber, P. Perego, P. Deho, P. Squarcina, P. Accornero, 
F. Lozupone, L. Lugini, A. Stringaro, A. Molinari, G. Arancia, M. Gentile, G. Parmiani 
and S. Fais (2002). "Induction of lymphocyte apoptosis by tumor cell secretion of FasL-
bearing microvesicles." J Exp Med 195(10): 1303-1316. 
Apps, R., A. Sharkey, L. Gardner, V. Male, P. Kennedy, L. Masters, L. Farrell, D. Jones, R. 
Thomas and A. Moffett (2011). "Ex vivo functional responses to HLA-G differ between 
blood and decidual NK cells." Mol Hum Reprod 17(9): 577-586. 
Arruvito, L., M. Sanz, A. H. Banham and L. Fainboim (2007). "Expansion of CD4+CD25+and 
FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: 
implications for human reproduction." J Immunol 178(4): 2572-2578. 
Atay, S., C. Gercel-Taylor, M. Kesimer and D. D. Taylor (2011). "Morphologic and proteomic 
characterization of exosomes released by cultured extravillous trophoblast cells." Exp 
Cell Res 317(8): 1192-1202. 
Atay, S., C. Gercel-Taylor, J. Suttles, G. Mor and D. D. Taylor (2011). "Trophoblast-derived 
exosomes mediate monocyte recruitment and differentiation." Am J Reprod Immunol 
65(1): 65-77. 
Atay, S., C. Gercel-Taylor and D. D. Taylor (2011). "Human trophoblast-derived exosomal 
fibronectin induces pro-inflammatory IL-1beta production by macrophages." Am J 
Reprod Immunol 66: 259-269. 
Attwood, H. D. and W. W. Park (1961). "Embolism to the lungs by trophoblast." J Obstet 
Gynaecol Br Commonw 68: 611-617. 
Auchincloss, H., Jr., R. Lee, S. Shea, J. S. Markowitz, M. J. Grusby and L. H. Glimcher (1993). 
"The role of "indirect" recognition in initiating rejection of skin grafts from major 
histocompatibility complex class II-deficient mice." Proc Natl Acad Sci U S A 90(8): 
3373-3377. 
Bachy, V., D. J. Williams and M. A. Ibrahim (2008). "Altered dendritic cell function in normal 
pregnancy." J Reprod Immunol 78(1): 11-21. 
Baietti, M. F., Z. Zhang, E. Mortier, A. Melchior, G. Degeest, A. Geeraerts, Y. Ivarsson, F. 
Depoortere, C. Coomans, E. Vermeiren, P. Zimmermann and G. David (2012). 
	   132	  
"Syndecan-syntenin-ALIX regulates the biogenesis of exosomes." Nat Cell Biol 14(7): 
677-685. 
Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of immunity." Nature 
392(6673): 245-252. 
Bartmann, C., S. E. Segerer, L. Rieger, M. Kapp, M. Sutterlin and U. Kammerer (2014). 
"Quantification of the predominant immune cell populations in decidua throughout 
human pregnancy." Am J Reprod Immunol 71(2): 109-119. 
Batard, P., D. A. Peterson, E. Devevre, P. Guillaume, J. C. Cerottini, D. Rimoldi, D. E. Speiser, 
L. Winther and P. Romero (2006). "Dextramers: new generation of fluorescent MHC 
class I/peptide multimers for visualization of antigen-specific CD8+ T cells." Journal of 
immunological methods 310(1-2): 136-148. 
Becroft, D. M., J. M. Thompson and E. A. Mitchell (2005). "Placental villitis of unknown origin: 
epidemiologic associations." Am J Obstet Gynecol 192(1): 264-271. 
Benichou, G., A. Valujskikh and P. S. Heeger (1999). "Contributions of direct and indirect T cell 
alloreactivity during allograft rejection in mice." J Immunol 162(1): 352-358. 
Benirschke, K. and P. Kaufmann (1995). Pathology of the Human Placenta. New York, 
Springer-Verlag. 
Benirschke, K., P. Kaufmann, R. Baergen, M. Castellucci and P. Kaufmann (2006). Basic 
Structure of the Villous Trees. Pathology &lt;i&gt;of the&lt;/i&gt; Human Placenta, 
Springer New York: 50-120. 
Benyo, D. F., A. Smarason, C. W. Redman, C. Sims and K. P. Conrad (2001). "Expression of 
inflammatory cytokines in placentas from women with preeclampsia." J Clin Endocrinol 
Metab 86(6): 2505-2512. 
Bergmann, C., L. Strauss, E. Wieckowski, M. Czystowska, A. Albers, Y. Wang, R. Zeidler, S. 
Lang and T. L. Whiteside (2009). "Tumor-derived microvesicles in sera of patients with 
head and neck cancer and their role in tumor progression." Head Neck 31(3): 371-380. 
Bevan, M. J. (1976). "Cross-priming for a secondary cytotoxic response to minor H antigens 
with H-2 congenic cells which do not cross-react in the cytotoxic assay." The Journal of 
Experimental Medicine 143(5): 1283-1288. 
Bevan, M. J. (1976). "Minor H antigens introduced on H-2 different stimulating cells cross-react 
at the cytotoxic T cell level during in vivo priming." Journal of immunology 117(6): 
2233-2238. 
Billington, W. D. (2003). "The immunological problem of pregnancy: 50 years with the hope of 
progress. A tribute to Peter Medawar." J Reprod Immunol 60(1): 1-11. 
Bleakley, M., B. E. Otterud, J. L. Richardt, A. D. Mollerup, M. Hudecek, T. Nishida, C. N. 
Chaney, E. H. Warren, M. F. Leppert and S. R. Riddell (2010). "Leukemia-associated 
minor histocompatibility antigen discovery using T-cell clones isolated by in vitro 
stimulation of naive CD8+ T cells." Blood 115(23): 4923-4933. 
Bleakley, M. and S. R. Riddell (2011). "Exploiting T cells specific for human minor 
histocompatibility antigens for therapy of leukemia." Immunol Cell Biol 89(3): 396-407. 
Blois, S., C. D. Alba Soto, S. Olmos, E. Chuluyan, T. Gentile, P. C. Arck and R. A. Margni 
(2004). "Therapy with dendritic cells influences the spontaneous resorption rate in the 
CBA/J x DBA/2J mouse model." Am J Reprod Immunol 51(1): 40-48. 
Blois, S. M., C. D. Alba Soto, M. Tometten, B. F. Klapp, R. A. Margni and P. C. Arck (2004). 
"Lineage, maturity, and phenotype of uterine murine dendritic cells throughout gestation 
indicate a protective role in maintaining pregnancy." Biol Reprod 70(4): 1018-1023. 
Bobrie, A., M. Colombo, G. Raposo and C. Thery (2011). "Exosome secretion: molecular 
mechanisms and roles in immune responses." Traffic 12(12): 1659-1668. 
	   133	  
Bodey, B., B. Bodey, Jr. and H. E. Kaiser (1997). "Dendritic type, accessory cells within the 
mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-
endocrine-immune cellular network." In Vivo 11(4): 351-370. 
Bouma, G. J., P. van Caubergh, S. P. van Bree, R. M. Castelli-Visser, M. D. Witvliet, E. M. van 
der Meer-Prins, J. J. van Rood and F. H. Claas (1996). "Pregnancy can induce priming of 
cytotoxic T lymphocytes specific for paternal HLA antigens that is associated with 
antibody formation." Transplantation 62(5): 672-678. 
Bretelle, F., F. Sabatier, D. Desprez, L. Camoin, L. Grunebaum, V. Combes, C. D'Ercole and F. 
Dignat-George (2003). "Circulating microparticles: a marker of procoagulant state in 
normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth 
restriction." Thromb Haemost 89(3): 486-492. 
Brickner, A. G., A. M. Evans, J. K. Mito, S. M. Xuereb, X. Feng, T. Nishida, L. Fairfull, R. E. 
Ferrell, K. A. Foon, D. F. Hunt, J. Shabanowitz, V. H. Engelhard, S. R. Riddell and E. H. 
Warren (2006). "The PANE1 gene encodes a novel human minor histocompatibility 
antigen that is selectively expressed in B-lymphoid cells and B-CLL." Blood 107(9): 
3779-3786. 
Brickner, A. G., E. H. Warren, J. A. Caldwell, Y. Akatsuka, T. N. Golovina, A. L. Zarling, J. 
Shabanowitz, L. C. Eisenlohr, D. F. Hunt, V. H. Engelhard and S. R. Riddell (2001). 
"The immunogenicity of a new human minor histocompatibility antigen results from 
differential antigen processing." J Exp Med 193(2): 195-206. 
Bulla, R., F. Bossi, C. Agostinis, O. Radillo, F. Colombo, F. De Seta and F. Tedesco (2009). 
"Complement production by trophoblast cells at the feto-maternal interface." J Reprod 
Immunol 82(2): 119-125. 
Bulmer, J. N. and P. M. Johnson (1984). "Macrophage populations in the human placenta and 
amniochorion." Clin Exp Immunol 57(2): 393-403. 
Burlingham, W. J. and E. Goulmy (2008). "Human CD8+ T-regulatory cells with low-avidity T-
cell receptor specific for minor histocompatibility antigens." Hum Immunol 69(11): 728-
731. 
Burton, G. J. (2009). "Oxygen, the Janus gas; its effects on human placental development and 
function." Journal of anatomy 215(1): 27-35. 
Burton, G. J., E. Jauniaux and A. L. Watson (1999). "Maternal arterial connections to the 
placental intervillous space during the first trimester of human pregnancy: the Boyd 
collection revisited." American journal of obstetrics and gynecology 181(3): 718-724. 
Burton, G. J. and C. J. Jones (2009). "Syncytial knots, sprouts, apoptosis, and trophoblast 
deportation from the human placenta." Taiwan J Obstet Gynecol 48(1): 28-37. 
Burton, G. J., A. W. Woods, E. Jauniaux and J. C. Kingdom (2009). "Rheological and 
physiological consequences of conversion of the maternal spiral arteries for 
uteroplacental blood flow during human pregnancy." Placenta 30(6): 473-482. 
Caligiuri, M. A. (2008). "Human natural killer cells." Blood 112(3): 461-469. 
Caniggia, I. and J. L. Winter (2002). "Adriana and Luisa Castellucci Award lecture 2001. 
Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal 
and pre-eclamptic pregnancies--a review." Placenta 23 Suppl A: S47-57. 
Chamley, L. W., Q. Chen, J. Ding, P. R. Stone and M. Abumaree (2011). "Trophoblast 
deportation: just a waste disposal system or antigen sharing?" J Reprod Immunol 88(2): 
99-105. 
Chaput, N., C. Flament, S. Viaud, J. Taieb, S. Roux, A. Spatz, F. Andre, J. B. LePecq, M. 
Boussac, J. Garin, S. Amigorena, C. Thery and L. Zitvogel (2006). "Dendritic cell 
derived-exosomes: biology and clinical implementations." J Leukoc Biol 80(3): 471-478. 
	   134	  
Chaput, N. and C. Thery (2011). "Exosomes: immune properties and potential clinical 
implementations." Semin Immunopathol 33(5): 419-440. 
Chatterjee-Hasrouni, S., B. Montgomery and P. K. Lala (1983). "Allo-antigenicity of trophoblast 
cells." Am J Reprod Immunol 3(3): 127-131. 
Chattopadhyay, P. K., J. J. Melenhorst, K. Ladell, E. Gostick, P. Scheinberg, A. J. Barrett, L. 
Wooldridge, M. Roederer, A. K. Sewell and D. A. Price (2008). "Techniques to improve 
the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-
major histocompatibility complex class I tetramers." Cytometry. Part A : the journal of 
the International Society for Analytical Cytology 73(11): 1001-1009. 
Chen, L. M., B. Liu, H. B. Zhao, P. Stone, Q. Chen and L. Chamley (2010). "IL-6, TNFalpha 
and TGFbeta promote nonapoptotic trophoblast deportation and subsequently causes 
endothelial cell activation." Placenta 31(1): 75-80. 
Chen, Y., Y. Huang, R. Jiang and Y. Teng (2012). "Syncytiotrophoblast-derived microparticle 
shedding in early-onset and late-onset severe pre-eclampsia." International journal of 
gynaecology and obstetrics: the official organ of the International Federation of 
Gynaecology and Obstetrics 119(3): 234-238. 
Christiansen, O. B., R. Steffensen and H. S. Nielsen (2010). "The impact of anti-HY responses 
on outcome in current and subsequent pregnancies of patients with recurrent pregnancy 
losses." J Reprod Immunol 85(1): 9-14. 
Christiansen, O. B., R. Steffensen and H. S. Nielsen (2011). "Anti-HY responses in pregnancy 
disorders." American journal of reproductive immunology 66 Suppl 1: 93-100. 
Chua, S., T. Wilkins, I. Sargent and C. Redman (1991). "Trophoblast deportation in pre-
eclamptic pregnancy." Br J Obstet Gynaecol 98(10): 973-979. 
Clayton, A., J. P. Mitchell, J. Court, S. Linnane, M. D. Mason and Z. Tabi (2008). "Human 
tumor-derived exosomes down-modulate NKG2D expression." J Immunol 180(11): 
7249-7258. 
Clifton, V. L., M. J. Stark, A. Osei-Kumah and N. A. Hodyl (2012). "Review: The feto-placental 
unit, pregnancy pathology and impact on long term maternal health." Placenta 33 Suppl: 
S37-41. 
Cocucci, E., G. Racchetti and J. Meldolesi (2009). "Shedding microvesicles: artefacts no more." 
Trends Cell Biol 19(2): 43-51. 
Collins, M. K., C. S. Tay and A. Erlebacher (2009). "Dendritic cell entrapment within the 
pregnant uterus inhibits immune surveillance of the maternal/fetal interface in mice." J 
Clin Invest 119(7): 2062-2073. 
Cronqvist, T., K. Salje, M. Familari, S. Guller, H. Schneider, C. Gardiner, I. L. Sargent, C. W. 
Redman, M. Morgelin, B. Akerstrom, M. Gram and S. R. Hansson (2014). 
"Syncytiotrophoblast vesicles show altered micro-RNA and haemoglobin content after 
ex-vivo perfusion of placentas with haemoglobin to mimic preeclampsia." PLoS One 9: 
e90020. 
Darmochwal-Kolarz, D., J. Rolinski, J. Tabarkiewicz, B. Leszczynska-Gorzelak, J. Buczkowski, 
K. Wojas and J. Oleszczuk (2003). "Myeloid and lymphoid dendritic cells in normal 
pregnancy and pre-eclampsia." Clin Exp Immunol 132(2): 339-344. 
Darrasse-Jeze, G., D. Klatzmann, F. Charlotte, B. L. Salomon and J. L. Cohen (2006). 
"CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice." 
Immunology letters 102(1): 106-109. 
de Bueger, M., A. Bakker, J. J. Van Rood, F. Van der Woude and E. Goulmy (1992). "Tissue 
distribution of human minor histocompatibility antigens. Ubiquitous versus restricted 
	   135	  
tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined 
non-MHC antigens." J Immunol 149(5): 1788-1794. 
de Kreuk, B. J., A. Schaefer, E. C. Anthony, S. Tol, M. Fernandez-Borja, D. Geerts, J. Pool, L. 
Hambach, E. Goulmy and P. L. Hordijk (2013). "The human minor Histocompatibility 
Antigen1 is a RhoGAP." PLoS One 8(9): e73962. 
de la Rosa, G., N. Longo, J. L. Rodriguez-Fernandez, A. Puig-Kroger, A. Pineda, A. L. Corbi 
and P. Sanchez-Mateos (2003). "Migration of human blood dendritic cells across 
endothelial cell monolayers: adhesion molecules and chemokines involved in subset-
specific transmigration." J Leukoc Biol 73(5): 639-649. 
de Luca Brunori, I., L. Battini, M. Simonelli, E. Brunori, V. Valentino, M. Curcio, M. L. 
Mariotti, S. Lapi and A. R. Genazzani (2003). "HLA-DR in couples associated with 
preeclampsia: background and updating by DNA sequencing." J Reprod Immunol 59(2): 
235-243. 
de Luca Brunori, I., L. Battini, M. Simonelli, F. Clemente, E. Brunori, M. L. Mariotti and A. R. 
Genazzani (2000). "Increased HLA-DR homozygosity associated with pre-eclampsia." 
Hum Reprod 15(8): 1807-1812. 
de Rijke, B., A. van Horssen-Zoetbrood, J. M. Beekman, B. Otterud, F. Maas, R. Woestenenk, 
M. Kester, M. Leppert, A. V. Schattenberg, T. de Witte, E. van de Wiel-van Kemenade 
and H. Dolstra (2005). "A frameshift polymorphism in P2X5 elicits an allogeneic 
cytotoxic T lymphocyte response associated with remission of chronic myeloid 
leukemia." J Clin Invest 115(12): 3506-3516. 
De Witt, F. (1959). "An historical study on theories of the placenta to 1900." J Hist Med Allied 
Sci 14: 360-374. 
den Haan, J. M., L. M. Meadows, W. Wang, J. Pool, E. Blokland, T. L. Bishop, C. Reinhardus, J. 
Shabanowitz, R. Offringa, D. F. Hunt, V. H. Engelhard and E. Goulmy (1998). "The 
minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid 
polymorphism." Science 279(5353): 1054-1057. 
den Haan, J. M., N. E. Sherman, E. Blokland, E. Huczko, F. Koning, J. W. Drijfhout, J. Skipper, 
J. Shabanowitz, D. F. Hunt, V. H. Engelhard and et al. (1995). "Identification of a graft 
versus host disease-associated human minor histocompatibility antigen." Science 
268(5216): 1476-1480. 
Dierselhuis, M. and E. Goulmy (2009). "The relevance of minor histocompatibility antigens in 
solid organ transplantation." Curr Opin Organ Transplant 14(4): 419-425. 
Dolstra, H., B. de Rijke, H. Fredrix, A. Balas, F. Maas, F. Scherpen, M. J. Aviles, J. L. Vicario, 
N. J. Beekman, F. Ossendorp, T. M. de Witte and E. van de Wiel-van Kemenade (2002). 
"Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 
by cytotoxic T lymphocytes." Eur J Immunol 32(10): 2748-2758. 
Dolstra, H., H. Fredrix, F. Maas, P. G. Coulie, F. Brasseur, E. Mensink, G. J. Adema, T. M. de 
Witte, C. G. Figdor and E. van de Wiel-van Kemenade (1999). "A human minor 
histocompatibility antigen specific for B cell acute lymphoblastic leukemia." J Exp Med 
189(2): 301-308. 
Dolstra, H., H. Fredrix, F. Preijers, E. Goulmy, C. G. Figdor, T. M. de Witte and E. van de Wiel-
van Kemenade (1997). "Recognition of a B cell leukemia-associated minor 
histocompatibility antigen by CTL." J Immunol 158(2): 560-565. 
Dragovic, R. A., C. Gardiner, A. S. Brooks, D. S. Tannetta, D. J. Ferguson, P. Hole, B. Carr, C. 
W. Redman, A. L. Harris, P. J. Dobson, P. Harrison and I. L. Sargent (2011). "Sizing and 
phenotyping of cellular vesicles using Nanoparticle Tracking Analysis." Nanomedicine 7: 
780-788. 
	   136	  
Duley, L. (2009). "The global impact of pre-eclampsia and eclampsia." Semin Perinatol 33(3): 
130-137. 
Dunn, P. M. (2003). "Dr Erasmus Darwin (1731-1802) of Lichfield and placental respiration." 
Arch Dis Child Fetal Neonatal Ed 88(4): F346-348. 
Enders, A. C. (1965). "A comparative study of the fine structure in several hemochorial 
placentas." Am J Anat 116: 29-67. 
Erlebacher, A. (2010). "Immune surveillance of the maternal/fetal interface: controversies and 
implications." Trends Endocrinol Metab 21(7): 428-434. 
Erlebacher, A., D. Vencato, K. A. Price, D. Zhang and L. H. Glimcher (2007). "Constraints in 
antigen presentation severely restrict T cell recognition of the allogeneic fetus." J Clin 
Invest 117(5): 1399-1411. 
Evans, P. C., N. Lambert, S. Maloney, D. E. Furst, J. M. Moore and J. L. Nelson (1999). "Long-
term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy 
women and women with scleroderma." Blood 93(6): 2033-2037. 
Filipazzi, P., M. Burdek, A. Villa, L. Rivoltini and V. Huber (2012). "Recent advances on the 
role of tumor exosomes in immunosuppression and disease progression." Semin Cancer 
Biol. 
Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore and A. 
O'Garra (1991). "IL-10 acts on the antigen-presenting cell to inhibit cytokine production 
by Th1 cells." J Immunol 146(10): 3444-3451. 
Flowers, M. E., M. S. Pepe, G. Longton, K. C. Doney, D. Monroe, R. P. Witherspoon, K. M. 
Sullivan and R. Storb (1990). "Previous donor pregnancy as a risk factor for acute graft-
versus-host disease in patients with aplastic anaemia treated by allogeneic marrow 
transplantation." Br J Haematol 74(4): 492-496. 
Fontenot, J. D., M. A. Gavin and A. Y. Rudensky (2003). "Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells." Nat Immunol 4(4): 330-336. 
Fukushi, J., M. Ono, W. Morikawa, Y. Iwamoto and M. Kuwano (2000). "The activity of soluble 
VCAM-1 in angiogenesis stimulated by IL-4 and IL-13." J Immunol 165(5): 2818-2823. 
Gardner, L. and A. Moffett (2003). "Dendritic cells in the human decidua." Biol Reprod 69(4): 
1438-1446. 
Germain, S. J., G. P. Sacks, S. R. Sooranna, I. L. Sargent and C. W. Redman (2007). "Systemic 
inflammatory priming in normal pregnancy and preeclampsia: the role of circulating 
syncytiotrophoblast microparticles." J Immunol 178(9): 5949-5956. 
Gilbert, J. S., M. J. Nijland and P. Knoblich (2008). "Placental ischemia and cardiovascular 
dysfunction in preeclampsia and beyond: making the connections." Expert Rev 
Cardiovasc Ther 6(10): 1367-1377. 
Gilbert, J. S., M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy and J. P. Granger (2008). 
"Pathophysiology of hypertension during preeclampsia: linking placental ischemia with 
endothelial dysfunction." Am J Physiol Heart Circ Physiol 294(2): H541-550. 
Goldman-Wohl, D. and S. Yagel (2002). "Regulation of trophoblast invasion: from normal 
implantation to pre-eclampsia." Mol Cell Endocrinol 187(1-2): 233-238. 
Gomez, L. M., L. Anton, S. K. Srinivas, M. A. Elovitz and S. Parry (2012). "Effects of increased 
fetuin-A in human trophoblast cells and associated pregnancy outcomes." Am J Obstet 
Gynecol 207(6): 484.e481-488. 
Gonzalez-Galarza, F. F., S. Christmas, D. Middleton and A. R. Jones (2011). "Allele frequency 
net: a database and online repository for immune gene frequencies in worldwide 
populations." Nucleic acids research 39(Database issue): D913-919. 
	   137	  
Gonzalez-Quintero, V. H., J. J. Jimenez, W. Jy, L. M. Mauro, L. Hortman, M. J. O'Sullivan and 
Y. Ahn (2003). "Elevated plasma endothelial microparticles in preeclampsia." Am J 
Obstet Gynecol 189(2): 589-593. 
Gorczynski, R. M., S. Hadidi, G. Yu and D. A. Clark (2002). "The same immunoregulatory 
molecules contribute to successful pregnancy and transplantation." Am J Reprod 
Immunol 48(1): 18-26. 
Goswami, D., D. S. Tannetta, L. A. Magee, A. Fuchisawa, C. W. Redman, I. L. Sargent and P. 
von Dadelszen (2006). "Excess syncytiotrophoblast microparticle shedding is a feature of 
early-onset pre-eclampsia, but not normotensive intrauterine growth restriction." Placenta 
27(1): 56-61. 
Goulding, H., S. Pinder, P. Cannon, D. Pearson, R. Nicholson, D. Snead, J. Bell, C. W. Elston, J. 
F. Robertson, R. W. Blamey and et al. (1995). "A new immunohistochemical antibody 
for the assessment of estrogen receptor status on routine formalin-fixed tissue samples." 
Human pathology 26(3): 291-294. 
Goulmy, E. (2004). "Minor histocompatibility antigens: allo target molecules for tumor-specific 
immunotherapy." Cancer journal 10(1): 1-7. 
Goulmy, E. (2006). "Minor histocompatibility antigens: from transplantation problems to therapy 
of cancer." Hum Immunol 67(6): 433-438. 
Goulmy, E., J. W. Gratama, E. Blokland, F. E. Zwaan and J. J. van Rood (1983). "A minor 
transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during 
graft-versus-host disease." Nature 302: 159-161. 
Goulmy, E., R. Schipper, J. Pool, E. Blokland, J. H. Falkenburg, J. Vossen, A. Gratwohl, G. B. 
Vogelsang, H. C. van Houwelingen and J. J. van Rood (1996). "Mismatches of minor 
histocompatibility antigens between HLA-identical donors and recipients and the 
development of graft-versus-host disease after bone marrow transplantation." N Engl J 
Med 334(5): 281-285. 
Goulmy, E., A. Termijtelen, B. A. Bradley and J. J. van Rood (1976). "Alloimmunity to human 
H-Y." Lancet 2(7996): 1206. 
Goulmy, E., A. Termijtelen, B. A. Bradley and J. J. van Rood (1977). "Y-antigen killing by T 
cells of women is restricted by HLA." Nature 266(5602): 544-545. 
Gratwohl, A., J. Hermans, D. Niederwieser, A. van Biezen, H. C. van Houwelingen and J. 
Apperley (2001). "Female donors influence transplant-related mortality and relapse 
incidence in male recipients of sibling blood and marrow transplants." Hematol J 2(6): 
363-370. 
Griffioen, M., M. W. Honders, E. D. van der Meijden, S. A. van Luxemburg-Heijs, E. G. 
Lurvink, M. G. Kester, C. A. van Bergen and J. H. Falkenburg (2012). "Identification of 
4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as 
targets for graft-versus-leukemia reactivity." Haematologica 97(8): 1196-1204. 
Grosser, O. (1909). Vergleichende Anatomie und Entwicklungsgeschichte der Eihaute und der 
Placenta mit besonderer Berucksichtigung des Menschen. Vienna, Braumuller. 
Grosser, O. (1927). Fruhentwicklung, Eihautbidung und Placentation des Menschen und der 
Saugetiere. Munich. 
Groux, H., M. Bigler, J. E. de Vries and M. G. Roncarolo (1996). "Interleukin-10 induces a long-
term antigen-specific anergic state in human CD4+ T cells." J Exp Med 184(1): 19-29. 
Groux, H., M. Bigler, J. E. de Vries and M. G. Roncarolo (1998). "Inhibitory and stimulatory 
effects of IL-10 on human CD8+ T cells." J Immunol 160(7): 3188-3193. 
Guerin, L. R., L. M. Moldenhauer, J. R. Prins, J. J. Bromfield, J. D. Hayball and S. A. Robertson 
(2011). "Seminal fluid regulates accumulation of FOXP3+ regulatory T Cells in the 
	   138	  
preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-
mediated recruitment." Biol Reprod 85(2): 397-408. 
Gunn, M. D. (2003). "Chemokine mediated control of dendritic cell migration and function." 
Semin Immunol 15(5): 271-276. 
Gustafsson, C., J. Mjosberg, A. Matussek, R. Geffers, L. Matthiesen, G. Berg, S. Sharma, J. Buer 
and J. Ernerudh (2008). "Gene expression profiling of human decidual macrophages: 
evidence for immunosuppressive phenotype." PLoS One 3(4): e2078. 
Hanna, J., D. Goldman-Wohl, Y. Hamani, I. Avraham, C. Greenfield, S. Natanson-Yaron, D. 
Prus, L. Cohen-Daniel, T. I. Arnon, I. Manaster, R. Gazit, V. Yutkin, D. Benharroch, A. 
Porgador, E. Keshet, S. Yagel and O. Mandelboim (2006). "Decidual NK cells regulate 
key developmental processes at the human fetal-maternal interface." Nat Med 12(9): 
1065-1074. 
Harding, C., J. Heuser and P. Stahl (1983). "Receptor-mediated endocytosis of transferrin and 
recycling of the transferrin receptor in rat reticulocytes." J Cell Biol 97(2): 329-339. 
Harlow, F. H., M. A. Brown, T. A. Brighton, S. L. Smith, A. E. Trickett, Y. L. Kwan and G. K. 
Davis (2002). "Platelet activation in the hypertensive disorders of pregnancy." Am J 
Obstet Gynecol 187(3): 688-695. 
Hart, D. N. (1997). "Dendritic cells: unique leukocyte populations which control the primary 
immune response." Blood 90(9): 3245-3287. 
Hedlund, M., A. C. Stenqvist, O. Nagaeva, L. Kjellberg, M. Wulff, V. Baranov and L. 
Mincheva-Nilsson (2009). "Human placenta expresses and secretes NKG2D ligands via 
exosomes that down-modulate the cognate receptor expression: evidence for 
immunosuppressive function." J Immunol 183: 340-351. 
Hegmans, J. P., M. P. Bard, A. Hemmes, T. M. Luider, M. J. Kleijmeer, J. B. Prins, L. Zitvogel, 
S. A. Burgers, H. C. Hoogsteden and B. N. Lambrecht (2004). "Proteomic analysis of 
exosomes secreted by human mesothelioma cells." Am J Pathol 164(5): 1807-1815. 
Heikkinen, J., M. Mottonen, J. Komi, A. Alanen and O. Lassila (2003). "Phenotypic 
characterization of human decidual macrophages." Clin Exp Immunol 131(3): 498-505. 
Herberman, R. B., M. E. Nunn and D. H. Lavrin (1975). "Natural cytotoxic reactivity of mouse 
lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and 
specificity." Int J Cancer 16(2): 216-229. 
Hiby, S. E., R. Apps, A. M. Sharkey, L. E. Farrell, L. Gardner, A. Mulder, F. H. Claas, J. J. 
Walker, C. W. Redman, L. Morgan, C. Tower, L. Regan, G. E. Moore, M. Carrington 
and A. Moffett (2010). "Maternal activating KIRs protect against human reproductive 
failure mediated by fetal HLA-C2." J Clin Invest 120(11): 4102-4110. 
Hiby, S. E., J. J. Walker, M. O'Shaughnessy K, C. W. Redman, M. Carrington, J. Trowsdale and 
A. Moffett (2004). "Combinations of maternal KIR and fetal HLA-C genes influence the 
risk of preeclampsia and reproductive success." J Exp Med 200(8): 957-965. 
Hladunewich, M. A., G. C. Derby, R. A. Lafayette, K. L. Blouch, M. L. Druzin and B. D. Myers 
(2006). "Effect of L-arginine therapy on the glomerular injury of preeclampsia: a 
randomized controlled trial." Obstetrics and gynecology 107(4): 886-895. 
Holets, L. M., J. S. Hunt and M. G. Petroff (2006). "Trophoblast CD274 (B7-H1) is differentially 
expressed across gestation: influence of oxygen concentration." Biol Reprod 74(2): 352-
358. 
Holland, O. J., C. Linscheid, H. C. Hodes, T. L. Nauser, M. Gilliam, P. Stone, L. W. Chamley 
and M. G. Petroff (2012). "Minor histocompatibility antigens are expressed in 
syncytiotrophoblast and trophoblast debris: implications for maternal alloreactivity to the 
fetus." Am J Pathol 180(1): 256-266. 
	   139	  
Holthe, M. R., T. Lyberg, A. C. Staff and L. N. Berge (2005). "Leukocyte-platelet interaction in 
pregnancies complicated with preeclampsia." Platelets 16(2): 91-97. 
Hori, S., T. Nomura and S. Sakaguchi (2003). "Control of regulatory T cell development by the 
transcription factor Foxp3." Science 299(5609): 1057-1061. 
Hou, Y., C. H. Ryu, J. A. Jun, S. M. Kim, C. H. Jeong and S. S. Jeun (2014). "IL-8 enhances the 
angiogenic potential of human bone marrow mesenchymal stem cells by increasing 
vascular endothelial growth factor." Cell Biol Int 38(9): 1050-1059. 
Hsu, C., Y. Morohashi, S. Yoshimura, N. Manrique-Hoyos, S. Jung, M. A. Lauterbach, M. 
Bakhti, M. Gronborg, W. Mobius, J. Rhee, F. A. Barr and M. Simons (2010). "Regulation 
of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C." J 
Cell Biol 189(2): 223-232. 
Hsu, P., B. Santner-Nanan, J. E. Dahlstrom, M. Fadia, A. Chandra, M. Peek and R. Nanan 
(2012). "Altered decidual DC-SIGN+ antigen-presenting cells and impaired regulatory T-
cell induction in preeclampsia." Am J Pathol 181(6): 2149-2160. 
Huber, V., S. Fais, M. Iero, L. Lugini, P. Canese, P. Squarcina, A. Zaccheddu, M. Colone, G. 
Arancia, M. Gentile, E. Seregni, R. Valenti, G. Ballabio, F. Belli, E. Leo, G. Parmiani 
and L. Rivoltini (2005). "Human colorectal cancer cells induce T-cell death through 
release of proapoptotic microvesicles: role in immune escape." Gastroenterology 128(7): 
1796-1804. 
Hung, T. H., D. S. Charnock-Jones, J. N. Skepper and G. J. Burton (2004). "Secretion of tumor 
necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation 
causes endothelial cell activation in vitro: a potential mediator of the inflammatory 
response in preeclampsia." The American journal of pathology 164(3): 1049-1061. 
Hung, T. H., J. N. Skepper and G. J. Burton (2001). "In vitro ischemia-reperfusion injury in term 
human placenta as a model for oxidative stress in pathological pregnancies." The 
American journal of pathology 159(3): 1031-1043. 
Hung, T. H., J. N. Skepper, D. S. Charnock-Jones and G. J. Burton (2002). "Hypoxia-
reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible 
etiological factor in preeclampsia." Circ Res 90(12): 1274-1281. 
Hunt, J. S., G. K. Andrews and G. W. Wood (1987). "Normal trophoblasts resist induction of 
class I HLA." J Immunol 138(8): 2481-2487. 
Hunt, J. S. and B. L. Hsi (1990). "Evasive strategies of trophoblast cells: selective expression of 
membrane antigens." Am J Reprod Immunol 23(2): 57-63. 
Hunt, J. S., M. G. Petroff, R. H. McIntire and C. Ober (2005). "HLA-G and immune tolerance in 
pregnancy." Faseb j 19(7): 681-693. 
Huotari, J. and A. Helenius (2011). "Endosome maturation." EMBO J 30(17): 3481-3500. 
Huppertz, B., H. G. Frank, J. C. Kingdom, F. Reister and P. Kaufmann (1998). "Villous 
cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta." 
Histochem Cell Biol 110(5): 495-508. 
Huppertz, B., P. Kaufmann and J. Kingdom (2002). "Trophoblast turnover in health and 
disease." Fetal Maternal Med Rev 13: 103-118. 
Huppertz, B., J. Kingdom, I. Caniggia, G. Desoye, S. Black, H. Korr and P. Kaufmann (2003). 
"Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast 
into the maternal circulation." Placenta 24(2-3): 181-190. 
Iero, M., R. Valenti, V. Huber, P. Filipazzi, G. Parmiani, S. Fais and L. Rivoltini (2008). 
"Tumour-released exosomes and their implications in cancer immunity." Cell Death 
Differ 15(1): 80-88. 
	   140	  
Ilke, F. A. (1964). "Dissemination of syncytiotrophoblastic cells in the maternal blood stream 
during pregnancy." Bull Schweiz Akad Med 20: 62-72. 
Ishihara, O., M. H. Sullivan and M. G. Elder (1991). "Differences of metabolism of 
prostaglandin E2 and F2 alpha by decidual stromal cells and macrophages in culture." 
Eicosanoids 4(4): 203-207. 
Ishitani, A., N. Sageshima, N. Lee, N. Dorofeeva, K. Hatake, H. Marquardt and D. E. Geraghty 
(2003). "Protein expression and peptide binding suggest unique and interacting functional 
roles for HLA-E, F, and G in maternal-placental immune recognition." J Immunol 
171(3): 1376-1384. 
Ivanov, R., T. Aarts, S. Hol, A. Doornenbal, A. Hagenbeek, E. Petersen and S. Ebeling (2005). 
"Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a 
lymphoblast-specific cytotoxic T lymphocyte response." Clin Cancer Res 11(5): 1694-
1703. 
James, E., J. G. Chai, H. Dewchand, E. Macchiarulo, F. Dazzi and E. Simpson (2003). 
"Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in 
mice and humans." Blood 102(1): 388-393. 
Jasper, M. J., K. P. Tremellen and S. A. Robertson (2006). "Primary unexplained infertility is 
associated with reduced expression of the T-regulatory cell transcription factor Foxp3 in 
endometrial tissue." Mol Hum Reprod 12(5): 301-308. 
Jauniaux, E., L. Poston and G. J. Burton (2006). "Placental-related diseases of pregnancy: 
Involvement of oxidative stress and implications in human evolution." Hum Reprod 
Update 12(6): 747-755. 
Jauniaux, E., A. L. Watson, J. Hempstock, Y. P. Bao, J. N. Skepper and G. J. Burton (2000). 
"Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in 
human early pregnancy failure." The American journal of pathology 157(6): 2111-2122. 
Jiang, S. P. and M. S. Vacchio (1998). "Multiple mechanisms of peripheral T cell tolerance to 
the fetal "allograft"." J Immunol 160(7): 3086-3090. 
Jones, C. J. and H. Fox (1980). "An ultrastructural and ultrahistochemical study of the human 
placenta in maternal pre-eclampsia." Placenta 1(1): 61-76. 
Kahn, D. A. and D. Baltimore (2010). "Pregnancy induces a fetal antigen-specific maternal T 
regulatory cell response that contributes to tolerance." Proceedings of the National 
Academy of Sciences of the United States of America 107(20): 9299-9304. 
Kamei, M., Y. Nannya, H. Torikai, T. Kawase, K. Taura, Y. Inamoto, T. Takahashi, M. Yazaki, 
S. Morishima, K. Tsujimura, K. Miyamura, T. Ito, H. Togari, S. R. Riddell, Y. Kodera, 
Y. Morishima, K. Kuzushima, S. Ogawa and Y. Akatsuka (2009). "HapMap scanning of 
novel human minor histocompatibility antigens." Blood 113(21): 5041-5048. 
Kanof, M. E., P. Smith and H. Zola (1996). "Isolation of whole mononuclear cells from 
peripheral blood and cord blood." Current Protocols in Immunology 19. 
Katzmann, D. J., C. J. Stefan, M. Babst and S. D. Emr (2003). "Vps27 recruits ESCRT 
machinery to endosomes during MVB sorting." J Cell Biol 162(3): 413-423. 
Kawase, T., Y. Akatsuka, H. Torikai, S. Morishima, A. Oka, A. Tsujimura, M. Miyazaki, K. 
Tsujimura, K. Miyamura, S. Ogawa, H. Inoko, Y. Morishima, Y. Kodera, K. Kuzushima 
and T. Takahashi (2007). "Alternative splicing due to an intronic SNP in HMSD 
generates a novel minor histocompatibility antigen." Blood 110(3): 1055-1063. 
Kawase, T., Y. Nannya, H. Torikai, G. Yamamoto, M. Onizuka, S. Morishima, K. Tsujimura, K. 
Miyamura, Y. Kodera, Y. Morishima, T. Takahashi, K. Kuzushima, S. Ogawa and Y. 
Akatsuka (2008). "Identification of human minor histocompatibility antigens based on 
	   141	  
genetic association with highly parallel genotyping of pooled DNA." Blood 111(6): 
3286-3294. 
Khostrotehrani, K. and D. W. Bianchi (2005). "Multi-lineage potential of fetal cells in maternal 
tissue: a legacy in reverse." J Cell Sci 118: 1558-1563. 
Kiessling, R., E. Klein and H. Wigzell (1975). ""Natural" killer cells in the mouse. I. Cytotoxic 
cells with specificity for mouse Moloney leukemia cells. Specificity and distribution 
according to genotype." Eur J Immunol 5(2): 112-117. 
King, A., C. Birkby and Y. W. Loke (1989). "Early human decidual cells exhibit NK activity 
against the K562 cell line but not against first trimester trophoblast." Cell Immunol 
118(2): 337-344. 
King, A., T. D. Burrows, S. E. Hiby, J. M. Bowen, S. Joseph, S. Verma, P. B. Lim, L. Gardner, 
P. Le Bouteiller, A. Ziegler, B. Uchanska-Ziegler and Y. W. Loke (2000). "Surface 
expression of HLA-C antigen by human extravillous trophoblast." Placenta 21(4): 376-
387. 
Kircher, B., S. Stevanovic, M. Urbanek, A. Mitterschiffthaler, H. G. Rammensee, K. Grunewald, 
G. Gastl and D. Nachbaur (2002). "Induction of HA-1-specific cytotoxic T-cell clones 
parallels the therapeutic effect of donor lymphocyte infusion." British journal of 
haematology 117(4): 935-939. 
Knight, M., C. W. Redman, E. A. Linton and I. L. Sargent (1998). "Shedding of 
syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic 
pregnancies." Br J Obstet Gynaecol 105(6): 632-640. 
Koch, A. E., P. J. Polverini, S. L. Kunkel, L. A. Harlow, L. A. DiPietro, V. M. Elner, S. G. Elner 
and R. M. Strieter (1992). "Interleukin-8 as a macrophage-derived mediator of 
angiogenesis." Science 258(5089): 1798-1801. 
Kollman, C., C. W. Howe, C. Anasetti, J. H. Antin, S. M. Davies, A. H. Filipovich, J. Hegland, 
N. Kamani, N. A. Kernan, R. King, V. Ratanatharathorn, D. Weisdorf and D. L. Confer 
(2001). "Donor characteristics as risk factors in recipients after transplantation of bone 
marrow from unrelated donors: the effect of donor age." Blood 98(7): 2043-2051. 
Krishnan, N. S., R. M. Higgins, F. T. Lam, H. Kashi, S. Jobson, K. Ramaiyan, M. Rahman and 
A. Morris (2007). "HA-1 mismatch has significant effect in chronic allograft nephropathy 
in clinical renal transplantation." Transplantation proceedings 39(5): 1439-1445. 
Kronborg, C. S., J. Gjedsted, E. Vittinghus, T. K. Hansen, J. Allen and U. B. Knudsen (2011). 
"Longitudinal measurement of cytokines in pre-eclamptic and normotensive 
pregnancies." Acta obstetricia et gynecologica Scandinavica 90(7): 791-796. 
Kshirsagar, S. K., S. M. Alam, S. Jasti, H. Hodes, T. Nauser, M. Gilliam, C. Billstrand, J. S. 
Hunt and M. G. Petroff (2012). "Immunomodulatory molecules are released from the first 
trimester and term placenta via exosomes." Placenta 33: 982-990. 
Lan, Y. Y., Z. Wang, G. Raimondi, W. Wu, B. L. Colvin, A. de Creus and A. W. Thomson 
(2006). ""Alternatively activated" dendritic cells preferentially secrete IL-10, expand 
Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with 
CTLA4-Ig." J Immunol 177(9): 5868-5877. 
Lapaire, O., W. Holzgreve, J. C. Oosterwijk, R. Brinkhaus and D. W. Bianchi (2007). "Georg 
Schmorl on trophoblasts in the maternal circulation." Placenta 28(1): 1-5. 
Larsen, C. P., P. J. Morris and J. M. Austyn (1990). "Migration of dendritic leukocytes from 
cardiac allografts into host spleens. A novel pathway for initiation of rejection." J Exp 
Med 171(1): 307-314. 
Laugel, B., H. A. van den Berg, E. Gostick, D. K. Cole, L. Wooldridge, J. Boulter, A. Milicic, D. 
A. Price and A. K. Sewell (2007). "Different T cell receptor affinity thresholds and CD8 
	   142	  
coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding 
properties." The Journal of biological chemistry 282(33): 23799-23810. 
Lee, S. M., R. Romero, Y. J. Lee, I. S. Park, C. W. Park and B. H. Yoon (2012). "Systemic 
inflammatory stimulation by microparticles derived from hypoxic trophoblast as a model 
for inflammatory response in preeclampsia." American journal of obstetrics and 
gynecology 207(4): 337 e331-338. 
Lee, X., J. C. Keith, Jr., N. Stumm, I. Moutsatsos, J. M. McCoy, C. P. Crum, D. Genest, D. Chin, 
C. Ehrenfels, R. Pijnenborg, F. A. van Assche and S. Mi (2001). "Downregulation of 
placental syncytin expression and abnormal protein localization in pre-eclampsia." 
Placenta 22(10): 808-812. 
Lessin, D. L., J. S. Hunt, C. R. King and G. W. Wood (1988). "Antigen expression by cells near 
the maternal-fetal interface." Am J Reprod Immunol Microbiol 16(1): 1-7. 
Levings, M. K., R. Sangregorio, F. Galbiati, S. Squadrone, R. de Waal Malefyt and M. G. 
Roncarolo (2001). "IFN-alpha and IL-10 induce the differentiation of human type 1 T 
regulatory cells." J Immunol 166(9): 5530-5539. 
Linscheid, C. and M. G. Petroff (2013). "Minor histocompatibility antigens and the maternal 
immune response to the fetus during pregnancy." Am J Reprod Immunol 69: 304-314. 
Lissauer, D., K. Piper, O. Goodyear, M. D. Kilby and P. A. Moss (2012). "Fetal-specific CD8+ 
cytotoxic T cell responses develop during normal human pregnancy and exhibit broad 
functional capacity." Journal of immunology 189(2): 1072-1080. 
Lockwood, C. J., S. J. Huang, G. Krikun, R. Caze, M. Rahman, L. F. Buchwalder and F. Schatz 
(2011). "Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia." Semin 
Thromb Hemost 37(2): 158-164. 
Lok, C. A., R. Nieuwland, A. Sturk, C. M. Hau, K. Boer, E. Vanbavel and J. A. Vanderpost 
(2007). "Microparticle-associated P-selectin reflects platelet activation in preeclampsia." 
Platelets 18(1): 68-72. 
Longo, L. D. (2013). The Rise of Fetal and Neonatal Physiology: Basic Science to Clinical Care, 
Springer Science & Business Media. 
Longo, L. D. and L. P. Reynolds (2010). "Some historical aspects of understanding placental 
development, structure and function." Int J Dev Biol 54(2-3): 237-255. 
Loren, A. W., G. R. Bunin, C. Boudreau, R. E. Champlin, A. Cnaan, M. M. Horowitz, F. R. 
Loberiza and D. L. Porter (2006). "Impact of donor and recipient sex and parity on 
outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation." 
Biol Blood Marrow Transplant 12(7): 758-769. 
Lu, L., W. Li, F. Fu, F. G. Chambers, S. Qian, J. J. Fung and A. W. Thomson (1997). "Blockade 
of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic 
cell progenitors to induce long-term cardiac allograft survival." Transplantation 64(12): 
1808-1815. 
Lutz, M. B., R. M. Suri, M. Niimi, A. L. Ogilvie, N. A. Kukutsch, S. Rossner, G. Schuler and J. 
M. Austyn (2000). "Immature dendritic cells generated with low doses of GM-CSF in the 
absence of IL-4 are maturation resistant and prolong allograft survival in vivo." Eur J 
Immunol 30(7): 1813-1822. 
Lyons, G. E., J. J. Roszkowski, S. Man, C. Yee, W. M. Kast and M. I. Nishimura (2006). "T-cell 
receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-
cell receptor transduced T cells." Cancer immunology, immunotherapy : CII 55(9): 1142-
1150. 
Marijt, W. A., M. H. Heemskerk, F. M. Kloosterboer, E. Goulmy, M. G. Kester, M. A. van der 
Hoorn, S. A. van Luxemburg-Heys, M. Hoogeboom, T. Mutis, J. W. Drijfhout, J. J. van 
	   143	  
Rood, R. Willemze and J. H. Falkenburg (2003). "Hematopoiesis-restricted minor 
histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete 
remissions of relapsed leukemia." Proc Natl Acad Sci U S A 100(5): 2742-2747. 
Martinez-Lorenzo, M. J., A. Anel, M. A. Alava, A. Pineiro, J. Naval, P. Lasierra and L. Larrad 
(2004). "The human melanoma cell line MelJuSo secretes bioactive FasL and 
APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor 
counterattack." Exp Cell Res 295(2): 315-329. 
Martinez-Varea, A., B. Pellicer, A. Perales-Marin and A. Pellicer (2014). "Relationship between 
Maternal Immunological Response during Pregnancy and Onset of Preeclampsia." J 
Immunol Res 2014: 210241. 
Mathivanan, S., C. J. Fahner, G. E. Reid and R. J. Simpson (2012). "ExoCarta 2012: database of 
exosomal proteins, RNA and lipids." Nucleic Acids Res 40(Database issue): D1241-
1244. 
Mathivanan, S. and R. J. Simpson (2009). "ExoCarta: A compendium of exosomal proteins and 
RNA." Proteomics 9(21): 4997-5000. 
Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. 
Wykoff, C. W. Pugh, E. R. Maher and P. J. Ratcliffe (1999). "The tumour suppressor 
protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis." Nature 
399(6733): 271-275. 
McIntire, R. H., K. G. Ganacias and J. S. Hunt (2008). "Programming of human monocytes by 
the uteroplacental environment." Reprod Sci 15(5): 437-447. 
Medawar, P. B. (1954). "Some immunological and endocrinological problems raised by the 
evolution of viviparity in vertebrates." Symp Soc Exp Biol 7(320). 
Meziani, F., A. Tesse, E. David, M. C. Martinez, R. Wangesteen, F. Schneider and R. 
Andriantsitohaina (2006). "Shed membrane particles from preeclamptic women generate 
vascular wall inflammation and blunt vascular contractility." Am J Pathol 169(4): 1473-
1483. 
Mincheva-Nilsson, L. and V. Baranov (2010). "The role of placental exosomes in reproduction." 
Am J Reprod Immunol 63(6): 520-533. 
Mincheva-Nilsson, L. and V. Baranov (2014). "Placenta-derived exosomes and 
syncytiotrophoblast microparticles and their role in human reproduction: immune 
modulation for pregnancy success." Am J Reprod Immunol 72(5): 440-457. 
Mincheva-Nilsson, L., O. Nagaeva, T. Chen, U. Stendahl, J. Antsiferova, I. Mogren, J. Hernestal 
and V. Baranov (2006). "Placenta-derived soluble MHC class I chain-related molecules 
down-regulate NKG2D receptor on peripheral blood mononuclear cells during human 
pregnancy: a possible novel immune escape mechanism for fetal survival." J Immunol 
176(6): 3585-3592. 
Miranda, S., S. Litwin, G. Barrientos, L. Szereday, E. Chuluyan, J. S. Bartho, P. C. Arck and S. 
M. Blois (2006). "Dendritic cells therapy confers a protective microenvironment in 
murine pregnancy." Scand J Immunol 64(5): 493-499. 
Mizuno, M., K. Aoki and T. Kimbara (1994). "Functions of macrophages in human decidual 
tissue in early pregnancy." Am J Reprod Immunol 31(4): 180-188. 
Moldenhauer, L. M., K. R. Diener, D. M. Thring, M. P. Brown, J. D. Hayball and S. A. 
Robertson (2009). "Cross-presentation of male seminal fluid antigens elicits T cell 
activation to initiate the female immune response to pregnancy." J Immunol 182(12): 
8080-8093. 
	   144	  
Moldenhauer, L. M., J. D. Hayball and S. A. Robertson (2010). "Utilising T cell receptor 
transgenic mice to define mechanisms of maternal T cell tolerance in pregnancy." J 
Reprod Immunol 87(1-2): 1-13. 
Molvarec, A., L. Kalabay, Z. Derzsy, A. Szarka, A. Halmos, B. Stenczer, P. Arnaud, I. Karadi, 
Z. Prohaszka and J. Rigo, Jr. (2009). "Preeclampsia is associated with decreased serum 
alpha(2)-HS glycoprotein (fetuin-A) concentration." Hypertens Res 32(8): 665-669. 
Mommaas, B., J. Kamp, J. W. Drijfhout, N. Beekman, F. Ossendorp, P. Van Veelen, J. Den 
Haan, E. Goulmy and T. Mutis (2002). "Identification of a novel HLA-B60-restricted T 
cell epitope of the minor histocompatibility antigen HA-1 locus." J Immunol 169(6): 
3131-3136. 
Mommaas, B., J. A. Stegehuis-Kamp, A. G. van Halteren, M. Kester, J. Enczmann, P. Wernet, 
G. Kogler, T. Mutis, A. Brand and E. Goulmy (2005). "Cord blood comprises antigen-
experienced T cells specific for maternal minor histocompatibility antigen HA-1." Blood 
105(4): 1823-1827. 
Morales, P. J., J. L. Pace, J. S. Platt, T. A. Phillips, K. Morgan, A. T. Fazleabas and J. S. Hunt 
(2003). "Placental cell expression of HLA-G2 isoforms is limited to the invasive 
trophoblast phenotype." J Immunol 171(11): 6215-6224. 
Mortensen, B. K., A. H. Rasmussen, M. E. Larsen, M. V. Larsen, O. Lund, P. Braendstrup, M. 
Harndahl, M. Rasmussen, S. Buus, A. Stryhn and L. Vindelov (2012). "Identification of a 
novel UTY-encoded minor histocompatibility antigen." Scandinavian journal of 
immunology. 
Munn, D. H., E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine and A. L. Mellor (1999). 
"Inhibition of T cell proliferation by macrophage tryptophan catabolism." J Exp Med 
189(9): 1363-1372. 
Murata, M., E. H. Warren and S. R. Riddell (2003). "A human minor histocompatibility antigen 
resulting from differential expression due to a gene deletion." J Exp Med 197(10): 1279-
1289. 
Murphy, S. P., J. C. Choi and R. Holtz (2004). "Regulation of major histocompatibility complex 
class II gene expression in trophoblast cells." Reprod Biol Endocrinol 2: 52. 
Mutis, T., G. Gillespie, E. Schrama, J. H. Falkenburg, P. Moss and E. Goulmy (1999). 
"Tetrameric HLA class I-minor histocompatibility antigen peptide complexes 
demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in 
patients with graft-versus-host disease." Nat Med 5(7): 839-842. 
Nancy, P., E. Tagliani, C. S. Tay, P. Asp, D. E. Levy and A. Erlebacher (2012). "Chemokine 
gene silencing in decidual stromal cells limits T cell access to the maternal-fetal 
interface." Science 336(6086): 1317-1321. 
Nelson, J. L. (2008). "Your cells are my cells." Sci Am 298(2): 64-71. 
Nelson, J. L., K. A. Hughes, A. G. Smith, B. B. Nisperos, A. M. Branchaud and J. A. Hansen 
(1993). "Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced 
amelioration of rheumatoid arthritis." N Engl J Med 329(7): 466-471. 
Nicholls, S., K. P. Piper, F. Mohammed, T. R. Dafforn, S. Tenzer, M. Salim, P. Mahendra, C. 
Craddock, P. van Endert, H. Schild, M. Cobbold, V. H. Engelhard, P. A. Moss and B. E. 
Willcox (2009). "Secondary anchor polymorphism in the HA-1 minor histocompatibility 
antigen critically affects MHC stability and TCR recognition." Proc Natl Acad Sci U S A 
106(10): 3889-3894. 
Nielsen, H. S., R. Steffensen, K. Varming, A. G. Van Halteren, E. Spierings, L. P. Ryder, E. 
Goulmy and O. B. Christiansen (2009). "Association of HY-restricting HLA class II 
	   145	  
alleles with pregnancy outcome in patients with recurrent miscarriage subsequent to a 
firstborn boy." Hum Mol Genet 18(9): 1684-1691. 
Norde, W. J., I. M. Overes, F. Maas, H. Fredrix, J. C. Vos, M. G. Kester, R. van der Voort, I. 
Jedema, J. H. Falkenburg, A. V. Schattenberg, T. M. de Witte and H. Dolstra (2009). 
"Myeloid leukemic progenitor cells can be specifically targeted by minor 
histocompatibility antigen LRH-1-reactive cytotoxic T cells." Blood 113(10): 2312-2323. 
North, R. A., C. Ferrier, D. Long, K. Townend and P. Kincaid-Smith (1994). "Uterine artery 
Doppler flow velocity waveforms in the second trimester for the prediction of 
preeclampsia and fetal growth retardation." Obstetrics and gynecology 83(3): 378-386. 
O'Neill, D. W. and N. Bhardwaj (2005). "Differentiation of peripheral blood monocytes into 
dendritic cells." Current Protocols in Immunology 70(22F.4.1-22F.4.9). 
Ofran, Y., H. T. Kim, V. Brusic, L. Blake, M. Mandrell, C. J. Wu, S. Sarantopoulos, R. Bellucci, 
D. B. Keskin, R. J. Soiffer, J. H. Antin and J. Ritz (2010). "Diverse patterns of T-cell 
response against multiple newly identified human Y chromosome-encoded minor 
histocompatibility epitopes." Clin Cancer Res 16(5): 1642-1651. 
Ooi, P. V., N. Russell and K. O'Donoghue (2011). "Secondary recurrent miscarriage is 
associated with previous male birth." J Reprod Immunol 88(1): 38-41. 
Oostvogels, R., M. C. Minnema, M. van Elk, R. M. Spaapen, G. D. Te Raa, B. Giovannone, A. 
Buijs, D. van Baarle, A. P. Kater, M. Griffioen, E. Spierings, H. M. Lokhorst and T. 
Mutis (2012). "Towards effective and safe immunotherapy after allogeneic stem cell 
transplantation: identification of hematopoietic-specific minor histocompatibility antigen 
UTA2-1." Leukemia : official journal of the Leukemia Society of America, Leukemia 
Research Fund, U.K. 
Ostrowski, M., N. B. Carmo, S. Krumeich, I. Fanget, G. Raposo, A. Savina, C. F. Moita, K. 
Schauer, A. N. Hume, R. P. Freitas, B. Goud, P. Benaroch, N. Hacohen, M. Fukuda, C. 
Desnos, M. C. Seabra, F. Darchen, S. Amigorena, L. F. Moita and C. Thery (2010). 
"Rab27a and Rab27b control different steps of the exosome secretion pathway." Nat Cell 
Biol 12(1): 19-30; sup pp 11-13. 
Overes, I. M., B. de Rijke, A. van Horssen-Zoetbrood, H. Fredrix, A. O. de Graaf, J. H. Jansen, 
J. H. van Krieken, R. A. Raymakers, R. van der Voort, T. M. de Witte and H. Dolstra 
(2008). "Expression of P2X5 in lymphoid malignancies results in LRH-1-specific 
cytotoxic T-cell-mediated lysis." Br J Haematol 141(6): 799-807. 
Pan, B. T., K. Teng, C. Wu, M. Adam and R. M. Johnstone (1985). "Electron microscopic 
evidence for externalization of the transferrin receptor in vesicular form in sheep 
reticulocytes." J Cell Biol 101: 942-948. 
Parhar, R. S., S. Yagel and P. K. Lala (1989). "PGE2-mediated immunosuppression by first 
trimester human decidual cells blocks activation of maternal leukocytes in the decidua 
with potential anti-trophoblast activity." Cell Immunol 120(1): 61-74. 
Peche, H., B. Trinite, B. Martinet and M. C. Cuturi (2005). "Prolongation of heart allograft 
survival by immature dendritic cells generated from recipient type bone marrow 
progenitors." Am J Transplant 5(2): 255-267. 
Pennington, K. A., J. M. Schlitt, D. L. Jackson, L. C. Schulz and D. J. Schust (2012). 
"Preeclampsia: multiple approaches for a multifactorial disease." Dis Model Mech 5(1): 
9-18. 
Perchellet, A. L., S. Jasti and M. G. Petroff (2013). "Maternal CD4(+) and CD8(+) T cell 
tolerance towards a fetal minor histocompatibility antigen in T cell receptor transgenic 
mice." Biol Reprod 89(4): 102. 
	   146	  
Perni, S. C., M. Predanic, J. E. Cho and R. N. Baergen (2005). "Placental pathology and 
pregnancy outcomes in donor and non-donor oocyte in vitro fertilization pregnancies." J 
Perinat Med 33(1): 27-32. 
Petroff, M. G. (2005). "Immune interactions at the maternal-fetal interface." J Reprod Immunol 
68(1-2): 1-13. 
Petroff, M. G. (2011). "Review: Fetal antigens--identity, origins, and influences on the maternal 
immune system." Placenta 32 Suppl 2: S176-181. 
Petroff, M. G., L. Chen, T. A. Phillips, D. Azzola, P. Sedlmayr and J. S. Hunt (2003). "B7 family 
molecules are favorably positioned at the human maternal-fetal interface." Biol Reprod 
68(5): 1496-1504. 
Petroff, M. G., T. A. Phillips, H. Ka, J. L. Pace and J. S. Hunt (2006). "Isolation and culture of 
term human trophoblast cells." Methods Mol Med 121: 203-217. 
Piccirillo, C. A. and E. M. Shevach (2001). "Cutting edge: control of CD8+ T cell activation by 
CD4+CD25+ immunoregulatory cells." J Immunol 167(3): 1137-1140. 
Pierce, R. A., E. D. Field, J. M. den Haan, J. A. Caldwell, F. M. White, J. A. Marto, W. Wang, L. 
M. Frost, E. Blokland, C. Reinhardus, J. Shabanowitz, D. F. Hunt, E. Goulmy and V. H. 
Engelhard (1999). "Cutting edge: the HLA-A*0101-restricted HY minor 
histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine 
residue as identified by a novel mass spectrometric technique." J Immunol 163(12): 
6360-6364. 
Pierce, R. A., E. D. Field, T. Mutis, T. N. Golovina, C. Von Kap-Herr, M. Wilke, J. Pool, J. 
Shabanowitz, M. J. Pettenati, L. C. Eisenlohr, D. F. Hunt, E. Goulmy and V. H. 
Engelhard (2001). "The HA-2 minor histocompatibility antigen is derived from a diallelic 
gene encoding a novel human class I myosin protein." J Immunol 167(6): 3223-3230. 
Pijnenborg, R., I. Brosens and R. Romero (2010). Placental Bed Disorders: Basic Science and its 
Translation to Obstetrics, Cambridge University Press. 
Pijnenborg, R. and L. Vercruysse (2007). "Erasmus Darwin's enlightened views on placental 
function." Placenta 28(8-9): 775-778. 
Piper, K. P., A. McLarnon, J. Arrazi, C. Horlock, J. Ainsworth, M. D. Kilby, W. L. Martin and P. 
A. Moss (2007). "Functional HY-specific CD8+ T cells are found in a high proportion of 
women following pregnancy with a male fetus." Biol Reprod 76(1): 96-101. 
Plaisier, M. (2011). "Decidualisation and angiogenesis." Best Pract Res Clin Obstet Gynaecol 
25(3): 259-271. 
Plaks, V., T. Birnberg, T. Berkutzki, S. Sela, A. BenYashar, V. Kalchenko, G. Mor, E. Keshet, 
N. Dekel, M. Neeman and S. Jung (2008). "Uterine DCs are crucial for decidua formation 
during embryo implantation in mice." J Clin Invest 118(12): 3954-3965. 
Ponte, M., C. Cantoni, R. Biassoni, A. Tradori-Cappai, G. Bentivoglio, C. Vitale, S. Bertone, A. 
Moretta, L. Moretta and M. C. Mingari (1999). "Inhibitory receptors sensing HLA-G1 
molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and 
CD94/NKG2A and acquire p49, an HLA-G1-specific receptor." Proc Natl Acad Sci U S 
A 96(10): 5674-5679. 
Porcheray, F., S. Viaud, A. C. Rimaniol, C. Leone, B. Samah, N. Dereuddre-Bosquet, D. 
Dormont and G. Gras (2005). "Macrophage activation switching: an asset for the 
resolution of inflammation." Clin Exp Immunol 142(3): 481-489. 
Power, M. and J. Schulkin (2012). The Evolution of the Human Placenta, JHU Press. 
Probst, H. C., K. McCoy, T. Okazaki, T. Honjo and M. van den Broek (2005). "Resting dendritic 
cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4." Nat Immunol 
6(3): 280-286. 
	   147	  
Rajagopalan, S., J. Fu and E. O. Long (2001). "Cutting edge: induction of IFN-gamma 
production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in 
resting NK cells." J Immunol 167(4): 1877-1881. 
Randolph, G. J., S. Beaulieu, S. Lebecque, R. M. Steinman and W. A. Muller (1998). 
"Differentiation of monocytes into dendritic cells in a model of transendothelial 
trafficking." Science 282(5388): 480-483. 
Randolph, S. S., T. A. Gooley, E. H. Warren, F. R. Appelbaum and S. R. Riddell (2004). 
"Female donors contribute to a selective graft-versus-leukemia effect in male recipients 
of HLA-matched, related hematopoietic stem cell transplants." Blood 103(1): 347-352. 
Ranella, A., S. Vassiliadis, C. Mastora, M. Valentina, E. Dionyssopoulou and I. Athanassakis 
(2005). "Constitutive intracellular expression of human leukocyte antigen (HLA)-DO and 
HLA-DR but not HLA-DM in trophoblast cells." Hum Immunol 66(1): 43-55. 
Raposo, G., H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief and H. 
J. Geuze (1996). "B lymphocytes secrete antigen-presenting vesicles." J Exp Med 183(3): 
1161-1172. 
Reddy, A., X. Y. Zhong, C. Rusterholz, S. Hahn, W. Holzgreve, C. W. Redman and I. L. Sargent 
(2008). "The effect of labour and placental separation on the shedding of 
syncytiotrophoblast microparticles, cell-free DNA and mRNA in normal pregnancy and 
pre-eclampsia." Placenta 29(11): 942-949. 
Redline, R. W. (2007). "Villitis of unknown etiology: noninfectious chronic villitis in the 
placenta." Hum Pathol 38(10): 1439-1446. 
Redman, C. W. and I. L. Sargent (2001). "The pathogenesis of pre-eclampsia." Gynecol Obstet 
Fertil 29(7-8): 518-522. 
Redman, C. W. and I. L. Sargent (2003). "Pre-eclampsia, the placenta and the maternal systemic 
inflammatory response--a review." Placenta 24 Suppl A: S21-27. 
Redman, C. W. and I. L. Sargent (2004). "Preeclampsia and the systemic inflammatory 
response." Semin Nephrol 24(6): 565-570. 
Redman, C. W. and I. L. Sargent (2005). "Latest advances in understanding preeclampsia." 
Science 308(5728): 1592-1594. 
Redman, C. W. and I. L. Sargent (2007). "Microparticles and immunomodulation in pregnancy 
and pre-eclampsia." J Reprod Immunol 76(1-2): 61-67. 
Redman, C. W. and I. L. Sargent (2008). "Circulating microparticles in normal pregnancy and 
pre-eclampsia." Placenta 29 Suppl A: S73-77. 
Reimand, J., T. Arak and J. Vilo (2011). "g:Profiler--a web server for functional interpretation of 
gene lists (2011 update)." Nucleic Acids Res 39(Web Server issue): W307-315. 
Ristich, V., S. Liang, W. Zhang, J. Wu and A. Horuzsko (2005). "Tolerization of dendritic cells 
by HLA-G." Eur J Immunol 35(4): 1133-1142. 
Robertson, S. A. (2005). "Seminal plasma and male factor signalling in the female reproductive 
tract." Cell Tissue Res 322(1): 43-52. 
Robertson, S. A., L. R. Guerin, J. J. Bromfield, K. M. Branson, A. C. Ahlstrom and A. S. Care 
(2009). "Seminal fluid drives expansion of the CD4+CD25+ T regulatory cell pool and 
induces tolerance to paternal alloantigens in mice." Biol Reprod 80(5): 1036-1045. 
Robertson, S. A., W. V. Ingman, S. O'Leary, D. J. Sharkey and K. P. Tremellen (2002). 
"Transforming growth factor beta--a mediator of immune deviation in seminal plasma." J 
Reprod Immunol 57(1-2): 109-128. 
Rodriguez, A., A. Regnault, M. Kleijmeer, P. Ricciardi-Castagnoli and S. Amigorena (1999). 
"Selective transport of internalized antigens to the cytosol for MHC class I presentation 
in dendritic cells." Nature cell biology 1(6): 362-368. 
	   148	  
Roelen, D. L., D. H. Schuurhuis, D. E. van den Boogaardt, K. Koekkoek, P. P. van Miert, J. J. 
van Schip, S. Laban, D. Rea, C. J. Melief, R. Offringa, F. Ossendorp and F. H. Claas 
(2003). "Prolongation of skin graft survival by modulation of the alloimmune response 
with alternatively activated dendritic cells." Transplantation 76(11): 1608-1615. 
Rosenberger, C., S. Mandriota, J. S. Jurgensen, M. S. Wiesener, J. H. Horstrup, U. Frei, P. J. 
Ratcliffe, P. H. Maxwell, S. Bachmann and K. U. Eckardt (2002). "Expression of 
hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys." J Am 
Soc Nephrol 13(7): 1721-1732. 
Rosenberger, C., J. Pratschke, B. Rudolph, S. N. Heyman, R. Schindler, N. Babel, K. U. Eckardt, 
U. Frei, S. Rosen and P. Reinke (2007). "Immunohistochemical detection of hypoxia-
inducible factor-1alpha in human renal allograft biopsies." J Am Soc Nephrol 18(1): 343-
351. 
Rosinski, K. V., N. Fujii, J. K. Mito, K. K. Koo, S. M. Xuereb, O. Sala-Torra, J. S. Gibbs, J. P. 
Radich, Y. Akatsuka, B. J. Van den Eynde, S. R. Riddell and E. H. Warren (2008). 
"DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic 
stem cells." Blood 111(9): 4817-4826. 
Rowe, J. H., J. M. Ertelt, L. Xin and S. S. Way (2012). "Pregnancy imprints regulatory memory 
that sustains anergy to fetal antigen." Nature 490(7418): 102-106. 
Ruocco, M. G., G. Chaouat, L. Florez, A. Bensussan and D. Klatzmann (2014). "Regulatory T-
cells in pregnancy: historical perspective, state of the art, and burning questions." Front 
Immunol 5: 389. 
Sabapatha, A., C. Gercel-Taylor and D. D. Taylor (2006). "Specific isolation of placenta-derived 
exosomes from the circulation of pregnant women and their immunoregulatory 
consequences." Am J Reprod Immunol 56(5-6): 345-355. 
Sakaguchi, S., K. Fukuma, K. Kuribayashi and T. Masuda (1985). "Organ-specific autoimmune 
diseases induced in mice by elimination of T cell subset. I. Evidence for the active 
participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible 
cause of autoimmune disease." J Exp Med 161(1): 72-87. 
Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh and M. Toda (2011). "Pillars article: 
immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor 
alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various 
autoimmune diseases. J. Immunol. 1995." J Immunol 186(7): 3808-3821. 
Sakai, M., H. Tsuda, K. Tanebe, Y. Sasaki and S. Saito (2002). "Interleukin-12 secretion by 
peripheral blood mononuclear cells is decreased in normal pregnant subjects and 
increased in preeclamptic patients." Am J Reprod Immunol 47(2): 91-97. 
Salomon, C., S. W. Yee, M. D. Mitchell and G. E. Rice (2014). "The possible role of extravillous 
trophoblast-derived exosomes on the uterine spiral arterial remodeling under both normal 
and pathological conditions." Biomed Res Int 2014: 693157. 
Sargent, I. L., S. J. Germain, G. P. Sacks, S. Kumar and C. W. Redman (2003). "Trophoblast 
deportation and the maternal inflammatory response in pre-eclampsia." J Reprod 
Immunol 59(2): 153-160. 
Sato, K., N. Yamashita, N. Yamashita, M. Baba and T. Matsuyama (2003). "Regulatory dendritic 
cells protect mice from murine acute graft-versus-host disease and leukemia relapse." 
Immunity 18(3): 367-379. 
Savina, A., C. M. Fader, M. T. Damiani and M. I. Colombo (2005). "Rab11 promotes docking 
and fusion of multivesicular bodies in a calcium-dependent manner." Traffic 6(2): 131-
143. 
	   149	  
Schmorl, G. (1893). Pathologisch-anatomische Untersunchungen uber Puerperal-Eklampsie. 
Leipzig, Verlag FCW Vogel. 
Semenza, G. L. (2004). "Hydroxylation of HIF-1: oxygen sensing at the molecular level." 
Physiology 19: 176-182. 
Sezen, D., A. M. Bongiovanni, S. Gelber, U. Perni, J. M. Hutson, D. Skupski and S. S. Witkin 
(2009). "Gelsolin down-regulates lipopolysaccharide-induced intraamniotic tumor 
necrosis factor-alpha production in the midtrimester of pregnancy." Am J Obstet Gynecol 
200(2): 191.e191-194. 
Sharma, S., W. E. Norris and S. Kalkunte (2010). "Beyond the threshold: an etiological bridge 
between hypoxia and immunity in preeclampsia." J Reprod Immunol 85(1): 112-116. 
Shima, T., Y. Sasaki, M. Itoh, A. Nakashima, N. Ishii, K. Sugamura and S. Saito (2010). 
"Regulatory T cells are necessary for implantation and maintenance of early pregnancy 
but not late pregnancy in allogeneic mice." Journal of reproductive immunology 85(2): 
121-129. 
Simonini, A., M. Moscucci, D. W. Muller, E. R. Bates, F. D. Pagani, M. D. Burdick and R. M. 
Strieter (2000). "IL-8 is an angiogenic factor in human coronary atherectomy tissue." 
Circulation 101(13): 1519-1526. 
Simpson, R. J., H. Kalra and S. Mathivanan (2012). "ExoCarta as a resource for exosomal 
research." J Extracell Vesicles 1. 
Skinner, A. M., S. L. O'Neill and P. Kurre (2009). "Cellular microvesicle pathways can be 
targeted to transfer genetic information between non-immune cells." PLoS One 4(7): 
e6219. 
Skokos, D., S. Le Panse, I. Villa, J. C. Rousselle, R. Peronet, B. David, A. Namane and S. 
Mecheri (2001). "Mast cell-dependent B and T lymphocyte activation is mediated by the 
secretion of immunologically active exosomes." J Immunol 166(2): 868-876. 
Slager, E. H., M. W. Honders, E. D. van der Meijden, S. A. van Luxemburg-Heijs, F. M. 
Kloosterboer, M. G. Kester, I. Jedema, W. A. Marijt, M. R. Schaafsma, R. Willemze and 
J. H. Falkenburg (2006). "Identification of the angiogenic endothelial-cell growth factor-
1/thymidine phosphorylase as a potential target for immunotherapy of cancer." Blood 
107(12): 4954-4960. 
Smith, R. N. and A. E. Powell (1977). "The adoptive transfer of pregnancy-induced 
unresponsiveness to male skin grafts with thymus-dependent cells." J Exp Med 146(3): 
899-904. 
Smith, S. D., C. E. Dunk, J. D. Aplin, L. K. Harris and R. L. Jones (2009). "Evidence for 
immune cell involvement in decidual spiral arteriole remodeling in early human 
pregnancy." Am J Pathol 174(5): 1959-1971. 
Soper, J. T., D. G. Mutch and J. C. Schink (2004). "Diagnosis and treatment of gestational 
trophoblastic disease: ACOG Practice Bulletin No. 53." Gynecologic oncology 93(3): 
575-585. 
Spaapen, R. M., H. M. Lokhorst, K. van den Oudenalder, B. E. Otterud, H. Dolstra, M. F. 
Leppert, M. C. Minnema, A. C. Bloem and T. Mutis (2008). "Toward targeting B cell 
cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility 
antigen using a novel genome-wide analysis." J Exp Med 205(12): 2863-2872. 
Spierings, E., A. G. Brickner, J. A. Caldwell, S. Zegveld, N. Tatsis, E. Blokland, J. Pool, R. A. 
Pierce, S. Mollah, J. Shabanowitz, L. C. Eisenlohr, P. van Veelen, F. Ossendorp, D. F. 
Hunt, E. Goulmy and V. H. Engelhard (2003). "The minor histocompatibility antigen 
HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis 
(Lbc) oncoprotein." Blood 102(2): 621-629. 
	   150	  
Spierings, E., C. J. Vermeulen, M. H. Vogt, L. E. Doerner, J. H. Falkenburg, T. Mutis and E. 
Goulmy (2003). "Identification of HLA class II-restricted H-Y-specific T-helper epitope 
evoking CD4+ T-helper cells in H-Y-mismatched transplantation." Lancet 362(9384): 
610-615. 
Steck, T., L. Rieger, E. Rodel, J. Dietl and U. Kammerer (2002). "[Expression of the molecules 
HLA-G and HLA-E modulates cytokine production of monocyte generated dendritic 
cells]." Zentralbl Gynakol 124(5): 304-309. 
Steel, S. A., J. M. Pearce, P. McParland and G. V. Chamberlain (1990). "Early Doppler 
ultrasound screening in prediction of hypertensive disorders of pregnancy." Lancet 
335(8705): 1548-1551. 
Stein, M., S. Keshav, N. Harris and S. Gordon (1992). "Interleukin 4 potently enhances murine 
macrophage mannose receptor activity: a marker of alternative immunologic macrophage 
activation." J Exp Med 176(1): 287-292. 
Steinman, R. M. and M. C. Nussenzweig (2002). "Avoiding horror autotoxicus: the importance 
of dendritic cells in peripheral T cell tolerance." Proc Natl Acad Sci U S A 99(1): 351-
358. 
Stenczer, B., A. Molvarec, G. Szabo, A. Szarka, G. Fugedi, J. Szijarto and J. Rigo, Jr. (2012). 
"Circulating levels of thrombospondin-1 are decreased in HELLP syndrome." Thromb 
Res 129(4): 470-473. 
Stillman, I. E. and S. A. Karumanchi (2007). "The glomerular injury of preeclampsia." Journal of 
the American Society of Nephrology : JASN 18(8): 2281-2284. 
Stone, B., M. Rieck, C. A. Rawlings, A. Kas, J. Shendure, H. Jones and J. H. Buckner (2012). 
"Identification of novel HLA class II target epitopes for generation of donor-specific T 
regulatory cells." Clinical immunology 145(2): 153-160. 
Stumpf, A. N., E. D. van der Meijden, C. A. van Bergen, R. Willemze, J. H. Falkenburg and M. 
Griffioen (2009). "Identification of 4 new HLA-DR-restricted minor histocompatibility 
antigens as hematopoietic targets in antitumor immunity." Blood 114(17): 3684-3692. 
Styer, A. K., H. J. Parker, D. J. Roberts, D. Palmer-Toy, T. L. Toth and J. L. Ecker (2003). 
"Placental villitis of unclear etiology during ovum donor in vitro fertilization pregnancy." 
Am J Obstet Gynecol 189(4): 1184-1186. 
Szajnik, M., M. Czystowska, M. J. Szczepanski, M. Mandapathil and T. L. Whiteside (2010). 
"Tumor-derived microvesicles induce, expand and up-regulate biological activities of 
human regulatory T cells (Treg)." PLoS One 5(7): e11469. 
Szarka, A., J. Rigo, Jr., L. Lazar, G. Beko and A. Molvarec (2010). "Circulating cytokines, 
chemokines and adhesion molecules in normal pregnancy and preeclampsia determined 
by multiplex suspension array." BMC Immunol 11: 59. 
Tafuri, A., J. Alferink, P. Moller, G. J. Hammerling and B. Arnold (1995). "T cell awareness of 
paternal alloantigens during pregnancy." Science 270(5236): 630-633. 
Taglauer, E. S., K. M. Adams Waldorf and M. G. Petroff (2010). "The hidden maternal-fetal 
interface: events involving the lymphoid organs in maternal-fetal tolerance." Int J Dev 
Biol 54(2-3): 421-430. 
Taglauer, E. S., T. M. Yankee and M. G. Petroff (2009). "Maternal PD-1 Regulates 
Accumulation of Fetal Antigen-Specific CD8+ T cells in Pregnancy." J Reprod 
Immunol(80): 12-21. 
Takami, A., C. Sugimori, X. Feng, A. Yachie, Y. Kondo, R. Nishimura, K. Kuzushima, T. 
Kotani, H. Asakura, S. Shiobara and S. Nakao (2004). "Expansion and activation of 
minor histocompatibility antigen HY-specific T cells associated with graft-versus-
leukemia response." Bone Marrow Transplant 34(8): 703-709. 
	   151	  
Tannetta, D. and I. Sargent (2013). "Placental disease and the maternal syndrome of 
preeclampsia: missing links?" Curr Hypertens Rep 15(6): 590-599. 
Tannetta, D. S., R. A. Dragovic, C. Gardiner, C. W. Redman and I. L. Sargent (2013). 
"Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: 
expression of Flt-1 and endoglin." PLoS One 8(2): e56754. 
Tarfuri, A., J. Alferink, P. Moller, G. J. Hammerling and B. Arnold (1995). "T cell awareness of 
paternal alloantigens during pregnancy." Science(270): 630-633. 
Tarrade, A., R. Lai Kuen, A. Malassine, V. Tricottet, P. Blain, M. Vidaud and D. Evain-Brion 
(2001). "Characterization of human villous and extravillous trophoblasts isolated from 
first trimester placenta." Lab Invest 81(9): 1199-1211. 
Taverna, S., A. Flugy, L. Saieva, E. C. Kohn, A. Santoro, S. Meraviglia, G. De Leo and R. 
Alessandro (2012). "Role of exosomes released by chronic myelogenous leukemia cells 
in angiogenesis." Int J Cancer 130(9): 2033-2043. 
Taylor, D. D., S. Akyol and C. Gercel-Taylor (2006). "Pregnancy-associated exosomes and their 
modulation of T cell signaling." J Immunol 176(3): 1534-1542. 
Taylor, D. D. and G. J. Doellgast (1979). "Quantitation of peroxidase-antibody binding to 
membrane fragments using column chromatography." Anal Biochem 98: 53-59. 
Terakura, S., M. Murata, E. H. Warren, A. Sette, J. Sidney, T. Naoe and S. R. Riddell (2007). "A 
single minor histocompatibility antigen encoded by UGT2B17 and presented by human 
leukocyte antigen-A*2902 and -B*4403." Transplantation 83(9): 1242-1248. 
Thery, C., M. Boussac, P. Veron, P. Ricciardi-Castagnoli, G. Raposo, J. Garin and S. Amigorena 
(2001). "Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular 
compartment distinct from apoptotic vesicles." J Immunol 166(12): 7309-7318. 
Thornton, R. D., P. Lane, R. C. Borghaei, E. A. Pease, J. Caro and E. Mochan (2000). 
"Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial 
fibroblasts." The Biochemical journal 350 Pt 1: 307-312. 
Timonen, T., J. R. Ortaldo and R. B. Herberman (1981). "Characteristics of human large 
granular lymphocytes and relationship to natural killer and K cells." J Exp Med 153(3): 
569-582. 
Torikai, H., Y. Akatsuka, H. Miyauchi, S. Terakura, M. Onizuka, K. Tsujimura, K. Miyamura, 
Y. Morishima, Y. Kodera, K. Kuzushima and T. Takahashi (2007). "The HLA-A*0201-
restricted minor histocompatibility antigen HA-1H peptide can also be presented by 
another HLA-A2 subtype, A*0206." Bone Marrow Transplant 40(2): 165-174. 
Torikai, H., Y. Akatsuka, M. Miyazaki, A. Tsujimura, Y. Yatabe, T. Kawase, Y. Nakao, K. 
Tsujimura, K. Motoyoshi, Y. Morishima, Y. Kodera, K. Kuzushima and T. Takahashi 
(2006). "The human cathepsin H gene encodes two novel minor histocompatibility 
antigen epitopes restricted by HLA-A*3101 and -A*3303." Br J Haematol 134(4): 406-
416. 
Torikai, H., Y. Akatsuka, M. Miyazaki, E. H. Warren, 3rd, T. Oba, K. Tsujimura, K. Motoyoshi, 
Y. Morishima, Y. Kodera, K. Kuzushima and T. Takahashi (2004). "A novel HLA-
A*3303-restricted minor histocompatibility antigen encoded by an unconventional open 
reading frame of human TMSB4Y gene." Journal of immunology 173(11): 7046-7054. 
Toth, B., C. A. Lok, A. Boing, M. Diamant, J. A. van der Post, K. Friese and R. Nieuwland 
(2007). "Microparticles and exosomes: impact on normal and complicated pregnancy." 
Am J Reprod Immunol 58(5): 389-402. 
Trams, E. G., C. J. Lauter, N. Salem, Jr. and U. Heine (1981). "Exfoliation of membrane ecto-
enzymes in the form of micro-vesicles." Biochim Biophys Acta 645: 63-70. 
	   152	  
Tseng, L. H., M. T. Lin, P. J. Martin, J. Pei, A. G. Smith and J. A. Hansen (1998). "Definition of 
the gene encoding the minor histocompatibility antigen HA-1 and typing for HA-1 from 
genomic DNA." Tissue Antigens 52(4): 305-311. 
Vacchio, M. S. and R. J. Hodes (2003). "CD28 costimulation is required for in vivo induction of 
peripheral tolerance in CD8 T cells." The Journal of Experimental Medicine 197(1): 19-
26. 
van Bergen, C. A., M. G. Kester, I. Jedema, M. H. Heemskerk, S. A. van Luxemburg-Heijs, F. 
M. Kloosterboer, W. A. Marijt, A. H. de Ru, M. R. Schaafsma, R. Willemze, P. A. van 
Veelen and J. H. Falkenburg (2007). "Multiple myeloma-reactive T cells recognize an 
activation-induced minor histocompatibility antigen encoded by the ATP-dependent 
interferon-responsive (ADIR) gene." Blood 109(9): 4089-4096. 
Van Bergen, C. A., C. E. Rutten, E. D. Van Der Meijden, S. A. Van Luxemburg-Heijs, E. G. 
Lurvink, J. J. Houwing-Duistermaat, M. G. Kester, A. Mulder, R. Willemze, J. H. 
Falkenburg and M. Griffioen (2010). "High-throughput characterization of 10 new minor 
histocompatibility antigens by whole genome association scanning." Cancer Res 70(22): 
9073-9083. 
van Halteren, A. G., E. Jankowska-Gan, A. Joosten, E. Blokland, J. Pool, A. Brand, W. J. 
Burlingham and E. Goulmy (2009). "Naturally acquired tolerance and sensitization to 
minor histocompatibility antigens in healthy family members." Blood 114(11): 2263-
2272. 
VanWijk, M. J., R. Nieuwland, K. Boer, J. A. van der Post, E. VanBavel and A. Sturk (2002). 
"Microparticle subpopulations are increased in preeclampsia: possible involvement in 
vascular dysfunction?" Am J Obstet Gynecol 187(2): 450-456. 
Verdijk, R. M., A. Kloosterman, J. Pool, M. van de Keur, A. M. Naipal, A. G. van Halteren, A. 
Brand, T. Mutis and E. Goulmy (2004). "Pregnancy induces minor histocompatibility 
antigen-specific cytotoxic T cells: implications for stem cell transplantation and 
immunotherapy." Blood 103(5): 1961-1964. 
Verreck, F. A., T. de Boer, D. M. Langenberg, M. A. Hoeve, M. Kramer, E. Vaisberg, R. 
Kastelein, A. Kolk, R. de Waal-Malefyt and T. H. Ottenhoff (2004). "Human IL-23-
producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert 
immunity to (myco)bacteria." Proc Natl Acad Sci U S A 101(13): 4560-4565. 
Vogt, M. H., E. Goulmy, F. M. Kloosterboer, E. Blokland, R. A. de Paus, R. Willemze and J. H. 
Falkenburg (2000). "UTY gene codes for an HLA-B60-restricted human male-specific 
minor histocompatibility antigen involved in stem cell graft rejection: characterization of 
the critical polymorphic amino acid residues for T-cell recognition." Blood 96(9): 3126-
3132. 
Vogt, M. H., J. W. van den Muijsenberg, E. Goulmy, E. Spierings, P. Kluck, M. G. Kester, R. A. 
van Soest, J. W. Drijfhout, R. Willemze and J. H. Falkenburg (2002). "The DBY gene 
codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen 
involved in graft-versus-host disease." Blood 99(8): 3027-3032. 
Wada, J., H. Onishi, H. Suzuki, A. Yamasaki, S. Nagai, T. Morisaki and M. Katano (2010). 
"Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of 
number and suppressive function of regulatory T-cells in malignant effusions." 
Anticancer Res 30(9): 3747-3757. 
Wang, T., Y. F. Leng, Y. Zhang, X. Xue and Y. Q. Kang (2011). "Oxidative stress and hypoxia-
induced factor 1alpha expression in gastric ischemia." World journal of gastroenterology 
: WJG 17(14): 1915-1922. 
	   153	  
Wang, W., L. R. Meadows, J. M. den Haan, N. E. Sherman, Y. Chen, E. Blokland, J. 
Shabanowitz, A. I. Agulnik, R. C. Hendrickson, C. E. Bishop and et al. (1995). "Human 
H-Y: a male-specific histocompatibility antigen derived from the SMCY protein." 
Science 269(5230): 1588-1590. 
Warren, E. H., N. Fujii, Y. Akatsuka, C. N. Chaney, J. K. Mito, K. R. Loeb, T. A. Gooley, M. L. 
Brown, K. K. Koo, K. V. Rosinski, S. Ogawa, A. Matsubara, F. R. Appelbaum and S. R. 
Riddell (2010). "Therapy of relapsed leukemia after allogeneic hematopoietic cell 
transplantation with T cells specific for minor histocompatibility antigens." Blood 
115(19): 3869-3878. 
Warren, E. H., M. A. Gavin, E. Simpson, P. Chandler, D. C. Page, C. Disteche, K. A. Stankey, P. 
D. Greenberg and S. R. Riddell (2000). "The human UTY gene encodes a novel HLA-
B8-restricted H-Y antigen." Journal of immunology 164(5): 2807-2814. 
Warren, E. H., N. J. Vigneron, M. A. Gavin, P. G. Coulie, V. Stroobant, A. Dalet, S. S. Tykodi, 
S. M. Xuereb, J. K. Mito, S. R. Riddell and B. J. Van den Eynde (2006). "An antigen 
produced by splicing of noncontiguous peptides in the reverse order." Science 313(5792): 
1444-1447. 
Wenandy, L., T. Kollgaard, A. Letsch, R. S. Andersen, D. Stather, T. Seremet, I. M. Svane, L. 
Vindelov, M. H. Andersen and P. thor Straten (2009). "The 1170 A-P single-nucleotide 
polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility 
antigen (mHag)." Leukemia 23(10): 1926-1929. 
Wilke, M., J. Pool, J. M. den Haan and E. Goulmy (1998). "Genomic identification of the minor 
histocompatibility antigen HA-1 locus by allele-specific PCR." Tissue Antigens 52(4): 
312-317. 
Wollert, T. and J. H. Hurley (2010). "Molecular mechanism of multivesicular body biogenesis 
by ESCRT complexes." Nature 464(7290): 864-869. 
Yelavarthi, K. K., J. L. Fishback and J. S. Hunt (1991). "Analysis of HLA-G mRNA in human 
placental and extraplacental membrane cells by in situ hybridization." J Immunol 146(8): 
2847-2854. 
Zhang, J., Z. Chen, G. N. Smith and B. A. Croy (2011). "Natural killer cell-triggered vascular 
transformation: maternal care before birth?" Cell Mol Immunol 8(1): 1-11. 
Zhou, M. and A. L. Mellor (1998). "Expanded cohorts of maternal CD8+ T-cells specific for 
paternal MHC class I accumulate during pregnancy." J Reprod Immunol 40(1): 47-62. 
Zitvogel, L., A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-Castagnoli, 
G. Raposo and S. Amigorena (1998). "Eradication of established murine tumors using a 
novel cell-free vaccine: dendritic cell-derived exosomes." Nat Med 4: 594-600. 
Zorn, E., D. B. Miklos, B. H. Floyd, A. Mattes-Ritz, L. Guo, R. J. Soiffer, J. H. Antin and J. Ritz 
(2004). "Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell 
Response after Allogeneic Stem Cell Transplantation." The Journal of Experimental 
Medicine 199(8): 1133-1142. 
 
